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The Bergen Respiratory Research Group is associated with the Department of Clinical 
Science, Faculty of Medicine and Dentistry at the University of Bergen and the 
Department of Thoracic Medicine at Haukeland University Hospital. The main 
research focus is on obstructive lung diseases, and the group has a broad experience 
with large epidemiologic studies of this patient category. The group has 
interdisciplinary capacities, and several researchers have a clinical background, 
holding positions in both institutions.  
Professor Tomas Mikal Lind Eagan was the main supervisor of this PhD-project. Co-
supervisors were Professor Per Sigvald Bakke and Assistant Professor Rune Nielsen 
(formerly Rune Grønseth).  
The PhD project was conducted as a part of the Bergen COPD cohort study (BCCS) 
and the related Bergen COPD exacerbation study (BCES). These studies were 
initiated, conducted and supervised by Professors Eagan, Bakke and Jon Andrew 
Hardie, with start of patient inclusion in 2006. 
For the whole period, I have shared my time between my PhD project and clinical 
work as a medical doctor. The first part of my project was funded by the Department 
of Thoracic Medicine by a 50 % research position. In 2015 I received a 6 year 50 % 
PhD-grant from the University of Bergen funding the last part of my project.  
 
  
TERMS AND ABBREVIATIONS 
 
6MWT 6-minute walk test 
A1AT alpha-1 antitrypsin 
ACOS asthma/COPD overlap syndrome 
AECOPD acute exacerbation of COPD 
ALK-1 activin receptor-like kinase 1 
AM alveolar macrophage 
AMP antimicrobial peptides 
ARDS acute respiratory distress syndrome 
ATS American Thoracic Society 
AUC  area under the curve 
BAL bronchoalveolar lavage  
BCCS Bergen COPD cohort study 
BCES Bergen COPD exacerbation study 
BMI body mass index 
BNP brain natriuretic peptide 
cAMP cyclic adenosine monophosphate 
CC16  club cell secretary protein 16 
CCL chemokine ligand 
CCS Charlson comorbidity score 
CD cluster of differentiation 
COPD chronic obstructive pulmonary disease 
CRP C-reactive protein 
CXCL CXC ligand 
DLCO diffusing capacity for carbon monoxide 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
EGF epithelial growth factor  
EIA enzyme immunoassay 
ELISA enzyme-linked immunosorbent assay 
ERK extracellular-signal-regulated kinase 
ERS European Respiratory Society 
FEV1 forced expiratory volume in 1 second 
FFMI fat free mass index 
FMI fat mass index 
FVC forced vital capacity 
GDF-15 growth differentiation factor 15 
GEE generalized estimation equation 
GFRAL GDFN family receptor α-like  
GM-CSF granulocyte-macrophage colony-stimulating factor 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
HR  hazard ratio 
HRCT high resolution computed tomography 
HU Hounsfield unit 
ICS inhaled corticosteroids 
IFN interferon 
IL interleukin 
ILC innate lymphoid cells  
IP-10 interferon gamma-induced protein 10 
IQR interquartile range 
IRR incidence rate ratio 
LAA low attenuation area 
LABA long-acting beta2 antagonist 
LAMA long-acting muscarine agonist 
LLN lower limit of normal 
LPS lipopolysaccharide 
MAIT mucosal associated t cells  
MAPK mitogen activated protein kinase 
MCP monocyte chemoattractant protein 
MIF macrophage migration inhibitory factor 
MIP macrophage inflammatory protein 
MKP-1 MAPK phosphatase-1  
MMP matrix metalloproteinase 
MPO myeloperoxidase 
MRC Medical Research Council  
NK natural killer 
NLR neutrophil/lymphocyte ratio 
NSE neutrophil elastase 
PAH pulmonary artery hypertension 
PCA principal component analysis 
PCR polymerase chain reaction 
PDE phosfodiesterase 
PI3K phosphoinositide 3-kinase 
PRR pattern recognition receptor 
PSFTPB Pro-surfactant protein B 
RCT randomized controlled trial 
RET receptor tyrosine kinase  
RNA ribonucleic acid 
ROC receiver operating characteristic 
ROS reactive oxygen species 
SAD small airway disease 
SARS severe acute respiratory syndrome 
SD standard deviation 
SGRQ St. George’s Respiratory Questionnaire 
SPD surfactant protein D 
sRAGE soluble receptor for advanced glycation end products 
TGF-ß transforming growth factor  
TIMP tissue inhibitors of metalloproteinases  
TLR toll-like receptor 
TNF-α  tumor necrosis factor  
VEGF vascular-endothelial growth factor 
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Chronic obstructive pulmonary disease (COPD) is major cause of morbidity and 
mortality worldwide. The prevalence is increasing worldwide, as a result of an 
increase in cigarette smoking the last decades. The main symptom of COPD is chronic 
and progressive dyspnea, often accompanied with cough and increased amounts of 
phlegm. A significant share of the patients suffers episodes with exacerbation of the 
disease, which may negatively impact quality of life, disease burden and survival.  
COPD pathophysiology is complex and consists of different disease mechanisms. 
Inflammation is a central component of COPD, and increased number of immune cells 
and cytokines are found both in the airways and in the systemic circulation. The 
COPD pathophysiology is incompletely understood, and there is comprehensive 
research on inflammatory biomarkers in order to improve diagnosis, identify patients 
with increased risk of adverse outcome, and to find targets for medical treatment. 
Aims 
1-Identify diagnostic biomarkers of stable COPD and acute exacerbation of COPD. 
2 -Identify inflammatory biomarkers as predictors for longitudinal outcome using 
longitudinal data: 
a. as predictors for future exacerbations 
b. as predictors for change in lung function 
c. as predictors for mortality and cause of death 
d. as predictors for lung cancer 
 
Methods 
The Bergen COPD cohort study (BCCS) included 433 COPD patients and 325 
controls between 2006 and 2009. The COPD patients were aged between 40-76, all 
were former or current smokers. The COPD diagnosis was based on a clinical 
evaluation combined with an obstructive post-bronchodilator spirometry. 
Of the 433 COPD patients, 356 patients living in the vicinity of Haukeland University 
Hospital were also included in the Bergen COPD Exacerbation Study (BCES). 
All patients and controls went through an extensive examination at inclusion including 
medical history, physical examination, lung function testing, bioelectrical impedance 
measurements, HRCT, blood sampling, and microbiological testing. The patients and a 
selection of the controls were followed up during study visits each 6 months for 3 
years, repeating lung function tests and blood sampling each 6 months, bioelectrical 
impedance each 12 months. In addition, patients were followed up to 9 years regarding 
mortality and cause of death as well as lung cancer development.  
Acute exacerbations of COPD (AECOPD) were registered both at each 6-month visit, 
in addition the patients in the BCES were telephoned each month and asked about 
symptoms regarding AECOPD. A selection of the patients was also examined at 
exacerbation where additional blood sampling was performed.  
The inflammatory biomarkers were evaluated at baseline and at AECOPD using both 
non-parametric and multiple regression models. For the analysis of the inflammatory 
biomarkers as predictors of future exacerbations, decline in lung function, mortality 
and lung cancer development, bi-level longitudinal regression models and cox-
regression models were used.  
Results 
Systemic inflammatory markers were measured in all 433 patients and 325 controls at 
inclusion, and in 149 patients at AECOPD. Macrophage migration inhibitory factor 
(MIF) was identified as potential biomarker both for stable COPD as well as AECOPD 
in Paper 2. 
Within the three years of the BCES, 350 of 403 COPD patients suffered 933 moderate 
and 370 severe COPD exacerbations. A history of exacerbations, female sex, chronic 
cough and a lower FEV1 were identified as predictors for future AECOPD in Paper 1. 
In Paper 3, high levels of GDF-15 were identified as a predictor for a higher future 
AECOPD count. 
The COPD patients experienced an average yearly FEV1 decline of 61 ml (1.31 %) in 
men and 36 ml (0.76 % women) in women. High levels of GDF-15 were identified as 
a predictor of a faster decline of both FEV1 and FVC in Paper 3. Other factors 
associated with a faster FEV1 decline were male sex and cachexia.  
Thirty-six COPD patients died with the first three years of follow up, 159 within 9 
years. High levels of GDF-15 were identified as a predictor of a higher mortality in 
Paper 3. Other factors associated with a higher mortality were a low FEV1, cachexia, 
obesity and a high degree of comorbidity. 
Twenty-eight patients developed lung cancer within 9 years. COPD was significantly 
associated with a higher lung cancer risk. Within COPD patients, emphysema and 
obesity was associated with a higher lung cancer risk. Of 44 inflammatory biomarkers, 
only IP-10 was associated with a higher lung cancer risk, whereas systemic 
inflammation evaluated by a PCA-analysis did not show any correlation with lung 
cancer development.  
Conclusion 
1 Macrophage migration inhibitory factor (MIF) was identified as potential 
biomarker for both for stable COPD as well as AECOPD.  
2 a. High levels of GDF-15 were identified as a predictor for a higher future 
AECOPD count in addition to several clinical characteristics. 
b. High levels of GDF-15 were identified as a predictor of a faster decline of both 
FEV1 and FVC.  
c. High levels of GDF-15 were identified as a predictor of all-cause mortality as 
well as mortality due to respiratory disease.  
d. IP-10 was significantly associated with a higher lung cancer risk, whereas 
systemic inflammation did not show any correlation with lung cancer development.   
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Epidemiology of COPD 
Chronic Obstructive Pulmonary Disease, COPD, has been a major cause of morbidity, 
hospitalization, health care costs, and mortality in Norway for many years. There are 
no accurate historical data on the prevalence of COPD before the 1980s, among else 
due to a lack of a general definition of COPD before this time. Tobacco smoking was 
introduced to the general public in Norway in the last part of the 19th century, at a 
time when life for the common Norwegian was miserable, life expectancy was about 
50 years, and it was more likely to die of tuberculosis before anyone had a chance to 
achieve the slightly less stigmatizing diagnosis of “smoker's lung”. Within 1950, 
tuberculosis was in decline, but instead, smoking prevalence was 75 % in males, 
giving rise to the COPD epidemic for the last part of the century. In 1969, the 
Norwegian Tuberculosis Association realized defeat and fused with the Norwegian 
Association of Pulmonary Medicine, retraining and embracing airway obstruction 
instead of acid-fast bacilli. 
The currently estimated prevalence of COPD in Norway varies between 150000 and 
300000 patients, where the smallest estimate is more updated and probably the most 
accurate as of today(1). Many patients are unaware of their diagnosis, as only 50000 
COPD patients were in contact with a physician in 2015, and only 60000 patients were 
prescribed COPD drugs (2), but it is still likely that many COPD patients are 
misdiagnosed with asthma, possibly due to stigmatization and more ample prescription 
refunds in asthma than in COPD. A more robust, but indirectly measure of COPD-
prevalence is hospital admission; 10819 patients were admitted 17386 times in 2015 
(2). There are indications that the both the incidence of hospital admission and COPD 
prevalence in Norway are stabilizing and possibly declining the last years (1).  
Whereas the smoking epidemic is on rapid decline in Western countries, the situation 
is different worldwide. COPD is an increasing cause of morbidity worldwide, and is 
expected to be the third leading cause of death worldwide by 2020 (3). 
Clinical characteristics of COPD 
Symptoms of COPD rarely appear before the age of 40, and are usually preceded by 
minimum a decade of cigarette smoking or other harmful airway exposure. The main 
symptom of COPD is chronic dyspnea (4). Initially it is only recognizable at exercise, 
but as the disease progresses, dyspnea may also be present at minor exertions and at 
rest. Cough with or without increased amounts of sputum/phlegm may be the first 
symptom of COPD, and is present in up to 30 % of the patients. Accompanying 
dyspnea, wheezing or tightness in the chest is another common characteristic. The 
intensity of symptoms may vary, but they never completely resolve even at best (by 
definition). On the other side of the scale patients may experience episodes of 
symptom worsening called acute exacerbations of COPD (AECOPD), which may have 
a large impact on quality of life and prognosis.  
COPD patients frequently have other medical concerns than poor lung function. 
Muscle loss, fatigue and development of cachexia are common findings in advanced 
COPD. Anxiety and depression are other conditions closely related to COPD, 
especially at disease progression. In addition, cardiovascular disease, diabetes and lung 
cancer are examples of common co-morbidities of COPD. In total, the disease burden 
in patients with COPD may be formidable, and it is not determined by lung affection 
alone. 
Definition of COPD 
The concept of COPD as a standalone disease was introduced in the 1960s as an 
umbrella term for emphysema, chronic bronchitis, chronic asthma and other less well 
defined pulmonary disorders (5). Initially, there was much effort in the evaluation of 
airway obstruction as the common and most important characteristic of these 
conditions. The work of Fletcher showing the associations between smoking, loss of 
FEV1, and time of death had much impact on how we diagnose and prognosticate 
COPD (6), and spirometry is still a cornerstone in the evaluation of COPD patients. 
When knowledge and research increased in the last decades of the 20
th
 century, it was 
obvious that COPD did not only affect the airways, and there was a need to reframe 
the picture of COPD pathophysiology. There have been several international 
collaborations in attempting to standardize COPD diagnostics and treatment. The most 
influential consortium is the Global Initiative for Chronic Obstructive Pulmonary 
Disease (GOLD). Although officially not creating guidelines, the GOLD has since 
2001 regularly released Consensus Reports, acting as strategy documents for 
international research and national guidelines. The GOLD 2006/2007 report, released 
during the start of our study, defines COPD (7): 
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
with some significant extrapulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by airflow limitation 
that is not fully reversible. The airflow limitation is usually progressive and associated 
with an abnormal inflammatory response of the lung to noxious particles or gases. 
This definition has later been somewhat simplified, but there is an increasing 
awareness on COPD comorbidity when evaluating and treating COPD patients. 
Spirometry is required or highly recommended for the diagnosis of COPD (4, 8). The 
GOLD criterion for airflow limitation is a Forced Expiratory Volume in 1 second 
(FEV1)/Forced Vital Capacity (FCV) ratio of less than 0.7 after bronchodilatation. 
GOLD further classifies the severity of airway obstruction into four categories:  
GOLD 1 Mild  FEV1 ≥ 80 % predicted 
GOLD 2 Moderate 50 % ≤ FEV1 ≤ 80 % predicted  
GOLD 3 Severe 30 % ≤ FEV1 50 % ≤ predicted  
GOLD 4 Very severe  FEV1 < 30 % predicted 
 
The criterion for airflow obstruction, the fixed FEV1/FVC ratio of < 0.70 is 
controversial since a fixed ratio is not the ideal for the different age classes. A fixed 
ratio was deliberately proposed and acknowledged in order to standardize and simplify 
diagnostics. However, the fixed ratio may lead to missing diagnostics in younger 
patients, and misclassification in the elderly, since the FEV1/FVC ratio gradually 
declines naturally by age. Some advocates for using the lower limit of normal (LLN) 
of the ratio, adjusted for age to avoid this circumstance (9, 10). 
FEV1 measurements alone was for many years the only guide for the medical 
treatment of stable COPD, but the 2011 GOLD Revision added criteria based both on 
symptoms and COPD exacerbation frequency (11). This was a recognition of that 
these parameters were of importance regarding the prognosis of the disease, but also of 
the heterogeneity of COPD. 
Phenotypes in COPD 
Introducing COPD in the 1960s as a general description of several similar airway 
disorders was a deliberate simplification. This might have been beneficial in order to 
coordinate and unite international research, but today there is an increasing interest in 
the differences between patient groups regarding symptoms, prognosis, medical 
treatment and the pathophysiology behind these differences. The term phenotype is 
derived from genetics. Although genetics might be of great importance for the 
differentiation of COPD phenotypes, it is obvious that the differences between 
different COPD characteristics cannot be explained fully explained by genes and gene 
expression. A proposal for a definition of COPD phenotypes was made by Han et al in 
2010: “a single or combination of disease attributes that describe differences between 
individuals with COPD as they relate to clinically meaningful outcomes (symptoms, 
exacerbations, response to therapy, rate of disease progression, or death)” (12) . 
There are no “official” phenotypes in COPD. Traditionally, the two most mentioned 
phenotypes correspond to the two main characteristics in COPD, namely chronic 
bronchitis and emphysema. However, the usefulness of these two phenotypes may be 
limited since there is a significant overlap between these two conditions, and since the 
presence of one or another not necessarily warrants any special treatment. Another 
proposed phenotype is asthma-COPD overlap syndrome (ACOS), a group of patients 
where the distinction between these two categories is difficult (13). ACOS patients 
may have a positive bronchodilator test, usually not fully reversible. They may have 
high levels of blood-eosinophils and are often sensitive to inhaled corticosteroids. 
Other more recently proposed phenotypes consider the different adverse outcomes of 
COPD. It is now recognized that the natural history of COPD as proposed by Fletcher 
is more heterogeneous, as some COPD patients have the same lung function decline as 
healthy controls, whereas others have a rapid decline and thus a severe prognosis. 
Similarly, while some COPD patients have stable symptoms over time, others suffer 
from frequent and often a vicious circle of self-replicating exacerbations. These “rapid 
decliners” and “frequent exacerbators” are often the same patients, since frequent 
AECOPDs is a risk factor for a faster FEV1 decline and vice versa (14, 15). Common 
for both categories is reduced quality of life and a higher mortality (16, 17). 
Finally, the last decades there has been a shift from considering COPD a disease 
limited to the airways, to a clinical syndrome with co-existing disorders sharing risk 
factors and pathogenesis. Patients with COPD have an increased prevalence of several 
non-communicable disorders like cardiovascular disease, diabetes and osteoporosis 
(18). A common denominator of many of these conditions is the finding of increased 
levels of inflammatory markers in the systemic circulation. This feature is present to 
different degree in several COPD patients, potentially representing a distinct 
phenotype (19, 20). This increase in systemic inflammation is associated with several 
characteristics as well as adverse outcome in COPD (20-22). The significance of 
systemic inflammation in COPD is incompletely understood, but there is a large 
research interest on this topic, and this is also of high relevance for this thesis. 
General pathology and pathophysiology in COPD 
The major risk factor for COPD is cigarette smoking, although several other types of 
noxious airway exposure are also of relevance (23). Examples include indoor cooking 
with biomass fuel combined with poor ventilation, occupational exposures or airway 
pollution form traffic or industry. In general, noxious smoke and gases contain 
hundreds of different compounds with a potential to trigger an inflammatory reaction 
involving different components of the airways. The inflammatory response involves 
cells and cytokines related to the both the innate but also the adaptive immune system, 
the latter especially in more advanced disease. The results of these inflammatory 
processes are several different pathological changes not only in the lungs, but also in 
the pulmonary circulation as well as systemic effects involving several different 
organs (24).  
Innate and adaptive immunity in the lungs 
The key to understand the pathophysiology in COPD is to understand how the immune 
systems of the lungs react to different exposure. The immune system has one main 
task; to clear the airways from harmful substances including microbes, viruses, organic 
or inorganic toxins, but also inert particles of any kind. This is a difficult task, given 
the range of different exposure to effectively remove. If the immune response is 
insufficient, death from microbial invasion may be the result; if the immune response 
is excessive, tissue damage or dysfunction may occur. Thus it is important to the host 
that the immune system strikes a balance between these two opposites. If this process 
is carried out suboptimally over time, COPD may be the result. 
The lungs including the alveoli contain by far the largest exposed surface of the human 
body, which is constantly exposed for a multitude of foreign elements. The innate 
immune system in the lungs consists of a combination of mechanical, cellular and 
humoral elements working both alone and together, but also in concert with the 
adaptive immune system (25). In a healthy and non-inflammatory lung, macrophages 
are the dominant inflammatory cells. Neutrophils, T- and B-lymphocytes are present 
only in small numbers but may be rapidly mobilized via the blood stream when called 
upon by cytokine signaling. The inflammatory response seen in COPD is similar to 
that of microbial and fungal infection, often denoted type 1 and 3 immunity (26).  It is 
characterized with increased number of macrophages, neutrophils, cytotoxic T- cells 
and TH1 and TH17-cells. This is in contrast to the type 2 immunity seen in parasitic 
infection and asthma, dominated by mast cells, eosinophils and TH2-cells. 
Cytokines 
The cytokines are essential mediators for all physiologic and metabolic processes in 
the human body. A cytokine can be defined as any molecule, usually a peptide or a 
protein, involved in cell signaling. The nomenclature of cytokines is complex and not 
always consistent (27). Many cytokines are named after its initial discovered function. 
As many cytokines have several functions, the same cytokine may have been given 
different names related to different functions, not always descriptive for its most 
important role.  
Chemokines are cytokines with the ability to induce chemotaxis, like migration of 
immune cells to the site of an infection. Chemokines are further classified into four 
subfamilies, the CXC, CC, CX3C and XC-families, all interacting with g-protein 
transmembrane receptors on their target cells.  
Interleukins are cytokines involved in the cell signaling between leukocytes. The 
interleukins are a heterogeneous group of proteins, more than 38 different families of 
interleukins are described, many of them crucial for the function of the immune system 
(28).  
Growth factors are cytokines involved in the regulation of proliferation, migration and 
differentiation of cells and tissue. This is a large and heterogeneous group of 
cytokines, and where the distinction between cytokines and hormones is not always 
straightforward. 
Interferons are cytokines released as a response to virus infections, many of these can 
also be classified as interleukins.  
In addition, molecules not classified as cytokines, like coagulation factors, 
complement factors or several enzymes may have cytokine functions. 
More than 50 different cytokines are described as likely components of COPD 
pathophysiology (29).  Tumor necrosis factor (TNF-α) and interleukin-8 (IL-8) were 
among the first cytokines identified in COPD (30), and are examples of up-stream pro-
inflammatory cytokines. TNF-α is associated with a diverse range of inflammatory 
responses, whereas IL-8 is closely related with chemoattraction of neutrophils, hence 
its second name chemokine (CXC motif) ligand 8 (CXCL8). The IL-1 family and IL-6 
are other examples of COPD related cytokines (31, 32). IL-1 is related to macrophage 
activity in COPD, IL-6 may have both pro- and anti-inflammatory effects and is linked 
to systemic inflammation and release of C-reactive protein (CRP) from the liver. 
Immune response of the lungs 
The first barrier in the lungs is the epithelium, which is covered by a protective mucus 
lining, which again is transported out of the lungs by cilia sweeping upwards. In 
addition to this mechanical component, the mucus also contains antimicrobial peptides 
(AMPs) and other compounds with antimicrobial and immunomodulating abilities 
(33). Furthermore, epithelial cells have the ability to detect pathogens by different 
semi-specific pattern recognition receptors (PRR), where the toll-like receptors (TLR) 
are the most studied (34). An activation of any PRR may again lead to release of pro-
inflammatory cytokines such as TNF-α, IL-1 and IL-8, activating a more potent 
immune response. Epithelial cells may also release growth factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF), important for immune cell 
production and survival. Other important growth factors secreted from the epithelium 
are transforming growth factor (TGF-ß), epithelial growth factor (EGF) and vascular-
endothelial growth factor (VEGF), related to fibroblast and smooth muscle cell 
proliferation, mucus secretion and vascular repair.  
The alveolar macrophages (AM) are the most abundant cells found in bronchoalveolar 
lavage (BAL) in a healthy lung (35). They are stationary and versatile cells with a 
relatively long life span. The AM has phagocytic abilities which are important both to 
the homeostasis of the healthy lung, but also in the defense against microbes. Also 
important, the AMs have the ability to bind foreign antigens via MHC molecules, 
which again is presented to T-cells. Thus, the AMs are specialized antigen presenting 
cells (APCs); a role shared with the dendritic cells also found in the airways. The AMs 
may be categorized in a pro-inflammatory M1 and an anti-inflammatory M2 
phenotype, although this differentiation is controversial (36). Upon recognition of 
foreign elements, or by cytokine signaling, the AMs may release pro- but also anti-
inflammatory cytokines, activating or modulating the immune response. The AMs are 
a major source of TNF-α, which illustrates their role as a central initiator of 
inflammation. Neutrophils and monocytes are attracted from the circulation by IL-8, 
CXCL1 and monocyte chemoattractant protein-1 (MCP-1). The AMs also release 
CXCL9, 10 and 12, examples of chemokines attracting both TC-cells and TH1-cells. 
Further, AMs are a source of growth factors, reactive oxygen species and also 
elastolytic enzymes similar to neutrophils, such as matrix metalloproteinases (MMPs). 
Altogether the macrophages, due to its versatility, have an essential role in COPD 
pathophysiology.  
Neutrophils are present in large numbers in the pulmonary circulation, lining the 
capillary bed, searching for pathogens or other pro-inflammatory signaling (37). 
Unlike the AMs they are normally not abundant in the lung parenchyma in a healthy 
lung, but their numbers can rapidly multiply in case of pathogen invasion or tissue 
damage. Like the AMs the neutrophils have phagocytic capabilities but are also known 
for their secretion of granules into infected tissue. These granules contain anti-
microbial molecules such as Myeloperoxidase (MPO), Neutrophil elastase (NSE), 
MMP8 and 9, but also other proteases or radical oxygen species. Such molecules have 
a potent anti-microbial effect, but they are also considered responsible for the 
breakdown of the alveoli, leading to development of emphysema, often denoted as a 
protease-antiprotease imbalance (38).  
Eosinophils are traditionally linked to the pathogenesis of asthma more than COPD, 
but as much as a third of COPD patients have elevated levels of eosinophils in sputum 
or blood, and the classification of these patients is still debated (39). Eosinophils have 
similar weaponry as the neutrophils, but eosinophils differ in ways of differentiation 
and activation which is addressed later, and they may also have a more complex 
relation to the adaptive immune system. Characteristic for eosinophilic COPD is the 
suppressive and clinically beneficial effect of corticosteroids in many patients, unlike 
in COPD patients with a predominant neutrophilic inflammation.  
Other cellular components of the innate immune system are NK-cells, innate lymphoid 
cells (ILC), mucosal associated T-cells (MAIT), all with roles less clearly defined in 
COPD. 
Although the innate immune system is more prominent in COPD pathophysiology, the 
role of the adaptive immune system has been highlighted the last decades. Cytotoxic 
T-cells (CD8+) are found in increased numbers in the lungs of COPD patients, 
especially is this seen together with increasing degree of emphysema and airway 
obstruction (40). Helper T-cells (CD4+) are less abundant than TC-cells but are also 
increased in COPD. Important TH1-cell cytokines are interferon gamma (IFN-γ), an 
activator of macrophages with antiviral properties, and IL-2, important for the 
differentiation of T-cells. The role of TH2-cells more evident in asthma than in COPD, 
and is addressed later. The more recently discovered TH17-cells, however, are likely to 
have an important role in COPD (41). TH17-cells attract and stimulate both 
macrophages and neutrophils, but also B-cells via IL-17 and IL-22 signaling. Lastly, 
B-cell lymphocytes, with their ability of antigen-specific antibody secretion are crucial 
elements in the defense against infection but may also have a role in auto-immune 
inflammation in a complex interaction with other cells and components of the immune 
system (42).  
 
Figure 1. Overview of central components of the immune response in the lungs. Cytokines: IL 
(interleukin), TNF-α (tumor necrosis factor), MCP-1 (monocyte chemoattraction protein), INF-γ 
(interferon). Growth factors: granulocyte-macrophage colony-stimulating factor (GM-CSF), 
transforming growth factor (TGF-ß), epithelial growth factor (EGF), vascular-endothelial growth 
factor (VEGF). Proteases/enzymes: myeloperoxidase (MPO), neutrophil elastase (NSE), different 
matrix metalloproteinases (MMPs). 
 
The innate immune system is the first line of defense and deals with the bulk of 
invading elements in the lungs, In COPD, several components of both the innate and 
adaptive immune system may be compromised 
Chronic bronchitis 
A common definition of chronic bronchitis is based on the presence of cough with 
phlegm for at least three months a year for two consecutive years (43). However, this 
definition is not consistently used in COPD research. Alternative definitions exist and 
may alter the composition of this group (44), whereas the GOLD strategy document 
does not use the term chronic bronchitis in its definitions or in its therapy 
recommendations (4). A problem with using a symptom based definition is its lack of 
specificity, since other diseases such as bronchiectasis or chronic infection provide 
similar symptoms. The pathophysiology behind chronic bronchitis is complex, as it 
includes most of the cells and tissue in the lungs in addition to several different 
mechanisms of immunity. The anatomical characteristics of chronic bronchitis consist 
of narrowing of the bronchial lumen due to several concurrent disease processes. Some 
use the term bronchitis to describe the hypersecretion seen in the larger bronchi, while 
the term small airway disease (SAD) or chronic obliterative bronchiolitis describes 
the obstruction of the smallest airways. Clinically it is difficult to differentiate between 
these two conditions, and whether it is purposeful to separate between them is unclear. 
Early stage bronchitis is characterized by hypertrophy of mucus secreting Goblet cells 
and smooth muscle cells which is considered at least partly reversible. In later stage 
disease, the number of Goblet cells increases, and there is also a reduction of the 
ciliated pseudostratified epithelium in favor of hyperplasia and/or metaplasia of 
squamous epithelium (45), both contributing to reduced mucus clearance. In the 
bronchial wall, the smooth muscle layer is thickened with an impaired ability of 
relaxation. There is also an increase in fibroblasts, and elastic fibers are replaced by 
stiffer collagen deposits. The total number of immune cells is increased, neutrophils 
and macrophages pass rapidly from the blood into the bronchial lumen, while the 
bronchial wall is dominated by T-lymphocytes (46).  
The cytokine pattern is corresponding to the cellular inflammatory response. Sputum 
samples display elevated levels of the proinflammatory IL-1, IL-6, IL-8 and TNF-α  
(30), in addition a range of different cytokines are involved to different degree (29). 
Growth factors may be released by epithelium, smooth muscle and macrophages upon 
tissue damage and inflammation, TGFβ, EGF and VEGF are likely involved in 
bronchial wall repair, but also in pathologic remodeling and cell apoptosis contributing 
to tissue destruction. It is also worth mentioning the intracellular messenger cyclic 
adenosine monophosphate (cAMP). This downstream messenger may promote 
relaxation of airway smooth muscle and thus bronchial dilatation. cAMP is degraded 
by phosfodiesterases (PDE), in the airways notably PDE4. The role of cAMP and 
PDE4 in COPD is not well described, but inhibition of PDE4 by roflumilast is 
established as a therapeutic option in COPD patients (47). 
An important characteristic of chronic bronchitis of COPD is the persistent 
inflammation seen in several patients after smoking cessation (48, 49). This is a large 
and complex topic involving heterogeneous disease mechanisms. Important factors 
likely includes memory T- and B-cells, altered transcription of proinflammatory genes, 
and possibly also changes of the bacterial microbiome (40, 50). 
Emphysema 
Unlike chronic bronchitis, emphysema is not defined based on symptoms, but on 
pathoanatomical changes in the distal airways. Emphysema is characterized with 
destruction of alveolar walls, replacing the alveoli with enlarged airspaces/bullae. A 
histologic diagnosis of emphysema is usually not available in clinical practice, 
whereas a plain chest x-ray is insensitive for early stage emphysema. The development 
of the high-resolution CT-scan (HRCT) has made both the diagnostics and grading of 
emphysema far more accessible in the clinic.  
The likely main mechanism behind this process is the earlier mentioned imbalance 
between anti-microbial proteases and the counter regulative anti-proteases (38). A 
main source of protease secretion is neutrophils and macrophages, releasing neutrophil 
elastase (NSE), different matrix metalloproteinases (MMPs) and a range of different 
other protease categories (51, 52). An important anti-protease is the α1-antitrypsin 
(A1AT), an inhibitor of NSE. Patients with genetically caused A1AT-deficiency have 
a higher risk of emphysema development. Other anti-proteases such as tissue inhibitors 
of metalloproteinases (TIMPs) are less explored in COPD, but are likely also involved 
in the pathophysiology of emphysema (38). A limitation of emphysema research is 
that emphysematic tissue in later stages is dominated by tissue destruction with a 
minimal volume and cell count left for sampling. 
 
Figure 2. Illustration of chronic bronchitis, with increased amount of inflammatory cells, smooth 
muscle contraction and fibrosis in the bronchial wall, combined with hypersecretion of mucus, all 
contributing to airway obstruction. Emphysema illustrated by destruction of alveolar membranes, 
leading to decreased alveolar surface, loss of capillaries, fibrous remodeling and loss of elastic recoil.   
(Copyright Shutterstock) 
Asthma/COPD overlap  
Asthma and COPD have several similarities regarding both symptoms as well as the 
objective recognition of airway obstruction. Early research on COPD proposed a 
common etiology and disease mechanism behind these two conditions, the so-called 
“Dutch hypothesis” (5). This theory has been extensively opposed, and it is today 
recognized that the epidemiology and the pathophysiology is mostly different for 
asthma and COPD (53). The immune response in COPD is dominated by 
macrophages, neutrophils and TH1 lymphocytes, whereas in asthma eosinophils, TH2 
lymphocytes and activated mast cells are more common. Similarly, inflammatory 
signaling in COPD is more dependent on IL-1, IL-8 and TNF-α , while in asthma, the 
TH2 cell signature cytokines IL-4, IL-5 and IL-13 are important (29). Further, asthma 
is considered a large/proximal airway disease, whereas COPD is more prominent in 
small airways, terminal bronchioles and alveoli. Also, structural changes related to 
elastin degrading, remodeling and development of fibrosis are typical for late stage 
COPD and not asthma (13).  
Nevertheless, in patients with severe asthma the picture is different. These patients 
often exhibit an immune cell and cytokine pattern with characteristics from both 
asthma and COPD. Similarly, COPD patients in the asthma-COPD overlap category 
may demonstrate eosinophilia and a Th2 cell related cytokine profile, possibly related 
to genetic factors/altered gene expression in some patients (54, 55). Other 
characteristics of ACOS are an increased response to corticosteroid treatment and 
elevated IgE levels compared to standard COPD (54, 56). 
 
Endovascular disease  
Although it is not regarded as a clinical phenotype of COPD, the presence of 
pulmonary vascular disease is of great importance in terms of symptoms and 
prognosis. The vasculature in the lungs of COPD patients may be affected due to 
several different disease processes promoting both anatomical and physiological 
changes. Possible consequences are pulmonary arterial hypertension (PAH) and right 
ventricular failure, which traditionally have been considered signs of end stage 
disease.  
The effects of cigarette smoking on vasculature in general are well known. Most 
attention has been given studies of the coronary and systemic circulation, but 
pulmonary arteries seem to be affected in a similar manner (57). Cigarette smoking is 
linked to an increased inflammatory response in the pulmonary endothelium, 
dominated by CD8+ T-cells (58). Pathophysiological changes includes thickening of 
the pulmonary endothelial wall and loss of caliber adaptation (59, 60), leading to 
impaired blood flow adjustment. Another smoking induced mechanism is the earlier 
mentioned protease-antiprotease imbalance related to emphysema. Lungs with 
significant emphysema expose a loss of pulmonary capillaries (61), as well as 
remodeling of the endothelium. Further adding to the disease process, the pulmonary 
endothelium is particularly prone to vasoconstriction due to hypoxia. In many patients, 
this may lead to a vicious cycle of increasing hypoxia, additional vasoconstriction and 
further arterial remodeling and stiffening. 
In sum, all these processes leads to an impaired ventilation/perfusion-ratio and 
development of PAH and consequent right ventricular failure in a share of COPD 
patients. The significance of PAH development is illustrated by several studies, 
describing associations between increasing PAH and a lower survival, increasing 
hypoxia and an increased exacerbation frequency, and where PAH is shown to have a 
higher predictive value than FEV1 (62-64). Consequently, PAH development may 
have a large impact on both symptoms and quality of life in affected COPD patients.  
The disease mechanisms behind PAH are complex and incompletely understood, and 
whether COPD related PAH should be considered a distinct disease in line with 
primary PAH is debated (65). It is now recognized that PAH may develop also in early 
disease, and not necessarily in proportion to the degree of airway obstruction (66). In 
this context, it may be relevant to compare the pathophysiology of COPD with that of 
general cardiovascular disorders. Conditions such as coronary disease, systemic 
hypertension and left ventricular failure are all conditions which occur more frequently 
in COPD patients (67, 68). Smoking is a common risk factor for all these conditions. 
Similarly, elevated levels of systemic inflammatory markers such as IL-6, TNF-α and 
CRP are found in patients with cardiovascular disease and PAH (69, 70) as well as in 
COPD, which is addressed later. Elevated levels of Troponin, BNP and markers of 
coagulation are other common observations in these conditions (71-73). Thus there are 
several indications on shared pathophysiological mechanisms between systemic and 
pulmonary circulation and COPD.  
COPD exacerbation and infection 
Acute exacerbation of COPD is a common disease characteristic, and is of great 
importance in terms of prognosis and quality of life (14, 16, 74, 75). AECOPD is 
usually a clinical diagnosis defined as an episode with worsening of symptoms, where 
severity assessment may be based on the increasing utilization of health care or on 
grading of symptoms. The concept “exacerbation” is very difficult to define exactly in 
pathophysiological terms. To further blur the picture, the differentiation between 
AECOPD and pneumonia may be unclear due to similarities both in symptoms as well 
as bacterial findings and inflammatory response (76). There is a multitude of potential 
triggers of an AECOPD, corresponding to a heterogeneous pathophysiology behind 
each episode. In a clinical context, an AECOPD can be classified as an infectious or a 
non-infectious episode. Bacterial and/or viral infection is the cause for a majority of 
cases, whereas non-infection exacerbation is a less defined group (77, 78).  
Bacterial infection has been regarded as the classical cause of symptom worsening of 
COPD, and isolation of bacterial strains by culture has been described in 50-60 % of 
AECOPDs (78-80). Streptococcus pneumoniae, Haemophilus influenza, Moraxella 
catarrhalis and Pseudomonas aeruginosa are frequently found isolates at AECOPD 
(79, 81). However, the distinction between stable COPD and AECOPD may be 
blurred. Pathogenic bacterial strains also may be present in non-exacerbated airways 
(82), and this has led to uncertainty regarding the causative role of bacteria in 
AECOPD, and also controversies concerning the necessity of antibiotic treatment (83). 
Using modern molecular and immunologic techniques, it has been demonstrated that 
AECOPDs may be associated with acquisition of new bacterial strains or subtypes of 
the microbes mentioned above (84). However, in many cases of AECOPD the 
microbiome seems unchanged from the stable state. The concept of respiratory 
dysbiosis has been proposed as an important factor of the clinically infectious 
AECOPDs, comprising a dysregulated host immune response leading to an altered 
microbial growth and sustained inflammation and clinical symptoms (85). 
Historically, viral infection was regarded as less important factor in AECOPD. Due to 
the development of PCR-techniques it is today recognized that viral infection may be a 
contributing cause of exacerbation in 40-60 % of cases, where rhinovirus, influenza 
viruses, respiratory syncytial virus and coronaviruses (other than Covid19/SARS) are 
most frequently found (86, 87). Viruses may also be found in the airways of stable 
state COPD (88), but it is more unclear whether this is an element of a persistent 
virome of the airways, or if they simply represent transient sub-clinical infections. In 
the case of rhinovirus, experimental studies indicate a temporal relationship between 
virus-induction and onset of AECOPD (89), and a causal mechanism seems more 
evident than in the case of bacteria.  
The picture becomes even more complicated since many AECOPDs display an 
increase in both viruses and bacteria. In such cases, viruses are often detected prior to 
an increase of bacterial load. (90). Further, there are indications that viral infection 
may hamper the effects of antimicrobial peptides, thus contributing to bacterial growth 
(91). Dual infection is associated with a higher bacterial load, decline in lung function 
and longer exacerbation duration (90-92). 
The inflammatory response in bacterial AECOPD is similar to that of pneumonia. 
Sputum and bronchial samplings display an increase in airway neutrophils as well as 
the neutrophil-related cytokines IL-8 and TNF-α, NSE (93), and also IL-1β, IL-6 and 
MIP-1 (94). Neutrophils, NSE and IL-8 are also increased at viral AECOPD, whereas 
eosinophils (92), IP10 and CCL5/RANTES seem more related to viruses (78). IFN is 
another important factor in the immune response against viral infection. In COPD 
some studies show that IFN secretion is lower in COPD patients than in non-COPD 
controls, indicating an impaired antiviral immunity in COPD (91). 
Non-infectious exacerbation is a heterogeneous category. In many cases the patient 
can identify a trigger of the exacerbation, such as specific allergens or air pollutants. 
Increased urban air pollution is associated with both decline in lung function and a 
higher AECOPD rate (95, 96). Similarly, COPD patients with characteristics of allergy 
have an increased risk of exacerbations (97). Allergen exposure as a trigger of 
exacerbations is a central disease characteristic of asthma, and similar disease 
mechanisms may be responsible for the high AECOPD rate seen in ACOS-patients 
(55).  
The number of chemical substances with a potential to harm the airways seems 
indefinite. Both organic and inorganic substances, often acting in synergy with 
physical factors such as temperature, wind or moisture, may trigger a range of immune 
responses in the lungs. Air pollutants such as NO2, SO2 or O3 may directly damage 
lung tissue by the formation of reactive oxygen species (ROS) (98), but in most cases 
tissue damage is related to inappropriate or excessive immune responses to the 
different allergens and pollutants. The pathophysiological mechanisms are 
heterogeneous, and the impact of different types of allergy makes the picture highly 
complex. Due to this, it is difficult to identify a common inflammatory pathway of 
non-infectious AECOPD.  
The role of eosinophils at AECOPD is increasingly receiving attention. Its role is not 
as obvious as in asthma, but it has emerged as a clinical useful marker at AECOPD 
(99). The role of eosinophilic inflammation in non-infectious exacerbations is yet 
unclear, and it does not appear to be a specific marker for this category as a whole. 
However, it is recognized that exacerbations characterized with increased sputum 
eosinophil cell count differs substantially from those related to viruses and bacteria 
both in symptoms and in response to corticosteroids (78).  
In some cases no particular inflammatory pathways seems to be activated, denoted as 
pauci-inflammatory exacerbations. Parameters of both local and systemic 
inflammation are to a lesser degree elevated. Some may argue that worsening of 
symptoms without a subsequent elevation of local or systemic inflammatory 
parameters should not be defined as an AECOPD (100), and the physician should 
investigate for an alternative diagnosis. On the other hand, compared with AECOPDs 
with an obvious trigger, the pauci-inflammatory exacerbations are more frequent in 
patients with a lower FEV1, a faster FEV1 decline, a higher pack-year number smoked 
and a higher AECOPD rate (78), all central characteristics of COPD. 
Due to similarities both in symptoms and risk factors, cardiovascular disease is an 
important AECOPD differential diagnosis in this context. Elevated serum troponin and 
ischemic ECG changes are both common observations at AECOPD (101, 102). It is 
also recognized that AECOPD is a risk factor of myocardial infarction (103), and that 
elevated serum troponin at AECOPD is a risk factor for all-cause mortality as well as 
an indicator of ischemic heart disease requiring revascularization (104, 105). 
Similarly, venous thromboembolism, most notably pulmonary embolism, is a common 
complication to AECOPD, especially in non-infectious events (106, 107).  
In general, hypercoagulability is a common observation in AECOPD as well as in 
several inflammatory disorders (108-110). There is a complex interaction between 
inflammation and coagulation with interlinked pathways of activation (111). It is not 
unlikely that some cases of non-infectious AECOPD actually are misdiagnosed events 
of ischemic heart disease or pulmonary embolism. Nevertheless, in other cases the 
picture is more unclear. Symptoms, biomarkers and diagnostic imaging often seem to 
indicate concurrent lung and cardiovascular pathology, and it may be impossible and 
perhaps unwanted to differentiate between the different systems.  
Systemic inflammation in COPD 
The immune system is constantly aware of any traumatic, toxic or infectious injury, 
and an insufficient or passive reaction to any threat can be fatal. On the other hand, an 
active immune system can also be harmful, as inflammation itself is implicated in the 
pathogenesis in numerous disorders (112). Although the term “systemic inflammation” 
is often referred to in COPD research, neither words of the term are well defined. The 
differentiation between low-grade inflammation and an alert immune system can be 
difficult in the absence of clinical symptom, and is often defined in research as 
increased levels of one or more inflammatory biomarkers.  
The term systemic can be defined as the opposite of localized, thus potentially 
involving all organ systems in the human body. Any “systemic” analysis or 
measurement, however, reflects in most cases blood or plasma/serum-sampling from 
the systemic circulation. An important question is to which degree systemic 
inflammation in COPD is representative of the inflammatory process in the lungs. A 
review by Sinden et al supports the concept of inflammation “overspill” from the lungs 
to the systemic circulation (113),  but there is not necessarily a proportionate 
“overspill” of all immune system components. 
Systemic inflammation was early recognized as an inflammatory characteristic in 
atherosclerosis, a frequent co-morbidity in COPD (114). In addition, diabetes, 
cachexia, osteoporosis, conditions often seen in COPD patients, have all been linked to 
increased systemic inflammation, thus it has been rational to also investigate this 
picture in also in COPD. 
 Biomarkers 
The US National Institutes of Health defines a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” (115). 
According to this definition any measureable parameter can be a biomarker in COPD, 
including clinical characteristics and lung function measurements, where FEV1 is an 
example of a frequently used biomarker. In medical science, however, research on 
biomarkers is frequently related to measurements or quantification of cells or 
molecules in tissue or blood. In 2009, Sin and Vestbo proposed criteria for useful 
biomarkers in COPD (116). First, the biomarker should have a biological plausible 
role in the pathophysiology of COPD. Second, the biomarker should be independently 
and consistently be associated with both COPD as well as hard clinical outcome like 
hospitalization or mortality. Third, and possibly most difficult to obtain, the biomarker 
should be modifiable by intervention, and a change in biomarker status should result in 
change of important clinical outcome. In addition to these criteria, clinical useful 
biomarkers in COPD should have the ability to aid in the diagnosis of COPD and 
AECOPD and its phenotypes.  
A common way of assessing clinical biomarkers is by the use of ROC (Receiver 
Operating Characteristic)-curves and AUC-values. Whereas good clinical biomarkers 
have AUC-values between 0.9 and 1.0, the best COPD biomarkers have AUC-values 
around 0.7, thus with limited clinical value (117).  
Diagnostic biomarkers of COPD 
A large number of potential biomarkers have been evaluated in COPD research. Due 
to its central role in COPD pathogenesis, components of the immune system have been 
of particular interest, and much emphasis has been put in the search of the most 
relevant markers. Many of the traditional markers of inflammation are elevated in 
patients with airway obstruction due to COPD. C-Reactive Protein (CRP) is a widely 
used clinical biomarker of inflammation (118). Several studies report elevated CRP at 
stable COPD, and there is an inverse relationship between increasing CRP and 
declining FEV1 (119-121). Further, increased CRP levels are associated with obesity, 
increasing dyspnea and functional impairment.  Although CRP seems to have an 
independent association with airway obstruction, its role in COPD pathogenesis is 
unclear. CRP is produced in the liver in response to several inflammatory cytokines 
and has a role in complement activation (118). CRP is not considered an upstream 
initiator of inflammation and it is not specific for lung pathology. Thus, despite being a 
sensitive biomarker in COPD, its lack of specificity implies a limited value in COPD 
diagnostics. TNF-α is mentioned several times as a central biomarker in COPD, but 
also for several different other conditions. TNF-α is found to be elevated in plasma and 
higher levels are also associated with a lower FEV1 (122). Similarly IL-1, IL-6 and IL-
8 may be regarded as general biomarkers of COPD. 
The mentioned markers are not specific for lung inflammation, which obviously is a 
shortcoming in the search of the ideal diagnostic biomarker. Surfactant protein D (SP-
D) is a lung specific protein with possible anti-inflammatory function, and where 
serum levels are significantly elevated in COPD patients (123, 124). Another lung 
specific protein is club cell secretary protein 16 (CC16, formerly known as Clara cell 
protein 16), which is secreted from Clara cells in the bronchioles. Serum CC16 is 
significantly reduced in COPD patients, which may be related to epithelial damage or 
dysfunction (125). Endocan, or endothelial cell specific molecule-1, is another marker 
of pulmonary epithelial injury, where elevated serum levels are found in COPD, but 
also other lung conditions (126). Common for all these markers, although specific, 
they are not yet clinically useful due to a too low sensitivity. 
Diagnostic biomarkers of AECOPD 
The identification of an acute exacerbation of COPD is not always straightforward, 
since acute dyspnea may represent several different diagnoses requiring urgent 
treatment. If comparing COPD and coronary atherosclerosis, AECOPD may be the 
equivalent to myocardial infarction. But where the cardiologist may rely on 
measurement of serum Troponin as a specific biomarker of myocardial damage with 
AUC-value above 0.9, no similar biomarker is available as a diagnostic marker of 
AECOPD. CRP is a widely measured parameter in suspected AECOPD. In a 
systematic review of biomarkers by Chen in 2016, 26 of 28 AECOPD biomarker 
studies report elevated levels of CRP at AECOPD (127). CRP is readily available as a 
frequently used clinical marker of inflammation, but correspondingly, its specificity is 
lacking.  Similarly, leucocyte cell count, and especially neutrophils, is frequently 
elevated at AECOPD, whereas lymphocytes are not seen to rise at a similar degree.  
The Neutrophil/Lymphocyte Ratio (NLR) is proposed as a sensitive marker of 
AECOPD, and may also be considered as a marker of bacterial infection (128, 129). 
TNF-α is described to be elevated at COPD exacerbation, which is expected due to its 
role. TNF-α has also been given much attention as a possible target of medical 
treatment, but with negative results (130).  
In 2006, Hurst et al examined 36 different inflammatory biomarkers both at stable 
COPD and at AECOPD (131). CRP and IL-6 were the two markers associated with the 
largest increase at AECOPD, but none of the examined inflammatory markers had the 
statistical ability to perform as an independent AECOPD biomarker. Bafadhel et al 
performed a cluster analysis of several sputum and serum/blood biomarkers at 
AECOPD in 145 patients (78). CRP and IL-1 were identified as markers of bacterial 
exacerbation, CXCL10 (IP10) was related to viral infection, whereas eosinophil count 
was a third significant marker. Again, no marker had a ROC-value above 0.7 in 
determining an AECOPD.  
Biomarkers as predictors of future AECOPD 
Parallel with research on the multifaceted mechanisms of AECOPD, several studies 
have also attempted to identify risk factors for encountering future AECOPD, thus 
finding the characteristics for the “frequent exacerbator” phenotype. In this research, 
the most apparent predictors of future AECOPD have been clinical observations, and 
one of the best predictors of exacerbations is simply a history of previous 
exacerbations (132). Increasing disease severity, measured by the degree of airway 
obstruction (131, 132), is associated with increase future AECOPD. Similarly, 
indications of pulmonary hypertension, measured by right heart catheterization (63), 
but also by a CT measurement of the pulmonary artery/aorta (PA/A) ratio >1, (64) are 
good predictors of future AECOPD. However, this information is more difficult to 
apprehend in a clinical setting. Measurement of plasma BNP is a more accessible, but 
also non-specific marker where high levels indicate a shorter time to AECOPD (133).  
Other clinical parameters associated with future AECOPD include gastroesophageal 
reflux, depression, and/or a low measured quality of life index (134-136). In addition, 
the presence of the traditional phenotypes chronic bronchitis and emphysema are both 
related with a higher AECOPD frequency (137-139). 
Many inflammatory biomarkers, especially those involved in present AECOPD, have 
also been evaluated as predictors of future AECOPD. Plasma fibrinogen was described 
as one of the first predictors of AECOPD, but also levels of WBC, CRP, IL-6, IL-8 
and TNF-α are indirectly associated with future AECOPD (15, 20, 21, 140). Among 
the differential counts of WBC, eosinophils may be associated with a higher AECOPD 
count, but this an uncertain finding since many studies reporting significant findings 
do not properly exclude patients with asthma or ACOS (141). Neutrophils and 
leucocytes are also evaluated independently as predictive biomarkers with uncertain 
findings, whereas the NLR may be more sensitive (128). Other described predictors of 
future AECOPD are serum uric acid and the lung specific SPD (142, 143), whereas 
Fetuin-A, a liver-synthesized inhibitor of systemic inflammation has an inverse 
relationship with AECOPD frequency (144). In addition to blood sampling, increased 
levels of sputum inflammatory markers are also shown to be related to the AECOPD 
frequency (145).  
Biomarkers as predictors of decline in FEV1 
Airway obstruction has always been the main characteristic in COPD, and a major 
research question has been why some patients have a faster decline in lung function 
than others. The initial theory by Fletcher et al proposing an ever accelerating decline 
of FEV1 as a common attribute of all COPD has been questioned the last decades, and 
today it seems obvious that the decline of FEV1 may vary significantly between 
patients or phenotypes (146, 147). Several biomarkers associated with a low FEV1 
have also been evaluated as predictors for a faster lung function decline in longitudinal 
studies. A study by Donaldson et al (2005) found an association between elevated 
sputum levels of IL-6, IL-8, neutrophils and eosinophils and a faster decline in FEV1 
(22). Similarly and in the same study, plasma fibrinogen was associated with a faster 
FEV1 decline, thus in a relative small number (n=147). Higashimoto et al (2009) 
described an association between both serum CRP, matrix metalloproteinase-9 (MMP-
9) and plasma fibrinogen and a faster decline in FEV1 (148), whereas in the larger 
Eclipse study, fibrinogen was only associated with baseline FEV1, and not longitudinal 
change (146). Also in the Eclipse study, IL-6, IL-8, CRP, TNF-α  and SPD were 
evaluated regarding the same outcome with negative results, however baseline levels 
of club cell secretory protein 16 (CC-16) was associated with a significant change in 
FEV1; 4 ml /SD increase (p=0.04), thus low CC-16 were associated with a faster 
decline, hence its potential protective role (149). Pro-surfactant protein B (PSFTPB) is 
another lung specific marker. Leung described an association between high levels of 
PSFTPB and a faster FEV1 decline (150).  
A drawback of several of these proposed biomarkers is the lack of validation in other 
studies. The OLIN-study evaluated serum levels of the protease MMP-9 and the 
antiprotease Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) in a large cohort of 
COPD patients, and found no association with decline in FEV1 over time (151). In the 
more recent SUMMIT-trial, the biomarkers CRP, SPD, soluble receptor of activated 
glycogen end-products (s-RAGE), and CC-16 were evaluated in a subpopulation with 
moderate COPD, no associations between any biomarker and decline in FEV1 were 
found (152). 
Biomarkers for increased mortality in COPD 
COPD is a major cause of death worldwide. Exacerbations of COPD and declining 
FEV1 are already mentioned as major factors associated with a higher mortality, and 
several of the biomarkers related to frequent AECOPDs and a faster drop in FEV1 have 
also been evaluated in this context. CRP and fibrinogen are both examples of 
biomarkers associated with a higher mortality in COPD (152-154). A study by Agusti 
et al investigated CRP, WBC, IL-6, IL-8 and TNF-α, and found a higher mortality in 
patients with persistent high levels of two or more markers. The NLR is another 
marker associated with higher mortality (155).  
The connection between COPD and cardiovascular disease has already been 
mentioned, and patients with these two conditions have a significantly worse prognosis 
compared with those with single disease (156). Even though it is specific for cardiac 
muscle injury, elevated levels of Troponin has emerged as an independent predictor 
for increased mortality, this is particularly obvious when measuring Troponin at 
AECOPD (71), but also when evaluating Troponin at stable COPD (157). B-type 
natriuretic peptides (BNP) are another class of cardiovascular biomarkers. They are 
frequently elevated in COPD, but their role as predictive biomarker is more uncertain 
as different studies report diverging results (72). 
Closely related to cardiovascular disease is the coagulation system. In addition to the 
already mentioned fibrinogen, elevated D-dimer at AECOPD is linked to a higher 
mortality (158). We have also demonstrated a similar association when measuring D-
dimer in stable COPD as a part of the BCCS (159). 
Biomarkers in clinical use 
In summary, clinically useful inflammatory biomarkers in COPD are sparse. Perhaps 
the most obvious shortcoming is the lack of biomarkers specific for lung damage or 
COPD pathophysiology. In clinical practice, CRP and leukocyte counts are widely 
used biomarkers, but then as markers of infection not specific for COPD. The 
eosinophil count is established as an indicator of expected corticosteroid treatment 
effect, but is unspecific and relevant in only a minority of COPD patients. There are no 
inflammatory biomarkers which can significantly aid the clinician when diagnosing 
COPD or AECOPD.  
Inflammatory biomarkers as therapeutic targets in airway inflammation are mostly 
linked to the type 2 immune response. Apart from eosinophils, especially IL-5, but also 
IL-4 and IL-13 are recognized as treatment targets in asthma (160, 161), but not ACOS 
or COPD. Attempts have been made to target other cytokines central in COPD 
inflammatory pathways such as TNF-α, IL-1, IL-8 and IL17, but without success (130, 
162-165).  
There has been a massive interest on COPD biomarker research the last decades. 
Hundreds of cytokines and other components of COPD pathophysiology have been 
identified and described according to the different characteristics and outcome of 
COPD. None of these are close to fulfill the requirements of the ideal COPD 
biomarker (116) due to the limitations mentioned. There is a great need for better 
biomarkers in COPD in order to better understand a multifaceted pathophysiology, to 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1. Summary of selected 
studies reporting associations 
between inflammatory biomarkers 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1. cont. 
OBJECTIVES 
 
1 Identify inflammatory biomarkers for the diagnosis of COPD and COPD 
exacerbation using cross-sectional data, and evaluate these biomarkers 
according to important COPD characteristics. 
 
2 Identify inflammatory biomarkers as predictors for longitudinal outcome in 
COPD using longitudinal data: 
a. As predictors for future exacerbations 
b. As predictors for change in lung function 
c. As predictors for mortality and cause of death 
d. As predictors for lung cancer 
  
MATERIALS AND METHODS 
 
Study design and study population 
The studies in this thesis are based on data from the Bergen COPD Cohort Study 
(BCCS) and the Bergen COPD Exacerbation Study (BCES), with additional data from 
the Norwegian Cancer registry and the Norwegian Cause of Death Registry. The 
BCCS consisted of 433 COPD patients and 325 healthy controls. Of the 433 COPD 
patients, 356 patients living in the vicinity of Haukeland University Hospital were also 
included in the BCES, which was conducted in parallel with the BCCS. Both studies 
were observation studies without specific intervention. Inclusion started in February 
2006 and was closed December 2009.  
 
Figure 3. Number of patients and controls invited, included and longitudinally assessed. Out of 433 
COPD patients, 8 patients died, 10 withdrew consent and 12 patients used oral corticosteroids, thus 30 
patients were. Number of invited controls is an estimate. Never-smoking controls were only examined 
at baseline. 
 
The Bergen COPD Cohort Study (BCCS) 
The BCCS was designed as a case-control cohort study with intentional follow-up 
each 6 months for 3 years. The COPD patients were recruited from several sources; 
two prior regional studies on lung patients; the Hordaland County Study (166, 167) 
and the GenKOLS Study (168), local private practices in pulmonary medicine, and 
outpatient clinics from regional hospitals. Controls were also recruited from the two 
studies mentioned above, both current and former smokers as well as never smokers. 
A total of 928 COPD patients were invited to the study, of these 433 patients were 
included. 12 patients used oral corticosteroids at the time of inclusion and were 
excluded from follow-up after the baseline visit. 668 subjects were invited as controls, 
325 were included in the study, of these were 46 never smokers not included in the 
longitudinal follow-up.  
Inclusion criteria for COPD patients and controls: 
 Women and men, age 40-80 years.  
 Approved, written consent to study participation before study inclusion. 
 Able to comply with the requirements of the study protocol, and available for 
study follow-up during the three years of the study. 
Inclusion criteria for COPD patients only: 
 Baseline post-bronchodilatation FEV1/FVC ≤ 70 % and FEV1 < 80 % of 
predicted. 
 Smoker or ex-smoker with a minimum exposure of 10 packyears. 
Inclusion criteria for controls only: 
 Baseline post-bronchodilatation FEV1/FVC > 70 % and FEV1 > 85 % of 
predicted. 
 Smoker or ex-smoker with a minimum exposure of 10 packyears or never 
smoker. 
Exclusion criteria: 
 Known respiratory disease (other than COPD for cases), including lung cancer, 
sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis or prior lung surgery 
including lung reduction surgery or lung transplantation. 
 Known significant inflammatory disorder, including rheumatoid arthritis or 
systemic lupus erythematosus. 
 Known severe alpha-1-antitrypsin deficiency (Pi- SZ or ZZ alleles). 
 Known severe and/or uncontrolled disease including severe psychological 
conditions that might disrupt study attendance or affect the safety of the study 
subjects. 
 Participation in randomized controlled intervention study involving medications 
or exposure to radiation. 
 Known alcohol or drug abuse. 
 Blood transfusion within the last 4 weeks. 
 COPD exacerbation (cases only) requiring treatment with oral corticosteroids or 
antibiotics, or hospitalization, within the last 4 weeks before study baseline. 
Any course with antibiotics of corticosteroids must be finished at least 2 weeks 
before study baseline (patients could be re-screened for inclusion later). 
 Unable to walk. 
The BCCS was based on an extensive data collection at study inclusion, combined 
with longitudinal measurements of several important COPD characteristics each 6 
months for 3 years. The most important aim of the BCCS was to identify and evaluate 
baseline parameters and COPD characteristics as predictors for different longitudinal 
outcome like change in lung function, Quality of Life, mortality, respiratory failure, 
6MWT change of body composition and more, not all relevant for this thesis, but 
published by other members of our research group. 
 
Figure4. Number of COPD patients and controls attending at study visits. Intervals between each study 
visit were 6 months, except Visit 2 which took place in a subgroup of the patients after 3 months.  
 
The Bergen COPD Exacerbation Study (BCES) 
The inclusion and exclusion criteria were the same for both the BCCS and the BCES, 
with the only difference that the BCES only included 356 COPD patients living in the 
vicinity in the city of Bergen, serviced by Haukeland University Hospital. All patients 
were given written and verbal information of the study, and all patients gave a written 
consent for study participation. The BCES and the BCCS were conducted in parallel 
with concurrent dates of study initiation. Similarly, the aims of the BCES were to 
identify and evaluate predictors for COPD exacerbations, but also to investigate 
exacerbations with bronchial and systemic sampling, assessing both biochemistry and 
microbiology. Thus, the BCES comprised the unscheduled examinations at COPD 
exacerbation, whereas the successive registration of exacerbation frequency was a part 
of the BCCS. 
Data collection 
Both patients and controls underwent examinations and measurements at inclusion, but 
also at the study visits. At baseline, all study subjects were examined and interviewed 
by study physicians. A thorough medical history was obtained, including medication 
use, clinical symptoms, comorbidities, socioeconomic status, family history, 
respiratory symptoms including exacerbation and smoking history. In addition, lung 
function, HRCT, 6-minute walking test, bioelectrical impedance measurement for 
body composition, blood sampling, sputum sampling and nasopharyngeal aspiration 
were performed. All patients and a selection of the controls were also intended 
followed up during study visits each 6 months, for a total of 7 half-yearly visits 
including baseline during the three years of the study. Patients were examined and 
interviewed by a study physician regarding symptoms, exacerbations or comorbidities 
since last visit and change in medication. Lung function was performed at all visits, 
bioelectrical impedance measurements yearly. Additionally, blood sampling or other 
microbiological sampling not related to this thesis. 
Medications and Comorbidities 
All medications and their doses were recorded at each visit, including medication use 
at exacerbation. Inhalation medications were recorded according to brand name as well 
as generic name. For the statistical analyses, the class of inhalation drug was used, thus 
not separating between the different LABAs or ICSs. There was only one LAMA on 
the market at the time of the study, tiotropium. 
All relevant comorbidities were recorded. In addition, the Charlson Comorbidity Score 
(CCS) was calculated for each study subject (169). The different comorbidities of 
clinical significance were designated a score of 1, 2, 3 or 6 based on their severity, and 
then summed up, not including age as a component. All COPD patients had a CCS of 
at least 1 due to their main disease. For the analyses in our study, CCS was categorized 
in 0, 1, 2, 3 or 4+.  
Symptoms and quality of life 
Information on symptoms was registered by different self –complete questionnaires at 
baseline and at later study visits. All questionnaires were checked for completion after 
having been filled in at the study center, by our study technicians, and participants 
given a chance to correct if they had forgotten a question for instance. Degree of 
breathlessness was assessed with the Medical Research Council (MRC) dyspnea scale 
(170), scoring dyspnea from 1-5. In addition, the St. George’s Respiratory 
Questionnaire (SGRQ) (171) was used as a measure of respiratory symptoms and 
quality of life. Clinically relevant symptoms such as coughing and cough with phlegm 
were recorded as dichotomous variables. The term chronic cough was defined as 
having cough for three months or more altogether during a year. 
COPD Exacerbations 
In both the BCCS and the BCES, an acute exacerbation of COPD (AECOPD) was 
defined as an event with acute worsening of respiratory symptoms with duration of 
more than 2 days, requiring treatment with antibiotics and/or oral corticosteroids, or 
hospitalization. This was a health care utilization definition, but in addition, in the 
BCES, additional symptoms were registered for the evaluation of exacerbations 
(Appendix C). Similarly, the severity of exacerbations was graded according to health 
care utilization; where a mild exacerbation did not require any change in treatment 
beyond short acting bronchodilators, a moderate exacerbation required treatment with 
antibiotics or oral corticosteroids, and any exacerbation requiring hospital admission 
was defined as severe. As an alternative, acute exacerbations in the BCES were also 
graded according to symptoms on a scale of 1-5 (Appendix C). 
The exacerbation frequency the year before study inclusion was based on self-report. 
After study start, all subsequent exacerbations were registered at each study visit; in 
addition, the patients were contacted by telephone each month where they were asked 
on symptoms regarding AECOPD. Patients included in the BCES were given a 
laminated card with contact information to study personnel and information on 
AECOPD criteria. The BCES telephone was operated 12 hours each day all week. 
Patients fulfilling AECOPD criteria were either hospitalized, or they were scheduled a 
visit at the outpatient at the Department of Thoracic Medicine at Haukeland University 
Hospital the same or the next working day. If the study physician agreed on the 
AECOPD criteria, clinical information was collected, and in addition blood sampling 
and sputum sampling was performed. The patients were all treated according to 
standard medical care for their AECOPD.  
Spirometry 
Spirometry was performed on all patients and controls in all regular visits. Spirometry 
was performed with a Viasys-Jaeger Masterscope CT system (Viasys, Höchberg, 
Germany) before and after inhalation with 0.4 mg Salbutamol by a metered-dose 
inhaler (Ventoline, GSK) with the use of an inhalation spacer. All subjects were 
supervised by trained personnel, and procedures were standardized in accordance with 
the European Respiratory Society (ERS)/American Thoracic Society (ATS) protocols 
(172). Spirometry was acceptable if three tests were reproducible and technically 
adequate, up to 12 attempts was allowed if the subject was able to perform. The test-
equipment was calibrated using a 3.0-liter syringe before each subject.  
The highest measured values for post-bronchodilatation FEV1 and FVC were used in 
the analyses. Predicted values in % were calculated with the use of reference values 
from a general Norwegian population sample (173). 
Body Impedance Measurements 
In addition to body weight (kg) and height (m), all subjects went through bioelectrical 
impedance measurements for calculation of fat mass and fat free mass. Four subjects 
had a pacemaker, and the measurement was not performed. The Bodystat 1500 (made 
by Bodystat Ltd, Isle of Man, UK) is a benign version of the electric chair, using low 
voltage/current to measure impedance of body tissue. The test was performed in 
supine position, extremities not touching and after resting for at least 50 seconds. Two 
pairs of electrodes were placed on the right arm and right foot before analysis was 
performed. Patients were asked to not drink water 4-5 hours before testing, not to 
smoke or perform physical activity within 12 hours. Bioelectrical impedance 
measurement was performed at study inclusion, but also at subsequent visits each 12 
months for three years.  
The Bodystat measurements give information on several parameters regarding body 
metabolism. For our study, fat mass (kg) and thus lean body mass/fat free mass was 
estimated. The variables Body Mass Index (BMI), Fat Mass Index (FMI) and Fat Free 
Mass Index (FFMI) were defined as Body Mass (kg)/ squared body height (m), Fat 
Mass (kg)/squared body height (m) and Fat Free Mass (kg)/ squared body height (m), 
respectively. 
The Bodystat impedance device was calibrated each week using a Bodystat calibrator, 
where impedance readings were kept within levels prespecified by the manufacturer. 
In addition, a reliability study was performed for quality control of the impedance 
measurer. FMI and FFMI were measured 10 times within one hour in 10 patients and 
10 healthy volunteers. The variance for FFMI was 0.47 and 0.54, and for FMI 1.14 and 
2.09, in patients and controls respectively (174). 
For the statistical analyses, the composite variable Body Composition was created, 
categorizing patients into three categories: normal, obesity and cachexia. Obesity was 
defined as having a FMI above 13.5 in women and 9.3 in men, whereas cachexia was 
defined as having a FFMI below 14.0 in women and 17.0 in men, according to the 
upper and lower 95 % confidence limit in a normal population (175). 
Radiology 
HRCT scans were performed on 384 COPD patients soon after inclusion. The CT 
scans of the thorax were performed using a GE Healthcare multidetector-row CT 
scanner. Scans were performed with patients in a supine position with full inspiration, 
without intravenous contrast. Exposure settings were 40 mAs and 120 kVp, images 
were reconstructed with 1.25 mm continuous slices. CT scans were analyzed with 
Pulmonary Workstation 2.0 software (VIDA Diagnostics, Iowa City, IA, USA). 
Emphysema was defined using a threshold technique, measuring the percent of lung 
parenchyma with an x-ray attenuation below -950 Hounsfield units (176, 177). The 
degree of emphysema was presented as % of low attenuation areas (% LAA), whereas 
the cut-off value for a dichotomized variable of emphysema was set at LAA > 10 %. 
Laboratory analysis 
Peripheral venous blood was drawn for both plasma and serum samples at all visits. 
Plasma was collected by sampling venous blood into pyrogen-free EDTA collection 
tubes and centrifuged within 30 minutes at 2150 g for 15 minutes at 4
o
C. The serum 
samples were coagulated at room temperature for 30-45 minutes, followed by 
centrifugation at 2500 x g for 15 minutes at 4
o
C. The plasma and serum samples were 
aliquoted in 1 mL aliquots and stored in -80
o
C ultra-freezers until measurements, thus 
the samples were unthawed up until biomarker measurements.  
The biomarkers were analyzed at different occasions after sampling:  
NGAL, OPG, CXCL16, TNF-R1, MCP4, NAP2, MBL were measured in 2007 and 
2008 by enzyme-linked immunosorbent assays (EIAs) (R&D Systems, Inc, 
Minneapolis, MN, USA) by our partners in Oslo University Hospital (Aukrust & 
Ueland et al, Rikshospitalet). The intra- and inter-assay coefficients of variation were 
<11% for all parameters. Hemoglobin, WBC, Granulocytes, TPC, s-Ferritin, s-
Creatinine and CRP were measured in 2007 and 2008 by routine laboratory methods 
(Modular PP, Roche Diagnostics, Basel, Switzerland). Plasma levels of TNF-α, IL-1, 
IL-6, were measured in 2009 by our partners at Mie University, Japan (Gabazza et al), 
using EIA kits (BD Biosciences Pharmingen, San Diego, CA). MIF, ALCAM, CD163, 
was measured in serum by EIAs provided from (R&D System Inc, Minneapolis, MN) 
in 2012, again by our partners in Oslo. The intra-assay and inter-assay coefficient of 
variations were <10% for all parameters.  
Plasma levels of IL-1β, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, 
IL-13, IL-15, IL-17, Eotaxin, Basic FGF, G-SF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-
1α, PDGF-BB, MIP-1β and VEGF were measured by Aveo Oncology in 2014 using a 
magnetic bead multiplex assay (Bio-Plex Pro, Bio-rad laboratories, Inc.). Plasma 
levels of GDF-15 and Activin A were measured by Aveo Oncology in 2014 using 
enzyme-linked immunosorbent assays (Quantikine, R&D Systems, Inc). All samples 
were measured in duplicates, and only accepted if intra-assay variance was less than 
10%.  
Statistical analysis 
The statistical analysis of our study was based on both cross-sectional baseline data at 
inclusion, and on longitudinal data from the three year follow-up on exacerbations and 
lung function, and nine years follow-up on cancer diagnosis and mortality. The 
baseline data was comprehensive for both COPD patients and smoking/non-smoking 
controls, whereas data from the longitudinal follow-up was relevant only for COPD 
patients, with the exception of the lung cancer data in paper 4.  
Computer software 
The statistical analyses were performed in Stata/SE versions 12.1, 13.1 and 14.1 
(StataCorp LLC, College Station, Texas, USA). Figures presented in the papers were 
made in Stata, in GraphPad Prism 7 (GraphPad Software, San Diego, California, USA) 
and in R version 3.3.2, qgraph package (R Foundation for Statistical Computing, 
Vienna Austria). 
Descriptive analyses 
Baseline data from both patients and controls consisted of dichotomous, multi-
categorical and continuous variables. For the description of the study populations, 
categorical variables were presented in numbers and percentages, continuous variables 
with normally distributed data were presented as mean and standard deviation (SD) 
values, whereas continuous non-normally distributed data were presented as median 
and inter quartile range (IQR) values. For the baseline comparison between groups, χ-
square test was used for categorical variables, t-test for normally distributed 
categorical variables, Wilcoxon rank-sum test for continuous variables in two 
categories, and Kruskal Wallis test for continuous variables in three or more 
categories. For comparison of paired data, a Wilcoxon equality test on matched data 
was performed. 
Regression models in paper 1:  
The main outcome variable was the yearly exacerbation count for each patient, 
including only moderate and severe exacerbations. The exacerbation count was 
analyzed according to a negative binomial distribution with repeated measurements for 
each year. A random-effects negative binomial model was fitted using the xtnbreg-
command in Stata. The effect estimates of each variable were reported as Incidence 
Rate Ratios (IRR) with a corresponding 95 % confidence interval. Several clinical 
variables as well as inflammatory markers, all with potential associations with the 
exacerbation rate, were first evaluated bivariately. A p-value of 0.05 was required for 
statistical significance for all clinical variables. Variables tested were sex, age, body 
composition (normal/obese/cachectic), smoking habits at study start, exacerbation 
count 12 months before inclusion (0-1 and 2+), GOLD stage 2-4, hypoxemia (pO2 < 8 
kPa), Charlson Comorbidity Score (CCS), chronic cough, use of inhaled steroids and 
the five inflammatory markers WBC, CRP, NGAL, sTNF-R1 and OPG.  All variables 
were later evaluated in the multiple regression model using a backwards stepwise 
approach, removing variables with the highest p-value and keeping variables with a p-
value below 0.05. All discarded variables were later tested against the model and kept 
if the p-value was changed to < 0.05. Sex, age, body composition and smoking were 
considered as important adjustment variables and were kept fixed in the model 
regardless of p-value. In general, this approach was used for all regression modelling 
in our project with minor adjustments. 
The secondary analysis in paper 1, on the duration of AECOPD, was done using a 
generalized estimation equation (GEE) model. The outcome was a binary variable of 
exacerbation duration with a cut-off at >21 days. The model was specified with 
binomial distribution with a logit link function and exchangeable correlation of the 
variance, using the xtgee-command. Effect estimations were given as odds ratios (OR). 
Variables tested in the model were the same as in the above model, with the addition 
of time since study start, exacerbation severity in three categories and season. 
Similarly, a stepwise approach as above was done finding the best fit for the model.  
Regression models in paper 2: 
For the comparison of serum MIF levels between COPD and controls, a linear 
regression model was fitted, using the regress-command in Stata. MIF-levels were 
used as the outcome variable. Due to a skewed distribution the variable was log-
transformed, and the exponentiated result coefficients were presented as geometric 
mean ratios. Variables tested were age, sex, body composition, smoking habits, and 
CCS. A stepwise approach was used for finding the best model. In addition, the 
inflammatory markers, WBC, CRP, NGAL, sTNF-R1 and OPG were tested in the 
model in order to evaluate potential confounding effects. Similarly, MIF-levels were 
evaluated according to COPD characteristics in COPD patients only, using a similar 
linear regression model with the same variables as above, and in addition including 
exacerbation frequency, GOLD stage and use of inhaled steroids. 
Regression models in paper3: 
The distribution of GDF-15 was skewed with several high values, and even after log-
transformation the distribution was not normal according to a distributional diagnostic 
plot (qnorm-command). Thus the GDF-15 variable was dichotomized in high versus 
low levels with cut-off at median, for its use as the outcome variable in the logistic 
regression models.  
Survival analysis was done in COPD patients only using a Cox proportional hazards 
regression model, with death as the failure indicator and time since inclusion (in years) 
as the time parameter, using the stset- and stcox-commands. Effect estimates were 
presented as Hazard Ratios (HR). Variables tested were sex, age, body composition, 
smoking habits, GOLD classification, CCS, and exacerbation frequency.  
Analysis of exacerbation frequency was done using a random effects negative 
binomial regression model similar as the model in paper 1, using the same variables 
mentioned above.  
Analysis of change in lung function (both FEV1 and FVC) and change in free fat mass 
index (FFMI) was done with a random effects linear regression model, using the 
xtmixed-command (mixed-command in Stata 13 and later). The outcome variables 
were FEV1 and FVC given in % of predicted, and FFMI-measurements from all 
available measurements; thus up to 7 repeated measurements per subject during the 3-
year follow-up. The identifier variable was each patient, whereas the time variable was 
specified as years after inclusion. The covariance structure of the random effects was 
set as unstructured, thus all variances and covariances were distinctly estimated. All 
variables were analyzed with a time-interaction, thus the effect estimates were 
presented both as standard coefficients representing baseline estimates as well as time-
interaction coefficients representing effect estimates due to change over time. 
Variables tested in the model were the same as in the models above, all also with the 
time-interaction. All three models were also presented as figures showing the modeled 
decline in FEV1, FVC and FFMI in high vs low levels of GDF-15, based on the 
estimated coefficients. 
Regression models in paper 4: 
The main outcome of this study was the diagnosis of lung cancer. Cox proportional 
hazards regression models were fitted using a diagnosis of lung cancer as the event 
variable and time from inclusion to cancer diagnosis as time indicator. For the 
comparison between COPD patients and smoking controls; age, sex, smoking status at 
inclusion, body composition, and CCS were evaluated as independent variables. For 
the analysis in COPD patients only, the presence of emphysema, use of inhaled 
steroids, GOLD classification, use of LAMA or LABA, exacerbation frequency, and 
chronic bronchitis were also evaluated.  
For the analysis of inflammatory markers, 44 different markers were evaluated one at a 
time added to the model above. Due to multiple testing of biomarkers, a Bonferroni 
adjusted p-value below 0.05/45=0.0011 was demanded for statistical significance. In 
addition, a principal component analysis (PCA) was performed, using the pca-
command in Stata. PCA is a data reduction method that extracts the variance of 
multiple and often correlated variables into a smaller number of principal components. 
The eigenvalue of the components corresponds to the variance explained by each 
component. All variables were standardized (divided by their standard deviation and 
subtracted the mean) before using an orthogonal transformation. For the statistical 
analysis in the regression model, we used the 11 largest principal components, which 
explained 70.8 % of the total variance. The 11 components were analyzed one at a 
time added to the main model. Furthermore, the 4 largest components were also 
visualized in scatterplots comparing lung cancer and non-cancer patients, and also a 
correlation diagram showing relations between 4 principal components and important 
COPD characteristics. 
SUMMARY OF PAPERS 
 
Paper 1  
Predictors of exacerbations in chronic obstructive pulmonary disease 
Acute exacerbations of COPD (AECOPD) are important contributors to both 
morbidity and mortality in COPD, but there are great differences in the frequency of 
exacerbations between patients. We aimed to unveil risk factors for exacerbations in a 
COPD cohort with longitudinal follow-up, evaluating both clinical variables as well as 
systemic inflammatory markers. Similarly, we aimed to find predictors for the duration 
of the exacerbations. 
We used data from the Bergen COPD Cohort Study and the Bergen COPD 
Exacerbation Study, including 403 patients with longitudinal follow-up each 6 months 
for three years. Exacerbations were counted consecutive, and graded in mild, moderate 
and severe exacerbations based on treatment necessary. Baseline variables evaluated 
as predictors were the variables sex, age, body composition and smoking history, as 
well as the COPD characteristics exacerbation count before inclusion, GOLD stage, 
Charlson comorbidity score, hypoxemia, chronic cough, cough with phlegm, use of 
inhaled steroids, as well as the systemic inflammatory markers Leucocyte count, C-
reactive protein (CRP), Neutrophil gelatinase associated lipocalin (NGAL), Soluble 
TNF-reseptor-1 (sTNF-R1) and Osteoprotegrin (OPG). For the statistical analysis we 
fitted a negative binomial regression model, allowing for random effects due to 
repeated measurements, estimating the annual incidence rate ratio (IRR) for the three 
study years. For the analysis of exacerbation duration, we fitted a generalized 
estimation equation logistic regression model, adjusting for the same variables, but in 
addition adjusting for season and AECOPD severity. 
Significant predictors for an increased rate (IRR) of exacerbations were female sex 
[IRR 1.45 (1.14-1.84)], age per 10-year increase [1.23 (1.03-1.47)], >1 AECOPD last 
year before baseline [1.65 (1.24-2.21)], GOLD III [1.36 (1.07-1.74)], GOLD IV [2.90 
(1.98-4.25)], chronic cough [1.64 (1.30-2.06)] and use of inhaled steroids [1.57 (1.21-
2.05)]. The inflammatory markers were not associated with the IRR. For predictors of 
exacerbation duration more than three weeks, significant predictors after adjustment 
were: hypoxemia [0.60 (0.39-0.92)], years since inclusion [1.19 (1.03-1.37)], 
AECOPD severity; moderate [OR 1.58 (1.14-2.18)] and severe [2.34 (1.58-3.49)], 
season; winter [1.51 (1.08-2.12)], spring [1.45 (1.02-2.05)] and sTNF-R1 per SD 
increase [1.16 (1.00-1.35)]. 
In summary, several COPD characteristics, especially an increased exacerbation rate 
before study inclusion, were associated with an increased AECOPD frequency. 
Increased duration of exacerbations was linked to increased AECOPD severity, 
winter- or spring season. Hypoxemia was inversely related to exacerbation duration. 
Paper 2  
Macrophage migration inhibitory factor, a role in COPD? 
Macrophage migration inhibitory factor (MIF) is a pluripotent cytokine, and has 
among else a unique ability to antagonize the anti-inflammatory effects of 
corticosteroids, making it an interesting study object in COPD research. We aimed to 
evaluate MIF as a biomarker in COPD. 
We used baseline data of 424 patients and 325 healthy controls from the Bergen 
COPD Cohort Study. Patients were instructed to contact the hospital if they 
experienced worsening of symptoms, and serum samples were taken from 146 patients 
at their first moderate or severe exacerbation. Baseline MIF-levels were compared 
between healthy controls with both non-parametric analyses as well as multivariable 
linear regression analysis, adjusting for the baseline variables sex, age, body 
composition, smoking habits and comorbidities. Similarly, we evaluated serum MIF 
levels both at stable phase as well as AECOPD according to the specific COPD 
characteristics GOLD stage, exacerbation count before inclusion, chronic bronchitis, 
presence of emphysema on CT scan and the use of inhaled steroids. Lastly, we 
compared paired measurements of serum MIF at stable phase vs exacerbation, 
evaluated with non-parametric analysis. 
Median MIF in COPD patients was 20.1 compared to 14.9 in controls (p<0.01). MIF 
was bivariately associated with sex, body composition and CCS (p<0.05 for all). In the 
regression analyses, MIF was significantly higher in COPD patients, coefficient 1.32 
(p<0.01) and 1.30 (p<0.01) unadjusted and adjusted respectively. In addition, in 146 
patients at AECOPD, MIF was significantly elevated, with median 23.2 (14.1-42.3) 
compared to measures at stable disease 19.3 (12.4-31.3), p<0.01. We also found a 
likely association between the use of inhaled corticosteroids and increased MIF levels, 
adjusted coefficient 1.15, p=0.054. 
In summary, serum levels of MIF were significantly higher in COPD patients 
compared with controls. We also identified an additional increase in MIF-levels at 
AECOPD and a likely association between use of inhaled corticosteroids and 
increased MIF-levels. 
Paper 3  
Growth differentiation factor-15 is a predictor of important disease outcomes in 
patients with COPD 
Growth differentiation factor-15 is a cytokine with known association with cachexia, 
especially in cancer, but also cardiovascular disease and all-cause mortality. We aimed 
to evaluate GDF-15 as a potential biomarker in COPD using both cross-sectional as 
well as longitudinal data. 
We used data from 413 patients from the Bergen COPD Cohort Study and the Bergen 
COPD Exacerbation Study. Plasma GDF-15 was evaluated against relevant baseline 
variables. For this study we also used data from longitudinal follow-up. AECOPD 
were registered consecutively for three years. Lung function and body impedance 
measurements were undertaken each 6 months for up to three years. Mortality- and 
cause of death data for up to 9 years were obtained from the Norwegian Cause of 
Death Registry. GDF-15 as a predictor of exacerbation IRR, change in lung function 
and body composition were analyzed with a negative binomial regression model and 
linear regression models respectively, all addressing random effects, and lastly a cox-
regression model evaluating mortality. 
Increased levels of GDF-15 were associated with cachexia, current smoking, 
increasing co-morbidities, exacerbations before inclusion and lastly low FEV1 at 
baseline. Also, when evaluating longitudinal data, increased levels of GDF-15 were 
associated with a higher three year exacerbation rate; IRR 1.39 (95% CI 1.1-1.74, 
p=0.006, a faster decline in both FEV1; 4.29 % vs 3.25 %, and FVC; 2.63 % vs 1.44 % 
(high vs low levels, p<0.01 for both), and a higher mortality; HR 2.07 (1.4-3.1,  
p<0.001), especially due to pulmonary and cardiovascular cause of death.  
In summary, increased levels of GDF-15 were associated with several COPD 
characteristics at baseline, and were also a predictor for an increased exacerbation rate, 
a faster decline of lung function, and a higher mortality.  
Paper 4  
Risk factors for lung cancer in COPD 
Lung cancer share risk factors with COPD and is a common and dreaded co-morbidity 
among COPD patients. We aimed to evaluate the consecutive incidence of lung cancer 
after study inclusion, and to identify predictors of lung cancer development. 
We used data from 433 COPD patients and 279 controls, all smokers, from the Bergen 
COPD Cohort Study. The main outcome of the study was a diagnosis of lung cancer 
during 9 years of follow-up. Lung cancer diagnosis was obtained from the Norwegian 
Cancer Registry. Baseline predictor variables evaluated was age, sex, lung function, 
body composition, smoking history, emphysema assessed by CT and clinical 
symptoms. I addition we evaluated 44 serum/plasma biomarkers both individually as 
well as combined in a principal component analysis. A cox-regression model was 
fitted for the evaluation of time to lung cancer diagnosis. 
When comparing COPD patients with smoking controls, COPD was an independent 
risk factor for lung cancer, HR 4.98 (1.45 – 17.1, p=0.01). When analyzing lung 
cancer patients only, the best predictors were the presence of emphysema, HR 4.35 
(1.74 – 10.8, p<0.01) and obesity 3.25 (1.25 – 8.45, p=0.02). Use of inhaled steroids 
was associated with a reduced risk of lung cancer. Of the 44 biomarkers, only IP-10 
was associated with an increased risk of lung cancer, whereas all 44 biomarkers 
combined the principal component analysis were not linked to increased lung cancer 
risk.  
In summary, COPD was an independent risk factor for lung cancer, and especially in 
patients with emphysema. Systemic inflammation, measured by serum/plasma 




DISCUSSION OF METHODS 
 
Study design 
The two studies BCCS and BCES consisted of two COPD patient cohorts, where the 
BCES cohort was simply a subgroup of the larger BCCS cohort. In addition, a cohort 
of healthy controls was included in order to compare with the two groups. However, 
the term “healthy control” is a misnomer since the study aimed to include controls 
with non-COPD morbidities at a similar amount as the general population, thus 
without "filtering" except for comorbidities conflicting with interpretation of say blood 
markers or participation, like dementia, cancer, or severe arthritis. The choice of study 
design is always a compromise between available resources, flexibility in the choice of 
research questions, and statistical strength. A randomized controlled trial is the gold 
standard in terms of resolving causal relationships, but is expensive, and the number of 
exposure variables available for analysis is limited. A longitudinal cohort study allows 
for the simultaneous investigations of a large number of variables, and allows at the 
same time for assessment of temporal relationships with higher statistical power than 
in a cross-sectional study (178). 
Some main advantages of our cohort should be mentioned. First, the patients and the 
controls went through rigorous and multidisciplinary examinations at the visits, 
providing us with a large number of variables available for the statistical analyses. 
Second, the large size of the study with 758 study subjects provided solid statistical 
strength, and allowed for stratification and adjustment for several variables in the 
regression models. Third, the longitudinal design of the study gave us the possibility to 
study temporal associations between variables of interest and different outcome, in 
addition, repeated measurements of central variables both increase data quality and 
describe changes over time. 
The obvious disadvantage with non-intervention research study such as a cohort study 
is that causal relationships cannot be clearly resolved. Even a strong association over 
time may occur due to confounding or other directions of causality, even though 
efforts are made to account for this. Besides, any observations from even a large 
cohort study such as the BCCS should be verified in other cohorts, thus a replication 
cohort would strengthen and increase the value of our findings. These are, however, 
not readily provided. Therefore, the term “predictor” and its derivatives frequently 
used both in this thesis and in the papers should be interpreted with these limitations in 
mind. 
We used a mixture of cross-sectional and longitudinal data in our study. Our main 
focus was on the longitudinal evaluation of COPD related outcome resulting in paper 
1, 3 and 4, whereas the more complete data collection at study entry, thus with a more 
cross-sectional structure, was used for the selection and evaluation of variables 
necessary for the longitudinal models. Ideally, all non-fixed variables (such as the 
inflammatory markers) should be measured repeatedly during a study. Single 
measurements carry the risk of obtaining random extreme values, whereas an average 
of repeated measurements gives a better indication of the true value, explained by the 
statistical phenomenon of regression to the mean. 
Internal validity 
The term internal validity is a general description of to which extent the findings of the 
study truly represent the reality of the studied population, and to which degree they are 
affected by systematic errors or biases that may provide inaccurate results. Systematic 
errors may occur at all stages of a study; when designing inclusion criteria and 
recruiting study subjects, when collecting data, or when analyzing and presenting data. 
The nomenclature of systematic errors is not always consistent, and some study 
procedures may be source of several different errors simultaneously. The terms 
selection bias, information bias, confounding and reliability are presented in more 
detail, as well as how the statistical analyses were conducted in order to account for 
potential biases. 
Selection bias 
Any cohort of study objects should be as representative as possible in order to 
generalize or extrapolate any findings on to the intended study population. Our study 
population was based on patients recruited from local outpatient clinics, but also from 
the earlier Bergen GenKOLS (study on genetics in COPD) and the Hordaland County 
Cohort study (based on a general population)(179, 180). 928 subjects with a presumed 
COPD diagnosis were invited, whereas 433 were included in the studies. Thus, 495 
subjects were not included, giving a potential for a selection bias on the study cohort. 
We have no accurate numbers on subjects with non-response/lack of willingness to 
participate in the study, but this was presumably a significant share of the invited, 
whereas others were excluded by various reasons. A sub-analysis from both the 
Hordaland County Cohort study and from the OLIN-study indicate that both education 
and employment may affect the willingness to participate in studies, also the symptom 
load may be larger in non-responders (181, 182). Similarly, the “healthy volunteer 
effect” suggests that patients willing to participate in studies are more likely to report a 
healthier lifestyle, possibly in an attempt to compensate for already acquired disease 
(183). Further, COPD patients with a mild disease, GOLD class 1 (FEV1>80 %) were 
excluded by design. Advantages of this is to better exclude for instance asthma 
patients misdiagnosed with COPD, and also more clearly separate COPD patients from 
smoking controls. Similarly, but on the other end of the severity scale, patients with a 
too poor performance status were not included since they were not able to attend to 
follow-up.  
The controls of the study were younger, especially the non-smokers, which was 
important to adjust for in the statistical analyses. Also, co-morbidities were less 
frequent in controls. This, however, was difficult and possibly undesirable to adjust for 
since co-morbidity might be a fundamental characteristic of COPD. 
Information bias and statistical analysis 
Information bias, also referred to as observational bias or misclassification bias, relates 
to any error in the measurement or collection of data, or misinterpretation of these. 
Other terms related to information bias are confounding, reliability and statistical 
analysis of data, which are discussed separately.  
Especially when collecting categorical and/or binary data, all variables should be 
precisely defined in advance. In our study, questions regarding symptoms such as 
breathing difficulties and chronic cough were standardized. The interpretation of the 
questions, however, will always depend on the study subject as well as the person 
conducting the interview. There are several gender differences when reporting 
smoking habits, dyspnea and symptoms such as cough and sputum/phlegm production 
(184, 185). Our study included 46 % female COPD patients. And, sex was always an 
adjustment variable in the statistical analyses in order to account for potential gender 
differences. Another example of potential information bias was the definition, 
counting and categorization of COPD exacerbations. The exacerbation screening was 
based on standardized questions on symptoms, but in the analyses we used definitions 
based on health care utilization (appendix). A result of this was that the counts on 
moderate and severe exacerbations were considered reliable, whereas the number of 
mild exacerbations, more based on the recollection of symptoms, was regarded as less 
certain, and thus not included in the regression models. The definition of COPD 
exacerbations is debated. Symptom based definitions, often based on diary cards, is an 
alternative to our approach (77), but there is no international consensus on this topic 
(hence the need of better biomarkers). 
All patients had their COPD diagnosis confirmed by spirometry. The definition of 
COPD based on the FEV1/FVC-ratio of 70 % is controversial and frequently debated 
(186). This topic is beyond the scope of this study but is an important issue in a larger 
debate on how to grade and differentiate COPD patients and its phenotypes. It should 
be noted, that younger COPD patients may "miss" their COPD diagnosis, whereas 
some elderly may be misclassified as COPD patients. In our study, all patients also had 
a clinical diagnosis of COPD, thus misclassification was less likely. Lung function 
(FEV1) was analyzed as a continuous variable in the longitudinal analyses but 
categorized into GOLD stage 2-4 as an adjustment variable, for easier interpretation of 
the data. An alternative approach could be to evaluate the GOLD A-D assessment 
from 2011, with more emphasis on symptoms and exacerbations. This classification, 
however, is less used clinically, and also did not add information when evaluated in 
exploratory analyses. The additional measurements of lung function FVC and the 
FEV1/FVC-ratio were also evaluated in the statistical analyses as adjustment variables 
but were consistently of less significance than FEV1. 
The diagnosis of emphysema was based on CT scans and a computerized analysis of 
the tissue density. Our definition of emphysema gave us a binary variable, not taking 
into account that emphysema develops gradually, and that its severity varies. Also, the 
threshold of 10 % lung tissue and the cut-off at -950 HU is debated (187), especially 
since it does not take into account the geographical distribution of emphysema. A 
more sophisticated approach might have given more detailed insight into emphysema 
severity, but emphysema severity per se was not a major topic in our study, and thus 
we used a simplified approach.  
An important assumption of our study was that the measurement of multiple 
serum/plasma (systemic) inflammatory biomarkers was descriptive of COPD, a lung 
disease. The role of systemic inflammation in COPD is well described (19), and it 
seems inconceivable to evaluate local or systemic inflammation independent of each 
other. In addition, systemic inflammation is associated with both co-morbidity as well 
as worsened prognosis in COPD patients (20), thus systemic inflammation should be 
regarded as a fundamental aspect of the disease. A main and yet unresolved question is 
to which degree peripheral blood sampling and measurement of systemic 
inflammatory markers truly reflects the pathophysiology of COPD, both regarding the 
abnormal inflammation of the lungs, but also COPD as a systemic disease. The 
concept of inflammatory overspill is already mentioned, and there is ample evidence 
of proteins being able to move from the lungs to the systemic circulation, but also in 
the other direction (113). Thus increased levels of a biomarker in the lung parenchyma 
may well go along with a similar increase in the circulation. On the other hand, there is 
no evidence that a lung/circulation overspill is applicable for all inflammatory 
biomarkers, or to the same degree. Thus, serum/plasma biomarkers may mirror 
components of, but very likely not the complete lung inflammation in COPD. Lastly, 
the issue concerning the time scale of our biomarker analyses needs to be addressed. It 
is uncertain to which degree systemic inflammation is persistent over months and 
years. We evaluated baseline measurements of biomarker levels as predictors of events 
of several years ahead, but we cannot exclude that biomarker levels have changed 
significantly during follow-up, possibly interfering with the outcome. A few studies 
support the concept of persistent inflammation in COPD (20), but research in this field 
is not fully evolved.   
The more technical parts of biomarker analysis are mentioned later, but some 
important factors affecting biomarkers levels need to be addressed. Gender is already 
mentioned as a source of bias, and this is also relevant in the matter of biomarker 
levels. Estrogen levels and other hormonal differences may partly explain differences 
in degree of inflammation, toxin degradation, but also a higher susceptibility to 
cigarette smoking than in males (188), and may be an underexplored topic. Further, 
age and increasing comorbidity are strongly correlated, and they are both important 
factors influencing biomarker levels, of particular interest is cardiovascular disease 
(189). Similarly, medication of COPD, especially corticosteroids, but also drugs 
prescribed for other conditions may have an impact on inflammation and should be 
accounted for. The last factor mentioned here, and possibly the most difficult to 
accurately adjust for, is body composition. Height, weight, amount and distribution of 
fat and muscle, diet and physical activity, are all factors influencing one's body 
composition. Body Mass Index (BMI) is a frequently used metric of body composition 
since it is easy to measure, but BMI does not account for the amount of fat or muscle 
in the body. The consequences of having a high BMI in COPD are debated (190, 191). 
Our approach was to use a combination of the Fat Mass Index (FMI) and the Fat Free 
Mass Index (FFMI), where obesity was defined according to a high FMI and cachexia 
by a low FFMI. This method is more likely to account for the likely beneficial effects 
of muscle tissue vs fat on the different outcome. In addition, the amount of body fat 
does not only affect systemic inflammation directly, but may also bind inflammatory 
biomarkers, thus influencing systemic levels. Nevertheless, the issues concerning body 
composition, nutrition and physical performance in COPD is complex, and have many 
unresolved research questions, and the perfect “lifestyle” adjustment variable does 
probably not exist. 
Statistical analysis and confounding 
The statistical analyses of the project used a combination of data from different study 
settings: There was an extensive data collection at inclusion, providing a basis for 
cross-sectional analyses. In addition, data measurements of important COPD 
characteristics were repeated both at each 6-month visit as well as ad hoc 
measurements at AECOPD. Two of the four papers use data from the healthy control 
groups for comparison to COPD patients. All four papers use longitudinal data from 
COPD patients to a different extent in the analyses.  
Many statistical analyses, especially regression models, are susceptible to 
confounding. Confounding refers to unknown or hidden variables that influence both 
the outcome as well as adjustment variables. Confounders should be controlled for 
when fitting statistical models if possible. Some general principles to variable 
adjustment and analysis were followed in all four papers. Age, sex and body 
composition are already mentioned, and these were considered central adjustment 
variables in all analyses of several reasons; the most important being that these 
variables frequently are correlated or associated with most central outcome variables, 
but also with serum/plasma levels of the inflammatory markers. Smoking is another 
central variable and potential confounder in COPD research. Smoking habits were 
analyzed both as a categorical never/prior/current smoker, but also in terms of 
smoking load, as pack-years smoked. Smoking also affects the prevalence of 
cardiovascular morbidity, thus it is an essential adjustment variable in several 
statistical models. In the analysis of lung cancer prevalence, non-smoking controls 
were excluded from the analysis entirely since lung cancer development in non-
smokers is rare and may occur due to different pathological processes than in smokers.  
Another example of confounding in COPD, which may also classify as an interaction 
or selection bias issue, is the analysis of any effect of COPD medication on different 
outcomes. The use of COPD medication may rely on several different factors like 
phenotype, symptoms and lung function, all with potential effects on the outcome.  
The use of propensity score matching may reduce this bias and is sometimes used in 
the analysis of medical treatment in observational data. This implies adding adjustment 
scores in the regression models based on any variables predicting medical treatment. 
However, this is difficult in the setting of COPD, since most factors predicting 
treatment will also be associated with the outcome; this will be further discussed later.  
Any regression model is always a compromise between the best possible fit to the 
available data set and how the real-life data truly is. A regression model aiming for the 
best possible fit will usually include a high number of adjustment variables, but will be 
at risk of overfitting (192). A potential example might be to include a high number of 
inflammatory biomarkers in the same regression model. Consequences may be 
identification of statistically significant associations, which are generated randomly 
and not due to biological factors (often referred to as data mining). Also, a too 
complex model will reduce the statistical strength in terms of recognizing the true and 
biological relevant associations between an adjustment variable and the outcome. On 
the other hand, the consequences of a too simple or parsimonious model might be to 
exclude essential confounders from the model, providing wrong results. The large 
number of participants of our study allowed us to liberally adjust for known biological 
correlations that were not statistically significant in terms of p-values. When analyzing 
multiple biomarkers however, adjusting for confounding was more complicated due to 
interactions and the pitfalls of data mining mentioned above. Thus, although using 
interaction testing and assessing biological plausibility, we cannot exclude that all 
confounding factors are accounted for regarding to inflammatory biomarkers.  
The use of longitudinal data and repeated measurements requires statistical methods 
that take into account the inherent dependencies between subjects examined 
repeatedly. These methods are known by several names, like mixed models, multi-
level models, random effects models, panel data analysis or simply longitudinal data 
analysis, and most of them utilize regression analysis in some form (193). Many 
statisticians look upon these models as special versions of ordinary regression analysis. 
However, ordinary one-level regression makes the central assumption that any 
measurement on an individual or on a group is independent of the next individual or 
group. Multi-level models adjust for many of these factors and should be regarded as 
the best models describing real life situations. However, a major problem with multi-
level models is a rapid increasing complexity when adding levels and groups, both in 
terms of model adjustment options, but also in interpretation of the results.  
The analysis of predictors of the exacerbation rate was done with a bilevel/ random 
effects negative binomial regression model. Traditionally, Poisson regression has been 
used for the analysis of count data, but in later years the slightly more complicated 
negative binomial regression is preferred since lack of computational power is no 
longer an issue, and also since it allows for better a statistical fit for the distribution of 
AECOPD (194). AECOPD tend to cluster in time and thus the individual yearly 
incidence rates vary. The ideal time unit should be short enough not to include too 
many AECOPD clusters, but also long enough to avoid too small counts (too many 
zeros), thus the time unit of one year was a compromise.  
For the analysis of duration of exacerbation, we used a generalized estimation equation 
(GEE) regression model. There is no consensus-based definition on a "long duration" 
exacerbation, and regression methods based on other distribution models could be 
considered. A GEE-model may be considered a compromise as it has a god statistical 
robustness, but with a potential cost of lack of statistical strength. The cut-off at 3 
weeks is arbitrary but corresponds roughly to the clinical perspective where a 
AECOPD patient is expected to recover within reasonable time and should be 
reassessed if not. Alternative approaches could include symptom diaries or lung 
function testing, but that would require study resources unavailable to us.  
Analysis of decline in lung function, but also change in FMI and FFMI, was done with 
a random effects linear regression model. An important question on the study of lung 
function decline is whether it is linear or varies with time. Whereas the (idealized) 
Fletcher curve indicates a deteriorating FEV1 decline with time (6), data from the 
COPDGene-study indicates that the FEV1 decline is faster in mild/moderate than in 
more severe COPD (147). Models with exponentiated time variables or linear splines 
were evaluated and might have provided a slightly better statistical fit. However, we 
chose a linear decline model as they are more statistically robust and interpretation of 
results is far easier. When modeling the variance, several subjects had one or more 
missing visits during follow-up, and an unstructured correlation structure was chosen 
for better robustness thus potentially trading off statistical strength (195).  
Survival analysis and time to lung cancer diagnosis were done with cox-regression 
(proportional hazards) analysis. Cox-regression is susceptible to inaccurate data (192). 
We used data from official and compulsory health care registries with close to 100 % 
completeness. Co-morbidities were, in addition to age, potential and important 
confounding factors, thus these were evaluated both individually and as a composite 
variable (CCS).  
In addition to the statistical analysis of the individual inflammatory biomarkers, we 
intended to also analyze systemic inflammation as whole. At the time of preparation 
for the 4
th
 paper, we had additional biomarker measurements available for analysis; but 
far too many for be included simultaneously in standard regression models for several 
reasons, but most importantly due to widespread interactions between the markers. 
Methods for analysis of large and complex data sets have evolved tremendously the 
last decade, providing researchers with plentiful opportunities, but also potential 
pitfalls as complexity increases. Our approach was a principal component analysis 
based on the variance of inflammatory markers between the established categories and 
phenotypes. An alternative approach might have been a cluster analysis with emphasis 
on identifying new groups/clusters of patients with similar inflammatory patterns, and 
then compare this to the recognized categories. Nevertheless, the analysis of complex 
data sets with a large number of variables sets great requirements on both the data 
quality as well and the interpretation of the data. In general, a principal component 
analysis should be looked upon as a hypothesis generating rather than testing method 
(196).  
Reliability 
Any measure has a high reliability if it generates the same results when repeated under 
similar conditions. Factors that may affect reliability should be identified in order to 
improve the quality of the results, but also in terms in interpreting the measurements. 
The term reliability is most relevant when applying tools for measurements involving 
several steps, and where increasing complexity may reduce reliability. Reliability may 
differ according the instruments used, different methods and between users. 
Lung function measured by spirometry was a main outcome in our study. The result of 
a spirometry is highly dependent of the study subject as well as the technician. All 
spirometries were performed according to ATS/ERS standardization (172). The 
different spirometries were identical, were calibrated as descried earlier, and were 
maintained according to specifications.  
Body impedance measurement is less affected by study subject performance, but on 
the other hand the compliance to restrictions on food, drink, smoking and physical 
activity could not be accounted for. As for spirometry, tests were done according to 
standardized protocols and the instruments were calibrated and maintained as 
recommended. The reliability test mentioned earlier indicated a high reliability on 
these tests (174). 
The laboratory measurements in the inflammatory biomarkers were done at different 
times, at different laboratories and with different methods, and thus with potentially 
various reliability. The in-house measurements of Hemoglobin, WBC, Granulocytes, 
TPC, s-Ferritin, s-Creatinine and CRP used hospital routine methods with high 
reliability, estimated < 5 %. For the biomarkers measured separately with commercial 
EIA kits, the samples were measured in duplicates, intra- and inter-assay were 
analyzed and were below 11 % for all. For the 25 biomarkers measured in the 
magnetic bead multiplex, the listed intra- and inter-assay variance was between 5- 
15% and 5-11 %. In our study only one measurement was done for each biomarker, 
thus reliability was not verified. 
In addition to reliability, other validity concerns regarding measurements of the 
biomarkers should be addressed. Only a few of the biomarkers were measured at 
laboratories accredited for providing validated reference values. Second, the serum and 
plasma samples were exposed for super-freezing and thawing, and for some 
biomarkers transportation on dry ice to overseas laboratories for analysis, thus 
potentially affecting the levels of the biomarkers. Altogether, the differences in 
biomarker levels between study subjects should be interpreted relatively rather than 
according to absolute values. Second, several of the measurements in the multiplex 
analysis had measurements below the lower limit of detection, and some had 
measurements above. This was only a minor problem when using the separate EIAs 
for the other biomarkers. Third, there are by nature several correlations between many 
inflammatory biomarkers, the measurements from the multiplex seemed to have a 
higher degree of correlation between them then the other markers, which was difficult 
to quantify and adjust for. In sum, these issues may influence the results of the 
statistical analyses and should be accounted for as mentioned earlier.  
External validity 
The term external validity refers to transferability of the results and conclusions of the 
study to a general population, in this case COPD patients overall. Some variants of 
potential selection bias are already mentioned; by design, COPD patients with mild 
disease were excluded, thus our results may not be representative for patients with 
mild or early disease. Similarly, our findings may not reflect the reality of COPD 
patients with severe disease and short life-expectancy as these were excluded for 
inclusion, but on the other hand, mortality was still high in our cohort, thus this 
category was to some degree represented.  
Most patients were selected from earlier studies or outpatient clinics and were not 
randomly recruited from the general population, potentially excluding patients not in 
contact with the health care system. In Norway, access to health care is universal and 
inexpensive, thus a large health care access bias is unlikely. Bias due to non-response 
is already mentioned, where COPD patients with a lower socio-economic status and a 
larger symptom burden may be under-represented. Nevertheless, it seems unlikely that 
this patient category, or other mentioned above, should differ dramatically from those 
included in the cohort in terms of epidemiology and pathophysiology. 
  
DISCUSSION OF MAIN RESULTS 
 
Predictors of AECOPD 
The “frequent exacerbator” does not exist as an independent category in COPD 
classifications or guidelines. Nevertheless, most pulmonary physicians are well 
acquainted with these patients as they are regular customers in both primary and 
specialized health care. The clinical observation that there is a frequent exacerbator 
phenotype has been confirmed by earlier studies (197), and it is recognized that one of 
the best predictors of exacerbations simply is a history of previous exacerbations 
(132). It is also recognized that the prognosis of the frequent exacerbator is worse, 
both when it comes to decline in lung function (14, 74), but also in life-span (16, 75). 
Inflammatory biomarkers may help identifying these patients before they enter a 
vicious circle of repeated COPD exacerbations and accelerated disease progression, 
but they may also help us understanding the special pathophysiology of the frequent 
exacerbator as well as acting as a guide to the optimal treatment.  
The inflammatory biomarkers analyzed in our first study were WBC, CRP, NGAL, 
sTNFR1 and OPG (198). These markers were chosen due to known associations with 
either COPD, or important COPD-characteristics, based upon prior cross-sectional 
studies on the baseline data from the Bergen COPD Cohort Study (199, 200). WBC, 
CRP and OPG were all bivariately related to the subsequent AECOPD count, but not 
after multivariable adjustment. Our negative findings were in accordance with some 
other studies (15, 140), describing bivariable associations between inflammatory 
markers and future AECOPDs, but not after statistical adjustment for other factors. In 
some cases, disease severity is a confounding factor for positive findings bivariately, 
whereas other studies do not report using regression adjustment methods. However, as 
mentioned in the introduction, there are several studies describing biomarkers with 
independent associations with future AECOPD (15, 20, 21, 128, 140, 142-144). One 
problem for many studies is the lack of replication studies, thus the findings have not 
been confirmed by others. A more recent and large study by Keene et al (2017) 
addresses this issue (201). Using prospectively collected plasma/serum samples from 
two large COPD cohorts, a total of 119 different inflammatory biomarkers were 
measured by multiplex panels. When analyzing each cohort alone, several biomarkers 
could independently predict AECOPDs, but when comparing the two cohorts, there 
was minimal overlap between them. Also, any one inflammatory biomarker had 
limited predictive value, especially compared to clinical characteristics.  
There may be several reasons for the negative findings in our, but also other studies. 
One explanation is the heterogeneity of AECOPDs. Potential triggers of AECOPDs 
include different viruses, bacteria, air temperature or pollution, and in many cases a 
combination of these (202), which may vary significantly between patients. Also, the 
increased susceptibility to having AECOPD may be more related to fixed, structural 
changes in the lungs than to an inflammatory response, which is not necessarily 
reflected by blood biomarkers. 
Women had more exacerbations them men with an IRR of 1.45 in our study, but when 
only looking at hospital admitted AECOPDs, there was no gender difference. The 
gender difference overall has been observed earlier but is difficult to explain. In the 
TORCH-study, female COPD patients reported a significant lower quality of life, but 
at the same time their lung function measurements were better than in male patients, 
and women trended towards a lower mortality (203). On the other hand, women 
reported a lower prevalence of chronic cough (and also cough with phlegm), another 
independent risk factor for AECOPD, a phenomenon also observed by Lindberg et al 
(204). A post-hoc evaluation or our data also indicate a potential interaction between 
male gender and chronic cough as risk factors of AECOPD, consequently this 
potential under-reporting of cough in females may partly explain a higher AECOPD 
frequency in females.  
We found an association between the use of inhaled corticosteroids (ICS) and an 
increased exacerbation count. This finding was valid both for fluticasone propionate 
and budesonide, the dominant ICSs on the market at the time, and there was also a 
dose-response relationship. This finding is obviously in contrast with the findings of 
the large randomized controlled trials (205, 206) providing the basis for ICS treatment 
in COPD. These RCTs may be criticized for their differentiation of AECOPD and 
pneumonia, as the latter is not properly incorporated in their statistical models. It is 
generally accepted that use of ICS increases the risk of pneumonia (207), and while 
having a protective effect against AECOPD, these two conditions may be difficult to 
distinguish between clinically. However, even though our results were statistically 
significant after adjustment for other known AECOPD risk factors, our findings could 
be a result of a selection/treatment bias, since COPD patients receiving ICS treatment 
are those with the highest risk even before study inclusion. A propensity score 
matching can in some cases adjust for medication use in the statistical models, but in 
our case, all relevant variables were already incorporated in the model. The topic of 
ICS use in COPD is still debated, and thus not fully resolved. There may be a need to 
better phenotype both COPD patients and AECOPDs to establish the optimal 
treatment protocols for the use of ICS.  
We did not have access to all variables at the time of publication of paper 1 (198), and 
as additional data became available, these were evaluated against the same regression 
model used in this study. Emphysema has been proposed as a risk factor of AECOPD 
(139), but in our study, the presence of emphysema on CT scan was not associated 
with AECOPD frequency. We also evaluated additional inflammatory markers 
analyzed by our international collaborators, and we did find a positive association 
between plasma levels of GDF-15, which is described later in this chapter. 
Furthermore, we conducted an investigation on coagulation markers in COPD as a part 
of the same study but not included in this thesis. Here we also identified Thrombin 
AntiThrombin-complex (TAT) as a predictor of future AECOPD (paper in 
submission)(208), which may be an illustration of the interactions between the 
coagulation and the immune system. Finally, we also analyzed blood eosinophil count 
post hoc, but without significant results in our model. Blood eosinophils have emerged 
as a predictor of both future AECOPD as well as treatment effect of corticosteroids 
(141). Our study specifically excluded asthma/ACOS patients where eosinophilia is 
more common, which may partly explain our negative findings. 
In addition to analyzing AECOPD frequency, we evaluated factors with potential 
associations to AECOPD duration as this might be another measure of disease 
severity. This topic is less explored before, and there is neither an established cut-off 
of a long lasting exacerbation, nor a general consensus on when an AECOPD is 
finished based on symptoms or other measures. AECOPD duration is likely to depend 
on its cause, and it is likely that infections, especially viral, are related to a longer 
duration of symptoms (88). Consequently, our observation of a longer duration in 
winter and spring may be related to the seasonal nature of virus infections. Alternative 
explanations include inorganic factors such as air temperature or air pollution, where 
the first has a significant impact on the other at low temperatures. Of the inflammatory 
biomarkers, only sTNF-R1 had a small but significant correlation with AECOPD 
duration. The TNF-α system is a central mediator in both bacterial and viral infection. 
Levels of soluble-TNF-receptor 1 (sTNF-R1) is related to TNF-α but have a longer 
half-time. The association between sTNF-R1 and AECOPDs is an uncertain finding, 
but it might be explained by a higher susceptibility for infection in some patients. 
Lastly, the observation of a longer AECOPD duration in patients with chronic 
bronchitis may also fit into a picture of infection as a main factor of delayed recovery. 
In short, our findings were that clinical parameters are superior to systemic 
inflammatory markers in predicting future exacerbations; this is also in accordance 
with most other studies on this topic. The already mentioned study by Keene (201) 
may indicate that a single, clinically useful inflammatory biomarker of future COPD 
exacerbations in general does not exist, and perhaps it is more fruitful to look into 
specific triggers of lung infection (202). A consequence of the lack of a systemic 
biomarker of AECOPDs is that assessment of clinical characteristics becomes more 
important. This is also reflected in several recently proposed AECOPD prediction 
models, which are mostly based on clinical parameters (209). 
Macrophage Migration Inhibitory Factor (MIF) as a biomarker in COPD 
The name Macrophage Migration Inhibitory Factor (MIF) is not a good descriptor of 
the function of the molecule, as MIF attracts monocytes and macrophages rather than 
inhibits them. Today MIF is generally described as a pro-inflammatory cytokine (210). 
MIF has been rather extensively evaluated as a biomarker the last decades, and 
increased MIF-levels are found in different inflammatory disorders, non-
communicable diseases, cancer, but also more lung specific conditions such as asthma 
and acute respiratory distress syndrome (ARDS) (210-215). MIF is found in a range of 
different immune cells, but as its name implies, macrophages (and monocytes) are 
central components in MIF-signaling, as they are both a source and a target of MIF. 
Macrophages contain preformed MIF available for rapid release upon stimulation 
(216), but MIF is also found in the pulmonary endothelium and in a range of other 
immune cells than macrophages. MIF is also secreted by the anterior pituitary in 
concert with ATCH acting more like a hormone than a cytokine, and it has several 
unique interactions with glucocorticoids which we address later. Systemic MIF levels 
have been seen to rise after lipopolysaccharide (LPS) or endotoxin-stimulation, and 
similarly levels of the central mediators TNF-α, IL-1, IL-6 and IL-8 were seen to rise 
after adding MIF before stimulation (217). Also, inhibiting MIF-signaling by MIF-
antibodies or by using MIF-/- mice seems to be protective against LPS or endotoxin-
induced inflammation, again indicating a central role of MIF as a pro-inflammatory 
mediator (218, 219). In a more clinical setting, increased levels of MIF are associated 
with idiopathic pulmonary fibrosis (IPF), bacterial sepsis and ARDS (219-221). 
Altogether, there are ample clinical and biochemical justifications to evaluate MIF as a 
biomarker also in COPD. 
In contrast to findings for other conditions, two early studies found an association 
between decreased MIF levels and COPD. Both Fallica (222) and Sauler (223) found 
lower plasma levels of MIF in 32 and 32 COPD patients versus 19 and 40 controls, 
respectively. We found increased levels of MIF in 424 COPD patients compared to 
325 controls, with median levels 20.1 vs 14.9 ng/ml, and also an additional increase 
during exacerbations. A study by Russell et al found increased MIF-levels in sputum 
and bronchial alveolar lavage (BAL) of COPD patients, but not in serum (224), 
whereas Milara et al found increased MIF-levels in peripheral neutrophils in COPD 
patients (225). We believe our study, due to its size and statistical adjustment for 
available co-factors, gives a better picture of serum MIF levels in COPD, in addition 
our findings are in accordance with the finding of increased MIF-levels in several 
other inflammatory conditions. Nevertheless, our findings should more clearly be 
replicated in other studies, preferably in larger cohorts with prospective sampling.  
Several factors may influence MIF levels and thus partly explain diverging finding. 
We found that increasing co-morbidity was associated with higher MIF-levels. 
Further, the studies of Fallica and Sauler found lower MIF-levels at increasing GOLD-
stage or a higher degree of emphysema, a similar trend to what we found in our GOLD 
3 and 4 patients. Another potentially important factor not adjusted for in the mentioned 
studies is genetic polymorphism. A second study by Sauler and Zhang describes 
differences in DLCO in COPD patients dependent on high vs low expression of 
different alleles of the MIF gene (226). Finally, plasma MIF levels are closely related 
to plasma levels of cortisol, fluctuating in a circadian rhythm (218). Thus, time of 
plasma sampling may significantly affect measurements if not standardized, and this 
may not be accounted for in the performed studies.  
Regarding COPD progression the most interesting characteristic of MIF is perhaps its 
unique ability to be induced by, but also to inhibit the effects of, glucocorticosteroids. 
Corticosteroid resistance is a hallmark of COPD, and a major problem for its 
treatment. There are several places of interaction between MIF and corticosteroids. A 
main MIF signaling cascade goes via the CD74 receptor found in most immune cells 
via the ERK1/2-MAPK cascade promoting release of pro-inflammatory cytokines and 
prostaglandins. Glucocorticoids can inhibit immunologic cells by binding to the 
glucocorticoid receptor, an inductor of MAPK phosphatase-1 (MKP-1), which again 
inhibits the ERK1/2-MAPK cascade. MIF may on the other hand suppress the effects 
of MKP-1 directly, as well as hamper glucocorticoid inhibition on pro-inflammatory 
DNA/RNA transcription (227). In addition is the already mentioned centrally 
regulated pituitary excretion of MIF. We found an association between the use of 
inhaled corticosteroid and serum MIF, although small and borderline significant. We 
could not find any similar effect when looking at MIF levels at AECOPD and the use 
of oral steroids, but serum sampling was conducted in an early stage of AECOPD.  
When evaluating MIF as a diagnostic biomarker of COPD and AECOPD according to 
the criteria of Sin and Vestbo (116), MIF checks off on biological plausibility, and it is 
independently associated with COPD as well as AECOPD which is an important 
clinical outcome. The problem with MIF as a diagnostic biomarker, however, is the 
strength of the association between the biomarker and the diagnosis. As mentioned in 
the introduction, there are several findings of elevated biomarkers, especially at stable 
COPD, but also at AECOPD. The sensitivity of MIF at COPD and AECOPD is at best 
mediocre as there is significant overlap between controls and COPD, and between 
COPD and AECOPD. Further is the lack of specificity, as MIF is not an organ specific 
marker (like cardiac Troponin for example). Not mentioned in the paper, the ROC-
value of MIF as a discriminator between stable COPD and AECOPD in our cohort was 
0.69, thus not discriminating enough to be a diagnostic marker in clinical practice. 
The last and probably most important characteristic of a useful biomarker according to 
Sin and Vestbo is related to treatment and subsequent change in biomarker status 
leading to a different outcome. Roflumilast was developed as a PDE4-inhibitor, and is 
in approved use worldwide in the treatment of COPD, with a preventive effect on the 
AECOPD frequency. The study by Milara evaluates the in-vitro effect of roflumilast 
on corticosteroid resistance in neutrophils from COPD patients. In-vitro treatment with 
roflumilast is described to reduce MIF-induction after cigarette smoke extract-
stimulation (225), thus antagonizing the MIF-level increase induced by corticosteroids, 
and thereby resulting in a decrease in levels of pro-inflammatory IL-8 and MMP-9. 
Although PDE4-inhibition with roflumilast induces several other complex 
mechanisms, reduced MIF-levels may have a role in its anti-inflammatory effect. 
Ibudilast (MN-166) is another PDE4 inhibitor, which is primarily designated as a MIF-
inhibitor. It is approved for use in Asia for treatment of asthma, but not yet for COPD. 
As of 2020, ibudilast may be more relevant in the treatment of respiratory failure, and 
studies on its effect on Covid-19 related ARDS are ongoing (228). Both MIF 
antibodies as well as small molecule inhibitors of MIF and its CD74 receptor are 
available (229). MIF is increasingly recognized as a factor in lung diseases (230), thus 
it is likely that we will see more clinical trials targeting MIF in pulmonary research. 
Growth Differentiation Factor 15 (GDF-15) as a biomarker 
Although GDF-15 was discovered more than 20 years ago, it is a relatively unknown 
cytokine in COPD and pulmonary research. GDF-15 has been known by different 
names, which is indication of scientific interest from several different branches of 
medical science (231). GDF-15 has been broadly studied as a biomarker in 
cardiovascular diseases and studies of metabolism and body weight regulation, and is 
considered a potential prognostic biomarker in these fields (232). GDF-15 differs 
substantially from other members of the Transforming Growth Factor β (TGF-β) 
superfamily, but it seems to involve the intracellular Smad-pathways characteristic for 
the TGF-βs. Much effort has been made in the search for the pathophysiological 
mechanisms related to GDF-15, however they are yet not fully revealed.  
Traditionally, the pathophysiology of any disease is extensively studied before trying 
to develop any medication, but in some cases the drug development precedes the 
understanding of the disease mechanisms. The AV-380 antibody has been identified 
and developed as an inhibitory antibody of GDF-15. Due to the association between 
GDF-15 and weight loss, AV-380 has been investigated as a potential therapy of 
cachexia (233); since GDF-15 (designated MIC-1 in that study) was described to 
induce cachexia in a murine model, and the weight loss was shown to be reversed 
MIC-1 antibody (AV-380) treatment. Due to a high share of cachexia among COPD 
patients, and due to the availability of longitudinal assessment of body-composition in 
our cohort, it was rational to investigate the potential role of GDF-15 as a COPD 
biomarker. 
In our study, we found not unexpectedly a clear relationship between GDF-15 and 
cachexia at baseline. However, we did not find indications of any predictive value of 
GDF-15 on the rate of weight loss during the study. More noteworthy was our 
observations of high GDF-15 levels as a predictor of a higher mortality, a faster 
decline in FEV1, and a higher exacerbation count. When analyzing these findings, it is 
difficult to provide a common mechanistic explanation for the differences in effect. 
Even though GDF-15 seems to be involved in a number of different conditions, the 
role of GDF-15 is incompletely understood (234, 235). An important question that 
emerges when analyzing our findings, is whether GDF-15 has a significant, up-stream 
role on our outcome, or if it is a by-product of other, more important disease processes.  
With the exception of the recently discovered GDFN family receptor α-like (GFRAL) 
predominantly found in the central nervous system, the biological targets of GDF-15 
elsewhere in the human body remain unrevealed (236). This is in contrast with the 
widespread distribution of GDF-15 to several different tissues in the body. GDF-15 is 
expressed in cardiac myocytes and adipose tissue (231). Of more relevance for lung 
disorders, it can be induced from macrophages, airway epithelium or vascular 
endothelium after stress-responses, including pro-inflammatory cytokine stimulation 
(234, 235).  
Our observation of GDF-15 as a biomarker of mortality is in accordance with other 
studies, as it is described as a predictor for both all-cause as well as cardiovascular 
mortality (237, 238). A smaller study supported this finding in a cohort of COPD 
patients (239). In our study, the analyses on cause-specific mortality showed the 
strongest association between high levels of GDF-15 and respiratory cause of death, 
whereas the trend of a higher risk of cardiovascular death was not statistically 
significant. However, it is difficult and perhaps unwanted to evaluate the mechanisms 
leading to a cardiovascular or a pulmonary cause of death separately as these may 
interact significantly, especially those potentially related to GDF-15. In cardiovascular 
disease, GDF-15 is induced by coronary ischemia including myocardial infarction. 
Further, high levels of GDF-15 are associated with heart failure, systemic 
hypertension, cardiac hypertrophy and pulmonary hypertension, the latter also being a 
significant risk factor for COPD related death (240). The biomechanics of GDF-15 in 
heart disease seems to involve intracellular Smad-pathways, which again is related to a 
possible cardioprotective role in murine and in-vitro models (241), but this is not 
verified in real-life studies. Another pathway leading to GDF-15 expression is 
induction by p53, a protein related to cancer but also cellular senescence (242) and 
thus also mortality. Altogether, GDF-15 seems to have value as a prognostic marker 
on mortality in general, whereas its causative role in all-cause or COPD-related death 
remains unclear. 
The relation between GDF-15 and both lung function decline and future AECOPD 
frequency were novel findings in our study. A few other smaller studies have 
evaluated GDF-15 as a diagnostic biomarker in COPD, reporting elevated levels in 
COPD patients compared with controls, and an additional increase at AECOPD (243-
246). Not reported in our paper, we also found a significant difference in GDF-15 
plasma levels between the COPD patients and a selection of the controls (median 
levels 0.86 vs 0.63, p=0.001, Wilcoxon rank-sum test). We did not, however, have 
GDF-15 measurements at AECOPD for comparison. A recent and unpublished study 
by Rydell et al (ATS-congress 2020 abstract) also describe an association between 
high plasma GDF-15 levels and a faster FEV1 decline, supporting our findings (247). 
Studies by Wu et al describe increased GDF-15 expression from airway epithelium 
after cigarette smoke exposure, associated with mucus production and cellular 
senescence (248, 249). A more recent study also describes an exaggerated GDF-15 
related inflammatory response after rhinovirus exposure (250). In these studies, both 
the Smad1 and PI3K-pathways seems to be involved in intracellular signaling, and the 
Activin receptor-like kinase 1 (ALK1) is a proposed mediator of signaling. These 
findings are not confirmed by others, and causal relationships are not clarified, but 
they provide some clues regarding the role of GDF-15 in COPD. Its role as a potential 
predictor of future AECOPD requires verification in other studies, as lack of 
consistency between studies is a common problem as discussed earlier in this chapter 
(paper 1). It may be even more difficult to identify biomarkers related to lung function 
decline, since studies reporting likely association are sparse (22, 146, 148, 149, 251) 
and reproducibility is limited. Most of the biomarkers described are not lung-specific, 
and as with GDF-15 they are also related to cardiovascular disease and other important 
co-factors related to COPD characteristics.    
The association between cachexia, especially related to cancer, and high GDF-15 
levels is thoroughly studied, and the recent discovery of GDNF family receptor α–like 
(GFRAL) and its co-receptor receptor tyrosine kinase (RET) sheds light on the 
biomechanics proposed to explain its effects. Binding of GDF-15 to the GFRAL/RET 
complex, probably involving ERK-signaling, has been shown substantially decrease 
food intake in murine models, leading to cachexia. Also, GFRAL receptor knock out 
models, and the above mentioned GDF-15 antibody studies support these findings 
(233, 236), and thus act as a basis for pharmaceutical trials. The blood-brain barrier 
might hamper the use of antibodies or other large molecule drugs, but development 
and utilization of small molecule GFRAL-receptor antagonists may be a better 
approach in medical treatment of cachexia, especially cancer related/ GDF-15 induced 
(252). Correspondingly, GFRAL-receptor agonists or the use of natural GDF-15 itself 
and their potential beneficial effects on obesity is also of great interest, and significant 
research effort is now put into this topic (252).  
When it comes to the other findings in our study, it is less clear whether GDF-15 
related pharmacological treatment may have an effect on mortality, lung function 
decline or exacerbation frequency. As long as no peripheral receptor or any other 
verified biological target of GDF-15 is discovered, it is difficult to provide a rationale 
for drug development targeting these outcomes. Still, GDF-15 may have a role in 
developing and understanding risk-models in COPD, especially in patients with 
cardiovascular co-morbidity. 
Risk factors for lung cancer 
The last paper in this thesis concerns both COPD and lung cancer (253). Lung cancer 
is one of many diseases which are observed more commonly in COPD patients, but it 
is by far the most serious when it comes to morbidity and reduction in life span. 
Smoking or noxious airway exposure is regarded as the main risk factors for both 
conditions. However, regardless of the amount of smoking, it is a common observation 
that patients developing COPD have a higher, independent risk of also developing 
lung cancer. Thus, it is rational to search for similarities in the pathophysiology of 
these diseases, both in order to understand the specific mechanisms linking COPD and 
cancer, but also due to the need to identify COPD patients with a high lung cancer risk. 
In this context, the term predictive biomarker should not be confused with the term 
tumor marker. The latter is usually referred to as a substance (often a protein) 
produced or excreted directly from cancer tissue, or indirectly correlated to these, such 
as an antigen. It is also worth mentioning the development towards the use of liquid 
biopsies in the diagnostics of cancer. Liquid biopsies utilize the presence of tumor 
DNA in the circulation, where small DNA-fragments are detected using PCR or NGS 
techniques. Their sensitivity in early cancer or pre-malignant lesions is nevertheless 
unclear, and their role as predictive markers is even more uncertain.  
There is extensive evidence of a link between systemic inflammation and cancer 
development generally (254). In lung cancer this relation has been less clear, but there 
is now research describing different levels of inflammatory biomarkers between 
patients with established lung cancer versus healthy controls, smokers and COPD 
patients (255-260). Biomarkers with predictive value on later lung cancer are harder to 
discover. A study by Spitz et al describes a lung cancer risk prediction model where 
markers of DNA repair increase sensitivity of the model (261). Efforts have also been 
made in looking into alternative biomarkers such as urine samples or exhaled air, by 
the measurement of volatile organic compounds using gas chromatography and/or 
mass spectrometry (262), but also here the predictive abilities seem limited.  
Of the 44 different biomarkers we measured, only interferon gamma-induced protein 
10, (also known as CXCL10, CXC motif chemokine ligand 10 or IP-10) was 
significantly associated with lung cancer development. IP-10 is secreted by several 
immune cell types as a response of induction by interferon- γ, INF-γ. IP-10 has several 
roles, but in the context of COPD it is best known as a marker of viral infection (263, 
264). The best described target of IP-10 is the CXCR3 receptor, found abundantly on 
T-cells and NK-cells, and IP-10 has been linked to tissue damage and emphysema 
development related to T-cell granzyme release upon CXCR3-activation (265). On the 
other hand, IP-10 is also associated with angiogenesis and regulation of cell growth 
and apoptosis and may have a protective role. Elevated levels of serum IP-10 has been 
observed in patients with lung cancer as well as other cancer types (266). However, the 
potential role of IP-10 in lung cancer development is unclear, and its value as a 
predictive biomarker should be confirmed in other studies.  
For the other biomarkers in our analysis, there was no significant association with lung 
cancer among our COPD patients. Similarly, in the principal component analysis 
assessing a combined biomarkers analysis, none of the largest components were 
significant associated with lung cancer. As shown in the correlation diagram from 
Paper 4, systemic inflammation was to a higher extent related to the clinical 
phenotypes of chronic bronchitis and frequent exacerbations, whereas the correlations 
to lung cancer and emphysema were weaker. 
An important topic of Paper 4 was the search for different patterns of systemic 
inflammations related to the different COPD phenotypes. When analyzing the three 
largest principal components, it is difficult to identify patterns of significance due to 
high number and large diversity of the biomarkers contributing to the components 
(loading of the eigenvectors). The fourth largest principal component had a relatively 
higher correlation with emphysema than the other components. When looking into the 
variables related to the fourth principal component, neutrophils and NGAL were the 
most important factors. Neutrophils are related to several different immune responses 
but are a main source of proteinases. NGAL may prevent inhibition of matrix 
metalloprotease 9 (MMP9), a protease related to emphysema development. It should 
be noted that a principal component analysis is not designed to resolve causal 
relationships. 
Our findings indicate a different and more significant impact of systemic inflammation 
on chronic bronchitis and frequent AECOPD than on emphysema and lung cancer 
development. However, our collection of biomarkers may not completely embrace the 
COPD pathophysiology. Several of our markers may be designated general or 
pluripotential inflammatory markers, whereas the number of markers more specific to 
emphysema may be limited. Emphysema-specific systemic biomarkers seem to be 
sparse, either because they do not exist, or because they are not yet discovered. 
Other important factors related to both emphysema and lung cancer are inorganic 
toxins, free radicals, and other toxic substances found in cigarette smoke and polluted 
air. Such compounds may in addition to trigger an inflammatory response directly 
damage cells and tissue as well as DNA, contributing to development of both 
emphysema and malignant lesions. However, the amount and composition of these 
compounds are not easily detected, and the impact of these compounds is likely not 
reflected by the measurement of systemic inflammatory biomarkers. 
Our observation of a lower lung cancer rate in COPD patients using inhaled 
corticosteroids (ICS) is also described in earlier studies (267, 268), and has been 
subject for debate. An association between chronic inflammation and cancer 
development has been described for many different cancer types. Thus, it is tempting 
to hypothesize that the anti-inflammatory effect of corticosteroids may prevent cancer 
development.  In COPD however, one must consider the potential treatment selection 
bias related to the different prescription of inhaled corticosteroids to the various COPD 
phenotypes. A patient with chronic bronchitis may be more likely to get ICS treatment, 
whereas the degree of emphysema is not necessarily reflected in coughing, 
exacerbations, or a low FEV1, which are common factors leading to ICS prescription. 
A systematic review by Raymakers describes potential beneficial effects of ICS on the 
cancer rate in several population based studies, but not in RCTs (269). Related to the 
prescription bias, another factor necessary to consider is time-related bias, thus 
duration of ICS exposure related to study inclusion. A recent study by Suissa et al 
adjusted for time-related bias, and reported no significant effect of ICS on the lung 
cancer rate (270).  
The lack of symptoms in early phase disease is a major problem when dealing with 
lung cancer. Development of symptoms is usually synonymous with metastatic 
disease, which usually renders curative treatment with surgery impossible. Screening 
with low-dose CT has long been debated and is now increasingly recommended (271, 
272). The main obstacle for lung cancer screening is of course the high costs, and a 
main objective for a study of risk factors for lung cancer is the identification of easily 
accessible clinical parameters that can be used for the development of screening 
protocols. The most obvious and most frequently used variables in different protocols 
are age and smoking, the latter including time of smoking, amount in pack-years and 
active vs former smoking. Other proposed variables are passive smoking, occupational 
exposure and other lung disease such as COPD or emphysema (273, 274). Screening 
protocols for lung cancer should not only aim to include subjects with increased cancer 
risk but should also allow for differentiation regarding re-screening. Compared to 
screening for several other major cancer types, lung cancer screening has a short 
expiration date which necessitates repeated CT-scans. The initial CT scan may also 
reveal emphysema, and our findings along with others may support a higher screening 










1 Systemic levels of inflammatory biomarkers were compared between COPD 
patients and healthy controls using cross-sectional data, and between stable COPD and 
COPD exacerbation.  Macrophage migration inhibitory factor (MIF) was identified as 
potential biomarker for both for stable COPD as well as AECOPD. 
 
2 Systemic levels of inflammatory biomarkers as well as clinical characteristics 
were evaluated as predictors for longitudinal outcome in COPD patients. 
 
a) A history of exacerbations, female sex, chronic cough and a lower FEV1 were 
identified as predictors for future AECOPD. High levels of GDF-15 were 
identified as a predictor for a higher future AECOPD count. 
 
b) High levels of GDF-15 were identified as a predictor of a faster decline of both 
FEV1 and FVC. Other factors associated with a faster FEV1 decline were male 
sex and cachexia.  
 
c) High levels of GDF-15 were identified as a predictor of all-cause mortality as 
well as mortality due to respiratory disease. Other factors associated with a 
higher mortality were a low FEV1, cachexia, obesity and a high degree of 
comorbidity.  
 
d) COPD was significantly associated with a higher lung cancer risk. Within 
COPD patients, emphysema and obesity was associated with a higher lung 
cancer risk. Of 44 inflammatory biomarkers, only IP-10 was significantly 
associated with a higher lung cancer risk, whereas systemic inflammation 





A perfect biomarker is specific and sensitive, predicts adverse outcome and is a target 
as well as an effect indicator of pharmacological treatment. In COPD, such a 
biomarker does probably not exist, but that does not mean that the search of 
biomarkers if futile. For a pulmonary physician, it is natural to compare the 
development in COPD research with that of lung cancer, the other major disease 
category in pulmonology apart from COPD. In lung cancer, there has been a 
significant change in both diagnostics and treatment the last 15 years. The traditional 
categorization based on histopathological patterns seen in the microscope, although 
still referred to by the pathologists, is of increasingly less clinical importance when 
choosing the optimal treatment. Today, the morphological lung cancer diagnosis is 
usually supplemented with an increasing number of biomarkers indicating the presence 
or absence of genetic mutations, translocations or expression of specific proteins, with 
the common attribute that they are all indicators of likely treatment effect from 
targeted therapy, specific for each marker. There is not necessary any logical 
relationship between these markers and the radiological or microscopic appearance, 
clinical symptoms or any other of the classical characteristics of lung cancer, but there 
is no doubt that this shift towards personalized medicine has been a major step forward 
in in lung cancer treatment. We will likely see a similar shift in COPD research for the 
next decades.  
As of today, the only established clinical biomarker is the eosinophil blood count. 
High blood levels of eosinophils is an indicator of treatment effect of corticosteroids, 
both inhaled and peroral treatment in both stable disease as well as AECOPD. 
Eosinophils, however, are not specific for COPD and they are only relevant to a 
fraction of COPD patients. There are, however, numerous biomarkers associated with 
different aspects of COPD pathophysiology, which have potential clinical usefulness. 
As we gain a better knowledge on the COPD inflammatory pathways, it is likely that 
additional clinical useful biomarkers will emerge. Some as direct therapeutic targets, 
others as markers of treatment indication, or hopefully, some as markers of both.  
Our project identifies novel biomarkers in COPD. The role of both MIF and GDF-15 
in COPD should be investigated further. They are not COPD-specific, but both have 
the potential as targets for therapeutic intervention. On the other hand our project also 
underpins the concept of COPD as a heterogeneous disease. It is likely that many 
COPD biomarkers will be relevant only for fractions of the patients, depending on the 
dominant phenotype, inflammatory pathways and several other factors. 
As mentioned in the introduction, COPD is an umbrella diagnosis containing different 
conditions with similar symptoms and airway obstruction as the common denominator. 
This has probably been beneficial in order to get attention from media, politicians and 
the general population to a low-status condition. A common disease definition has also 
likely contributed in uniting research environments and societies of thoracic and 
pulmonary medicine around the globe. This simplification has nevertheless had a 
backside, since it has contributed to an incomplete understanding of COPD. For the 
last decades it has been obvious that airway obstruction is just one of many symptoms 
of the disease instead of an all-important attribute. As a result, COPD is again being 
looked upon as a collection of similar conditions, having fundamental differences (12, 
275, 276). As a consequence, future research on COPD should to a greater extent 
differentiate between disease phenotypes and take into consideration significant 
comorbidities such as cardiovascular disease when designing studies (156, 277).  
There are several knowledge gaps in COPD, and future research should focus on 
closing these. Differences between smokers in terms of COPD development, 
differences between COPD patients in AECOPD frequency, lung function decline and 
life span, and differences in treatment effect are only a few. Differences due to 
genetics have been an obvious hypothesis, but apart from the genetic mechanisms 
behind emphysema due to A1AT-defiency, findings have been limited. Nonetheless, 
improved DNA-sequencing techniques have identified several genes associated with 
COPD (278). Epigenetic studies on COPD have only scratched the surface (23), but is 
a research area likely to accelerate the next years. 
Genetics and epigenetics related to COPD is an exceedingly comprehensive research 
topic. However, the largest and most diverse source of genes in the lungs does not 
originate in the patients genome, but to the microbiome residing in the airways. The 
distal airways were until recently considered sterile. New technology, especially 
techniques utilizing 16s-RNA sequencing have drastically changed this view (279). 
The role of bacteria, viruses and fungi in stable and exacerbated COPD is 
understudied, but is under investigation in several research environments including 
ours (280). There are likely complex interactions within the microbiome, and between 
the microbiome and the human immune system. Illuminating the functional role of the 
microbiome may be vital to fully understand the immune responses in COPD, and may 
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Visit 1 Bergen COPD Cohort study 
Questionnaire 2 
Questionnaire on symptoms and exposures at study inclusion/visit 1 
 
Subject ID:  Date of birth:  Date:  Visit nr: 
A. Airway symptoms 
1. Do you usually cough or clear your throat in the morning? (yes/no) 
2. Do you usually cough during the day? (yes/no) 
3. Do you usually have phlegm when coughing? (yes/no) 
4. Do you have cough for three months or more altogether during a year? (yes/no) 
5. Are you more breathless than people of your own age when walking uphill? 
(yes/no) 
6. Are you breathless walking at a normal pace on level ground? (yes/no) 
7. Are you breathless while at rest? (yes/no) 
8. Do you experience breathlessness at rest? (yes/no) 
9. Do you experience attacks of breathlessness? (yes/no) 
10. Have you ever have had wheezing (a wheezing sound) in your chest? (yes/no) 
11. Have you had wheezing (a wheezing sound) in your chest during the last 12 
months? (yes/no) 
12.  Have you been breathless in conjunction with wheezing in your chest? (yes/no) 
13. Have you had wheezing when not having symptoms of a cold? (yes(no) 
14. Were you hospitalized before you were 2 years old because of lung disease 





Visit 3-8 Bergen COPD Cohort study 
Questionnaire 1 
Questionnaire on exacerbation history and changes in medication or clinical 
status at subsequent visits 3-8 
 
B COPD exacerbations and newly diagnosed diseases 
Number of COPD exacerbations since Visit 1___ 
For exacerbation 1, register: 
From date____ to____ 
Antibiotics:  Prednisolone/corticosteroids: Hospital admission:  
☐No   ☐Yes  ☐No   ☐Yes    ☐No   ☐Yes 
1. Name of medication ____________ Dose  ____________ 
Start date (dd.mm.yyyy) ____________ Stop date ____________ 
2. Name of medication ____________ Dose  ____________ 
Start date (dd.mm.yyyy) ____________ Stop date ____________ 
 
For exacerbation 2, register: 
From date____ to____ 
Antibiotics:  Prednisolone/corticosteroids: Hospital admission:  
☐No   ☐Yes  ☐No   ☐Yes    ☐No   ☐Yes 
1. Name of medication ____________ Dose  ____________ 
Start date (dd.mm.yyyy) ____________ Stop date ____________ 
2. Name of medication ____________ Dose  ____________ 
Start date (dd.mm.yyyy) ____________ Stop date ____________ 
 
 
Have you been diagnosed with heart disease since Visit 1? ☐No   ☐Yes 
If yes, specify_________ 
Have you been diagnosed with hypertension since Visit 1? ☐No   ☐Yes 
Have you been diagnosed with diabetes since Visit 1?  ☐No   ☐Yes 
Have you been diagnosed with cancer since Visit 1?  ☐No   ☐Yes 
If yes, specify_________ 
 
C Regular medication 
Have you been given influenza vaccine last season?   ☐No   ☐Yes 
Regular use of medication      ☐No   ☐Yes 
Have you started/stopped any medication since Visit 1? ☐No   ☐Yes 
If stopped any medication, describe name and date of stop. 
_______________________________________________________ 
Name of all regular medication:    Started before or after Visit 1? 
1. Name_______________Dose_____________  ☐Before   ☐After 
If AFTER Visit 1: Start date (dd.mm.yyyy)_____________ 
2. Name_______________Dose_____________  ☐Before   ☐After 
If AFTER Visit 1: Start date (dd.mm.yyyy)_____________ 
 
D Smoking habits 
Has the patient changed smoking habits since Visit 1? 
☐No, still non-smoker ☐No, still smoker  ☐Yes, reduced smoking 





Ad hoc visit Bergen COPD Exacerbation Study 
Exacerbation questionnaire  
Questionnaire for the outpatient clinic/study physician at an event of suspected 
acute exacerbation of COPD 
 
B. Airway symptoms (physician) 
Constitution of the exacerbation: 
(exacerbation is defined as the presence of 2 major symptoms or 1 major combined 
with 1 minor symptom for 2 consecutive days) 
 
Major symptoms:  
Do you have increased dyspnea?       ☐Yes   ☐No 
Do you have increased amount of phlegm?     ☐Yes   ☐No 
Have you had a change of color of the phlegm?    ☐Yes   ☐No 
 
Minor symptoms 
Do you have symptoms of a cold (nasal congestion/discharge)? ☐Yes   ☐No 
Do you have wheezing?       ☐Yes   ☐No 
Have you had body temperature > 38℃     ☐Yes   ☐No 
Have you had cold attacks or shiverings?    ☐Yes   ☐No 
Date of onset of exacerbation (dd.mm.yyyy):_______________ 
 
Worsening of dyspnea – the last 24 hours 
☐Grade 1 = I am just as breathless as I usually am. 
☐Grade 2 = I have been more breathless than usually when making errands outside 
the house (going to the grocery store etc.) 
☐Grade 3 = I have been more breathless than usually during daily housework or 
similar activities. 
☐Grade 4 = I have been more breathless than usual while at rest.  
☐Grade 5 = I have been so breathless that I had to sit in an upright position during the 
night.  
 
C. Other symptoms 
Have you had chest pain during this exacerbation?  ☐Yes   ☐No 
If yes, did they fluctuate with respiration?    ☐Yes   ☐No 
 
D. Medication (physician) 
 





E. Clinical findings 
Respiratory rate (counted during 30 sec. minimum):_______ 
Heart rate:_______    Regular heart rate? ☐Yes   ☐No 
If irregular, measure ECG. Result ECG, atrial fibrillation?  ☐Yes   ☐No 
Temperature (1 decimal):________ Method applied (ear, mouth, rectal):________  
Systolic blood pressure:________ Diastolic blood pressure:________ 
Expiratory wheezing sounds?  ☐Yes   ☐No  
Crepitations?     ☐Yes   ☐No 
If crepitations, localization (mark all applicable):  
Right   Left 
☐Apical   ☐Apical 
☐Middle field    ☐Middle field    






Monthly telephone contact Bergen COPD Cohort Study 
Questionnaire 15 
Questionnaire for monthly telephone interviews recording acute exacerbations of 
COPD 
How long time has passed since the last telephone contact? 
☐4 weeks ☐8weeks ☐12 weeks ☐16 weeks ☐>16 weeks  
Date last visit:________ 
Questions 
1. Have you during the last 4 weeks felt unwell or had an exacerbation of your COPD? 
 If yes, during the last weeks, which symptoms of your disease have worsened? 
a) Cough during the day.     ☐Yes   ☐No 
b) Cough during the night.     ☐Yes   ☐No 
c) Phlegm.       ☐Yes   ☐No 
d) Breathlessness      ☐Yes   ☐No 
e) Fatigue, ability to do ordinary activities.  ☐Yes   ☐No 
2. If telephone contact was not achieved at the previous attempt, i.e. it is more than 4 
weeks since last contact: Have you since the last contact had an exacerbation of your 
COPD, i.e. more than 4 weeks ago?   ☐Yes   ☐No 
 If no, go to question 9, if yes, continue: 
3. Have you made contact with a physician during the last 4 weeks due to worsening 
of your COPD?      ☐Yes   ☐No 
4. Have you dialed the phone number on the laminated card (94807715) due to an 
exacerbation of your COPD during the last 4 weeks (or since last time we phoned you 
if more than 4 weeks ago)?    ☐Yes   ☐No 
5. Have you consulted a physician at the outpatient for an acute examination as a result 
of a telephone contact with us?    ☐Yes   ☐No 
6. Have you during the last 4 weeks had an exacerbation for which you received 
treatment from anyone other than the exacerbation team? ☐Yes   ☐No 
If yes, by whom did you receive treatment for your exacerbation? 
a) your regular physician 
b) another general practitioner 
c) a specialist outside the hospital 
d) a physician at the hospital 
7. Have you during the last 4 weeks been admitted to an emergency ward due to your 
COPD?       ☐Yes   ☐No 
If yes, which places:_______________ 
8. Have you been hospitalized and stayed overnight at a hospital as a consequence of 
your COPD?       ☐Yes   ☐No 
If yes, how many times?_________ If yes, how many days and nights?_________ 
If yes, which hospital?__________ 
9. Have you had a regular follow-up/consultation with a physician for your COPD 
during the last 4 weeks?     ☐Yes   ☐No 
If yes, what type of physician?____________ 
10. Have you during the last 4 weeks taken any new medication for your COPD? 
        ☐Yes   ☐No 
11. Have you just supplemental oxygen during the last 4 weeks?   
        ☐Yes   ☐No 
If yes, how many hours have you used oxygen therapy?________ 
Have you used oxygen therapy during exercise or physical activity? ☐Yes   ☐No 
Have you used oxygen therapy while at rest?    ☐Yes   ☐No 
Have you used oxygen therapy during the night?   ☐Yes   ☐No 
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Overview of systemic inflammatory markers measured in COPD patients and 
controls 







Gran granulocytes, neutrophils 
  Eos eosinophils 
  TPC trombocyte platelet count 
  Creatinine creatinine 
  Ferritine ferritine     
NGAL neutrophil gelatinase-associated lipocalin LCN2 Oslo 
CRP C-reactive protein 
 
2007-2008 
OPG osteoprotegrin TNFRSF11B 
 CXCL-16 CXC-motif ligand 16 
  TNF-R1 tumor necrosis factor-receptor 1 TNFRSF1A 
 MCP-4 monocyte chemotactic protein-4 CCL13 
 NAP-2 neutrophil activating protein 2 CXCL7 
 MBL mannose-binding lectin     
micro-CRP high sensitive C-reactive protein 
 
Japan 
TNF-α tumor necrosis factor α cachectin 2009 
IL-1 interleukin 1 
  IL-6 interleukin 6     
MIF  macrophage migration inhibitory factor GIF Oslo 
Alcam activated leukocyte cell adhesion molecule CD166 2012 
CD163 cluster of differentiation 163     
GDF-15 growth differentiation factor 15 
 
USA 
Activin-A activin-A   2014 





IL-1rα interleukin 1 receptor α 
 
2014 
IL-2 interleukin 2 
  IL-4 interleukin 4 
  IL-5 interleukin 5 
  IL-6 interleukin 6 
  IL-7 interleukin 7 
  IL-8 interleukin 8 CXCL8 
 IL-9 interleukin 9 
  IL-10 interleukin 10 
  IL-12 interleukin 12 
  IL-13 interleukin 13 
  
IL-15 interleukin 15 
  IL-17 interleukin 17 
  Eotaxin eotaxin 
  Basic FGF basic fibroblast growth factor 
  G-CSF granulocyte colony stimulating factor 
  GM-CSF granulocyte-macrophage colony stimulating factor 
  IFN-γ interferon gamma 
  IP-10 interferon gamma-induced protein 10 CXCL10 
 MCP-1 monocyte chemoattraction protein 1 CCL2 
 MIP-1α macrophage inflammatory protein 1α CCL3 
 MIP-1β macrophage inflammatory protein 1β CCL4 
 PDGF-BB platelet derived growth factor-BB 
  CCL5 chemokine (C-C motif) ligand 5 RANTES 
 TNF-α tumor necrosis factor α cachectin 
 VEGF vascular-endothelial growth factor     
#
 IL1, IL6 and TNF-α were measured in duplicates, last measurements were not used in the analyses. 
IL15 and CCL5 were excluded from analysis due to technical errors. 
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Abstract
Background: COPD exacerbations accelerate disease progression.
Aims: To examine if COPD characteristics and systemic inflammatory markers predict the risk for acute COPD exacerbation
(AECOPD) frequency and duration.
Methods: 403 COPD patients, GOLD stage II-IV, aged 44–76 years were included in the Bergen COPD Cohort Study in 2006/
07, and followed for 3 years. Examined baseline predictors were sex, age, body composition, smoking, AECOPD the last year,
GOLD stage, Charlson comorbidity score (CCS), hypoxemia (PaO2,8 kPa), cough, use of inhaled steroids, and the
inflammatory markers leucocytes, C-reactive protein (CRP), neutrophil gelatinase associated lipocalin (NGAL), soluble tumor
necrosis factor receptor 1 (sTNF-R1), and osteoprotegrin (OPG). Negative binomial models with random effects were fitted
to estimate the annual incidence rate ratios (IRR). For analysis of AECOPD duration, a generalized estimation equation
logistic regression model was fitted, also adjusting for season, time since inclusion and AECOPD severity.
Results: After multivariate adjustment, significant predictors of AECOPD were: female sex [IRR 1.45 (1.14–1.84)], age per 10
year increase [1.23 (1.03–1.47)], .1 AECOPD last year before baseline [1.65 (1.24–2.21)], GOLD III [1.36 (1.07–1.74)], GOLD IV
[2.90 (1.98–4.25)], chronic cough [1.64 (1.30–2.06)] and use of inhaled steroids [1.57 (1.21–2.05)]. For AECOPD duration more
than three weeks, significant predictors after adjustment were: hypoxemia [0.60 (0.39–0.92)], years since inclusion [1.19
(1.03–1.37)], AECOPD severity; moderate [OR 1.58 (1.14–2.18)] and severe [2.34 (1.58–3.49)], season; winter [1.51 (1.08–2.12)],
spring [1.45 (1.02–2.05)] and sTNF-R1 per SD increase [1.16 (1.00–1.35)].
Conclusion: Several COPD characteristics were independent predictors of both AECOPD frequency and duration.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a common
illness worldwide, and its prevalence is increasing. The disease is
heterogeneous where some patients are more prone to have
exacerbations than other, proposed to be representing a pheno-
type of its own [1]. COPD exacerbations are associated with
accelerated worsening of lung function [2,3], increased disease
burden and mortality [4,5], thus making it important to identify
and treat these patients.
So far, the best predictors found for future exacerbations are a
history of previous exacerbations and decline in forced expiratory
volume in one second (FEV1)[6–8], together with direct or
indirect indicators of pulmonary hypertension [9,10]. Inflamma-
tory biomarkers may also be of value, alone or several combined
[11–15]. Other described predictors are depression [16], gastro-
esophageal reflux disease (GERD) [17], and quality of life [18].
However, the existing knowledge of markers that could predict
exacerbation of COPD is still limited. The inflammatory markers
associated with COPD exacerbations found so far are unspecific,
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where abnormal values can be seen in a range of conditions, thus a
continued evaluation of novel markers is warranted. Second,
although several studies have linked exacerbations with increased
inflammation [19,20], it is not fully understood whether this is a
cause or a consequence, and for this purpose longitudinal studies
are needed. Third, another measure of disease burden apart from
exacerbation frequency is their duration, for which some
associations have been described [21–24], but patients with
delayed exacerbation recovery remains difficult to identify.
This study aimed to find predictors for COPD exacerbations
and exacerbation duration, using longitudinal data from a large
Table 1. Characteristics of COPD patients according to exacerbation frequency during follow-up.
Less than 1 exacerbations
per year, n = 231
1 or more exacerbations




Age, Mean (SD) 62.6 (6.8) 64.3 (6.8) 0.01







Exacerbations last year prior to inclusion, % ,0.001
0–1 93.5 70.4
2+ 6.5 29.7
GOLD 2007 classification, % ,0.001
FEV1 50–80% 58.9 33.7
FEV1 30–50% 37.2 47.7
FEV1,30% 3.9 18.6
Hypoxemia, % 0.07
PaO2.8 kPa 90.9 84.7
PaO2,8 kPa 9.1 15.3





Chronic cough, % 0.002
No 61.5 45.6
Yes 38.5 54.4
Cough with phlegm, % 0.02
No 45.9 34.3
Yes 54.1 65.7
Use of inhaled steroids, % ,0.001
No 39.4 22.1
Yes 60.6 77.9
Inflammatory markers, Median (IQR)
Leucocyte count (WBC), x109/l 7.7 (6.3 29.1) 7.9 (6.6 29.6) 0.11
C-reactive protein (CRP), ng/ml 3.4 (1.7 26.8) 4.9 (2.1 212.6) 0.003
Neutrophil gelatinase lipocalin (NGAL), 10 mg/ml 6.7 (5.1 29.5) 6.7 (5.2 29.2) 0.77
Soluble TNF receptor-1 (sTNF-R1), 100 mg/ml 6.8 (5.8 28.1) 7.1 (5.6 28.5) 0.43
Osteoprotegrin (OPG), ng/ml 5.5 (3.8 27.1) 5.9 (4.5 27.3) 0.10
*x-square for categorical variables, t-test for means and Kruskal Wallis test for medians
doi:10.1371/journal.pone.0109721.t001
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cohort study in Western Norway, examining both clinical
characteristics and novel systemic inflammatory markers.
Materials and Methods
Study population
433 Patients with COPD were included in the Bergen COPD
Cohort Study (BCCS) between February 2006 and February 2008.
All subjects in the study received written and oral information
prior to inclusion and signed informed consent. The study was
approved by the Regional Committee for Medical and Health
Research Ethics, region West (REC-West), case number 165.08.
The patients were aged between 44–76 years at the time of
inclusion. All patients had a clinical diagnosis of COPD, and a
ratio of forced expiratory volume in one second (FEV1) to forced
vital capacity (FVC) ,0.7 at least 15 minutes after bronchodila-
tion, FEV1,80% predicted by Norwegian reference values [25],
and a smoking history of more than 10 packyears. Exclusion
criteria were lung diseases other than COPD, additional active
inflammatory disease such as various autoimmune disorders, and
having a COPD-exacerbation within 4 weeks prior to inclusion.
No patients were using long-term prophylactic macrolides or other
antibiotics except one patient who was using a tetracycline for a
skin disease. The details of study design, patient selection and data
collection have been described previously [26].
Data collection
Briefly, all patients were examined by a study physician. A
physical examination, blood gas sampling, and a clinical interview
that included exacerbation history, comorbidities and medication
history were undertaken. All patients performed spirometry,
before and after bronchodilation with 0.4 mg salbutamol, using
a Viasys Masterscope. The patients were categorized into Global
Initiative for Chronic Obstructive Lung Disease (GOLD 2007)
categories II-IV based on post-bronchodilation FEV1.
Body composition was determined with bioelectrical impedance
measurements. Cachexia was defined as a fat free mass index
(FFMI) less than 17 kg/m2 in men or less than 14 kg/m2 in
women, which corresponds to the lower 95% confidence limit in a
normal population [27]. Obesity was defined as a fat mass index
(FMI) of more than 9.3 kg/m2 in men or more than 13.5 kg/m2 in
women [27].
All patients were examined and interviewed by a study
physician at the out-patient clinic every 6 months for 3 consecutive
years. At each visit, the study physician performed a detailed
clinical interview, where all exacerbations were registered.
The exacerbation count was the main outcome in this study and
was prospectively registered by the patients. We defined an
exacerbation as a worsening of respiratory symptoms for two
consecutive days or more. Exacerbations that did not require any
change in treatment were defined as mild, those requiring
treatment with antibiotics or systemic steroids by the decision of
a physician were considered moderate, and those in need for
hospital admission were considered severe [28]. Exacerbation
duration was patient reported, based entirely on symptomatic
recovery. The cut off for late recovery was set at three weeks; there
exists no definition on a long lasting exacerbation, our limit for
when to normally expect recovery was based on clinical
experience.
Laboratory measurements
Peripheral blood sampling and analyses of total leukocyte
(WBC) count, C-reactive protein (CRP), neutrophil gelatinase
associated lipocalin (NGAL), soluble tumor necrosis factor
receptor-1 (sTNF-R1), and osteoprotegrin (OPG) were performed
as previously described [26,29]. WBC and CRP were chosen as
inflammatory markers due to their availability as established
indicators of inflammation. NGAL [29], sTNF-R1 [26], and OPG
[26] have all been shown in cross-sectional analyses from our
cohort to be associated with important COPD disease character-
istics including FEV1 and exacerbation frequency.
Arterial blood gas analysis was sampled and examined within 5
minutes with a Radiometer ABL520 analyzer [30]. Hypoxemia
was defined as a partial oxygen pressure ,8.0 kPa.
Missing Values
30 patients only participated in the baseline visit. Of the 30
patients, 9 were excluded due to use of oral steroids, 8 died before
any follow-up visits were performed, in 2 patients CT scans
revealed lung cancer, and finally 11 patients withdrew their
consent to participate. Thus, 403 patients were included in the
statistical analyses. Information regarding chronic cough and
cough with phlegm was missing in 8 and 2 patients, respectively.
Plasma-sampling failed in 12 patients, and for 1, 2, and 7 patients
we lacked sufficient plasma to measure sTNF-R1, OPG, and
NGAL, respectively. Arterial blood gas analysis failed in 37 cases,
most commonly a sampling error where the patient did not want
puncture.
Statistical analyses
The exacerbation count distribution was heavily skewed to the
right. For the baseline characteristics analysis the exacerbation
count was dichotomized into patients with an average exacerba-
tion count of less than 1 per year, and those with 1 or more per
year. Mild exacerbations were not included in the exacerbation
count analysis, as in concordance with prior studies [6–8], and due
to suspected under-reporting [31]. Bivariate associations were
examined with t-tests or non-parametric tests for continuous
variables, and x-square tests for categorical variables.
Random effects negative binomial regression models condition-
al on gamma errors were fitted to estimate the incidence rate ratios
(IRR) for each potential predictor variable. Correspondingly, a
multivariate model was fitted including all the predictor variables
from the bivariate analyses except for cough with phlegm, which
showed a strong colinearity with chronic cough. The inflammatory
markers also showed strong colinearity with each other, and were
therefore tested separately added to the main model. To test for
possible interactions by sex, all variables that differed statistically
by sex at baseline were tested one at a time with an interaction
term in the final multivariate model.
In addition, exacerbations were analyzed according to duration,
searching for factors associated with recovery time exceeding three
weeks. A generalized estimating equation logistic regression model
with exchangeable correlation structure was fitted, testing poten-
tial predictor variables both separate and multivariate. Stata 12.1
(StataCorp LP, College Station, TX, USA) was used for the
statistical analyses.
Results
350 out of the 403 COPD patients experienced one or more
exacerbations during the three years of follow-up. A total of 1696
exacerbations were registered, of which 393 were classified as
mild, 933 as moderate, and 370 as severe. Women had more
exacerbations than men, the difference consisting of more
exacerbations of moderate severity (p = 0.001). The median
duration for an exacerbation was 14 days (interquartile range
15 days) .
Predictors of COPD Exacerbations
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The baseline characteristics of the study population are
presented in Table 1. Patients with a higher exacerbation rate
were slightly older, more cachectic or obese, had a higher number
of exacerbations before inclusion, had a lower FEV1 in %
predicted, and had higher frequencies of chronic cough and cough
with phlegm. They were also more frequent users of inhaled
corticosteroids (ICS). Of the measured inflammatory markers
upon inclusion, only CRP was significantly higher in patients with
more frequent exacerbations during follow-up.
Table 2. Bivariate predictors of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a
random effects negative binomial model.
Baseline explanatory variables IRR (95% CI) p-Value
Sex
Men 1
Women 1.27 (0.99 21.63) 0.06
Age
per 10 years increase 1.24 (1.04 21.48) 0.02
Body Composition
Normal 1
Cachectic 1.41 (1.07 21.85) 0.02
Obese 1.23 (0.88 21.71) 0.23
Smoking
Ex 1
Current 0.83 (0.65 21.06) 0.13
Exacerbations 12 months before inclusion
0–1 1
2+ 2.74 (2.08 23.61) ,0.001
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.75 (1.38 22.23) ,0.001
FEV1,30% 3.59 (2.51 25.13) ,0.001
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 1.61 (1.11 22.34) 0.01
Charlson comorbidity Score
1 1
2 1.07 (0.79 21.43) 0.67
3 1.21 (0.82 21.77) 0.33
4+ 1.37 (0.86 22.21) 0.19
Chronic cough
No 1
Yes 1.73 (1.36 22.19) ,0.001
Cough with phlegm
No 1
Yes 1.38 (1.08 21.77) 0.01
Use of inhaled steroids
No 1
Yes 2.11 (1.62 22.74) ,0.001
Inflammatory markers *
Leucocyte count (WBC) 1.13 (1.00 21.29) 0.05
C-reactive protein (CRP) 1.13 (1.01 21.26) 0.04
Neutrophil gelatinase lipocalin (NGAL) 1.01 (0.90 21.13) 0.89
Soluble TNF receptor-1 (sTNF-R1) 1.05 (0.94 21.18) 0.36
Osteoprotegrin (OPG) 1.13 (1.01 21.27) 0.04
*Per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t002
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Factors associated with annual exacerbation rate
Table 2 shows bivariate associations between possible predictor
variables and annual exacerbation rate. Age, cachexia, number of
exacerbations the year before inclusion, GOLD stage, hypoxemia,
cough symptoms, and use of ICS were all associated with a higher
IRR. Higher levels of CRP and OPG at baseline, but not levels of
WBC, NGAL and sTNF-R1, were predictive of a higher
exacerbation rate within the follow-up.
The adjusted IRRs are shown in Table 3. Significant predictors
of a higher risk for moderate or severe exacerbations were female
sex, higher age, a history of frequent exacerbations prior to
inclusion, higher GOLD stage, chronic cough and use of ICS. Of
all potential interactions between sex and the other variables
tested, none were found to be statistically significant.
Thus, mostly the associations seen in the bivariate analyses were
confirmed, except for the inflammatory markers, which were not
Table 3. Multivariate model of the annual incidence rate ratio (IRR) of moderate or severe COPD exacerbations, estimated by a
random effects negative binomial model.
Baseline explanatory variables IRR 95% CI p-Value
Sex
Men 1
Women 1.45 (1.14 21.84) 0.002
Age
per 10 years increase 1.23 (1.03 21.47) 0.02
Body composition
Normal 1
Cachectic 1.19 (0.91 21.56) 0.22
Obese 1.23 (0.90 21.69) 0.19
Smoking
Ex 1
Current 0.93 (0.73–1.19) 0.56
Exacerbations last year
0–1 1
2+ 1.65 (1.24–2.21) 0.001
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.36 (1.07–1.74) 0.01
FEV1,30% 2.90 (1.98–4.25) ,0.001
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 1.10 (0.79–1.54) 0.58
Charlson comorbidity Score
1 1
2 0.97 (0.74–1.27) 0.81
3 0.98 (0.68–1.42) 0.93
4+ 0.98 (0.61–1.57) 0.93
Chronic cough
No 1
Yes 1.64 (1.30–2.06) ,0.001
Use of inhaled steroids
No 1
Yes 1.57 (1.21–2.05) 0.001
Inflammatory markers added one each, to the above model *
Leucocyte count (WBC) 1.04 (0.93–1.17) 0.49
C-reactive protein (CRP) 1.03 (0.93–1.14) 0.56
Neutrophil gelatinase lipocalin (NGAL) 0.99 (0.89–1.10) 0.85
Soluble TNF receptor-1 (sTNF-R1) 1.03 (0.92–1.16 0.56
Osteoprotegrin (OPG) 0.92 (0.82–1.03) 0.15
*IRR per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t003
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Table 4. Bivariate predictors of copd-exacerbation duration more than three weeks, estimated by a generalized estimation
equation logistic regression model.
Baseline explanatory variables OR 95% CI p-Value
Sex
Men 1
Women 1.02 (0.79 21.31) 0.90
Age
per 10 years increase 0.94 (0.78 21.13) 0.52
Body Composition
Normal 1
Cachectic 1.07 (0.81 21.43) 0.63
Obese 1.43 (1.02 22.00) 0.04
Smoking
Ex 1
Current 1.24 (0.96 21.59) 0.10
Exacerbations 12 months before inclusion
0–1 1
2+ 1.20 (0.91 21.59) 0.20
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.11 (0.84 21.45) 0.47
FEV1,30% 1.05 (0.72 21.53) 0.79
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 0.83 (0.57 21.22) 0.34
Charlson comorbidity Score
1 1
2 1.51 (1.13 22.02) 0.005
3 1.26 (0.85 21.85) 0.25
4+ 1.21 (0.77 21.89) 0.42
Chronic cough
No 1
Yes 1.43 (1.11 21.85) 0.005
Cough with phlegm
No 1
Yes 1.18 (0.91 21.53) 0.22
Use of inhaled steroids
No 1
Yes 0.97 (0.72 21.30) 0.83
Time since inclusion
Per year increase 1.2 (1.05–1.36) 0.006
Exacerbation severity
Mild 1
Moderate (use of antibiotics or steroids) 1.51 (1.12 22.01) 0.006
Severe (admission to hospital) 2.25 (1.60 23.17) ,0.001
Season
Summer 1
Autumn 1.24 (0.90 21.71) 0.18
Winter 1.48 (1.09 22.01) 0.01
Spring 1.36 (0.99 21.86) 0.06
Inflammatory markers *
Leucocyte count (WBC) 1.11 (0.98 21.25) 0.10
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significant predictors of later exacerbations in the model where a
large number of covariables were included.
Factors associated with exacerbation duration more than
three weeks
Table 4 and 5 show bi- and multivariate associations between
potential predictor variables and exacerbations lasting more than 3
weeks. Variables with significant bivariate associations were
obesity, Charlson comorbidity score (CCS) 2, chronic cough,
increasing time since inclusion, increasing exacerbation severity,
exacerbations during winter and spring (December-February and
March-May), and higher levels of baseline sTNF-R1. The same
variables remained significant after multivariate adjustment, with
the exception of obesity, CCS and chronic cough. The presence of
hypoxemia was after adjustment associated with exacerbation
duration shorter than three weeks. Age, sex, GOLD-stage,
smoking status and use of medication along with the other
inflammatory markers did not show a significant association with
exacerbation duration.
Discussion
We used prospective follow-up data from a large cohort study
from western Norway to identify predictors for COPD exacerba-
tion frequency and duration. The best predictors of future
exacerbations in this study were a history of frequent exacerba-
tions prior to inclusion, lower lung function, increasing age, and
female sex, confirming the findings of earlier studies [6–8].
Furthermore, we identified some easily accessible clinical variables
independently associated with increased exacerbation rates such as
chronic cough and the use of inhaled steroids.
Exacerbation duration was significantly associated with exacer-
bation severity and season, which is in accordance with other
studies [21,22,24]. In addition, we identified an association
between exacerbation duration and both hypoxemia and sTNF-
R1 not demonstrated before.
The main strengths of this study were the prospective design,
the large number of patients, and the assessment of a series of
different variables. This allowed for the use of complex regression
analysis and adjustment for several key variables. Attendance rate
at the visits was high, varying between 86 and 97 percent. The
longitudinal design allowed for predictive statistical modeling,
however, no intervention was done, and the concept prediction
should not be confused with causality.
The statistical analysis of exacerbation frequency is complex,
due to its distorted distribution and due to clustering both in
subject and time [32]. One approach is to compare the frequent
vs. the non-frequent exacerbator using logistic regression. How-
ever, negative binomial or Poisson regression may be more suited
[33]. In our study we treated the exacerbation frequency as a
count variable. Both Poisson and negative binomial models were
considered, but due to overdispersion of the data the latter model
was preferred, though a Poisson model was also fitted producing
almost identical results (not shown here).
The exacerbation data was acquired through interview by the
study physician, with the aid of the patients’ journal present. The
majority of patients (n = 350) lived in a proximity to our hospital,
which would have led them to attend our hospital in an
emergency. Due to the long follow-up, we did not use an
exacerbation diary or other grading tools although these methods
have been validated [34]. Thus, we believe under-reporting of
severe exacerbations were highly unlikely and under-reporting of
moderate exacerbations unlikely but probably present to some
extent. Regarding severe exacerbations, apart from hospital
admission and duration, we had no other clinical information to
validate its severity, and due to this we chose to analyze severe and
moderate exacerbations together. For the analysis of exacerbation
duration, mild exacerbations were included in the model despite
the limitations in in the data collection mentioned above, and this
should be taken into consideration when interpreting the data.
This study showed a large diversity in both exacerbation
frequency and duration. In agreement with earlier studies, a
person with exacerbations in the past is more likely to experience
exacerbations in the future [6–8]. Earlier studies have shown that
women experience more symptoms from their illness, but
mortality rates have shown gender equality [35]. A similar picture
emerged in our study, where women experienced a higher rate of
moderate exacerbations, but not severe exacerbations requiring
hospital admission. Whether this represents a genuine increase in
exacerbations or an increased tendency among women to seek
medical attention remains unclear.
Somewhat surprising, but also seen before [6], was the finding
that ex-smokers had no reduction of the exacerbation count
compared to active smokers. This could imply that smoking
cessation was too late, and that disease progression continued after
smoking cessation. Another explanation may be that most of our
cohort consisted of a selection of COPD patients having had prior
consultations with pulmonary physicians [26], which might affect
smoking habits, where perhaps the most symptomatic patients
were more likely to have quit prior to entering the study. Different
exacerbation rates between smokers and ex-smokers have been
seen in COPD patients selected from a more general population
[36]. Finally, time since smoking cessation was not a significant
variable in our study (data not shown), but our study may not have
been powered to examine that properly.
The association between exacerbation frequency and use of ICS
may seem paradoxical as large randomized studies have shown a
modest, but significant decrease in exacerbation risk with their use
[37–40]. Nevertheless, randomized trials often include highly
selected study populations, and non-intervention cohort studies as
ours add to the existing knowledge. Several studies have shown an
association between ICS and pneumonia rate [41–43], and it is
Table 4. Cont.
Baseline explanatory variables OR 95% CI p-Value
C-reactive protein (CRP) 0.94 (0.83 21.07) 0.36
Neutrophil gelatinase lipocalin (NGAL) 1.06 (0.93 21.21) 0.37
Soluble TNF receptor-1 (sTNF-R1) 1.14 (1.01 21.28) 0.04
Osteoprotegrin (OPG) 0.97 (0.85 21.09) 0.59
*IRR per 1 SD increase of marker value.
doi:10.1371/journal.pone.0109721.t004
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possible that use of ICS comes with an increased risk for infectious
exacerbations of COPD. We observed an exacerbation IRR of
1.57 in ICS-users after multivariate adjustments, but still we
cannot exclude a selection bias since these patients may have
received their ICS due to worsening of symptoms not accounted
for in our model. Also, in our study, a majority of the patients
using ICS (91%) were using them in combination with a long
acting beta-2-agonist (LABA), making it difficult to separate the
effect of the ICS vs. the LABA. Thus, our observation of increased
exacerbation rate in ICS-users cannot be interpreted as a causal
effect, but nonetheless, an observation of ICS-use may aid in
identifying a patient with increased risk for future exacerbations.
A primary objective in this study was to evaluate the association
between systemic inflammation and exacerbation rate measuring
inflammatory markers at inclusion. In our study we only measured
the inflammatory markers at baseline, and their predictive value
Table 5. Multivariate model of copd-exacerbation duration more than three weeks, estimated by a generalized estimation
equation logistic regression model.
Baseline explanatory variables OR 95% CI p-Value
Sex
Men 1
Women 1.17 (0.88–1.56) 0.29
Age
per 10 years increase 0.88 (0.70–1.10) 0.27
Body Composition
Normal 1
Cachectic 0.92 (0.66–1.29) 0.63
Obese 1.35 (0.93–1.98) 0.11
Smoking
Ex 1
Current 1.29 (0.95–1.76) 0.11
GOLD 2007 classification
FEV1 50–80% 1
FEV1 30–50% 1.23 (0.90–1.67) 0.19
FEV1,30% 1.18 (0.75–1.87) 0.48
Hypoxemia
PaO2.8 kPa 1
PaO2,8 kPa 0.60 (0.39–0.92) 0.02
Charlson comorbidity Score
1 1
2 1.14 (0.81–1.59) 0.46
3 1.15 (0.72–1.82) 0.56
4+ 1.36 (0.76–2.42) 0.30
Chronic cough
No 1
Yes 1.29 (0.97–1.71) 0.08
Time since inclusion
Per year increase 1.19 (1.03–1.37) 0.02
Exacerbation severity
Mild 1
Moderate (use of antibiotics or steroids) 1.58 (1.14–2.18 0.006
Severe (admission to hospital) 2.34 (1.58–3.49) ,0.001
Season
Summer 1
Autumn 1.33 (0.94–1.89) 0.11
Winter 1.51 (1.08–2.12) 0.02
Spring 1.45 (1.02–1.35) 0.04
Soluble TNF receptor-1 (sTNF-R1)
per 1 SD increase of marker value 1.16 (1.00–1.35) 0.05
doi:10.1371/journal.pone.0109721.t005
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for an event up to three years later is likely to decrease as time goes
by. CRP and OPG at baseline were bivariately associated with the
exacerbation rate, but not after multivariate adjustment. WBC,
fibrinogen and uric acid have independently shown predictive
value in other studies [6,11,14], indicating that systemic inflam-
mation may be a prerequisite for exacerbations. CRP has shown
predictive value in combination with the WBC and fibrinogen
[12], and the specificity and sensitivity may be further improved
with the construction of so called inflammomas [15], containing
three or more easily accessible markers, or with sputum samples,
nonetheless these approaches have still yielded limited clinical
value, so the search for additional markers should continue.
It is challenging to predict those patients in risk for a long lasting
exacerbation. Dissimilar from the exacerbation rate, factors like
prior exacerbations and FEV1 did not seem to affect the duration.
Increasing values of sTNF-R1 as a marker of activity in the TNF
system was associated with late exacerbation recovery, and may be
a marker of chronic inflammation in COPD. On the other hand,
sTNF-R1 is associated with important comorbidities difficult to
adjust for [26], and this finding must be confirmed in other studies.
The association between duration and season can be linked to
both lower temperature [44] and seasonality of viral infections
[45], and was anticipated; on the other hand, the observation of
reduced recovery time in patients with hypoxemia was unexpect-
ed. Hypoxemic patients are likely to have more symptoms in their
stable state, perhaps making it difficult to distinguish between the
exacerbated and the stable state, which might affect their
exacerbation reporting. Nonetheless, this observation should be
confirmed in other studies.
This study illustrates the vicious circle affecting a large
proportion of COPD patients, where one exacerbation predisposes
for the next, leading to an ever increasing disease burden. This
underscore the need for markers that could further identify
patients at risk, as well as the need for proper intervention in these
patients. We identify several clinical parameters for recognition of
patients at risk for frequent or long lasting exacerbations, making it
possible for earlier or more extensive preventive intervention.
Finally, there is still a lack of useful inflammatory markers, both to
identify patients with high risk of future exacerbations, as well as a
diagnostic tool to detect ongoing exacerbations.
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A B S T R A C T
Background: COPD patients have an increased risk of developing lung cancer, but the underlying mechanisms
are poorly understood. We aimed to identify risk factors for lung cancer in patients from the Bergen COPD
Cohort Study.
Methods: We compared 433 COPD patients with 279 healthy controls, all former or current smokers. All COPD
patients had FEV1<80% and FEV1/FVC-ratio< 0.7. Baseline predictors were sex, age, spirometry, body
composition, smoking history, emphysema assessed by CT, chronic bronchitis, prior exacerbation frequency,
Charlson Comorbidity Score, inhalation medication and 44 serum/plasma inflammatory biomarkers. Patients
were followed up for 9 years recording incidence of lung cancer. Cox-regression models were fitted for the
statistical analyses. The biomarkers were evaluated using principal component analysis.
Results: 28 COPD patients and 3 controls developed lung cancer, COPD patients had a significantly higher risk of
developing lung cancer, (HR 5.0; 95% CI 1.5–17.1, p < 0.01, adjusted values). Among COPD patients, em-
physema (HR 4.4; 1.7–10.8, p < 0.01) and obesity (HR 3.3; 1.3–8.5, p=0.02) were associated with a higher
cancer rate. Use of inhaled steroids was associated with a lower rate (HR 0.4; 0.2–0.9, p=0.03). Smoking status,
pack-years smoked or levels of systemic inflammatory markers, except for interferon gamma-induced protein 10,
did not affect the lung cancer rate in patients with COPD.
Conclusion: Patients with COPD have a higher lung cancer rate compared to healthy controls adjusted for
smoking. The presence of emphysema and obesity in COPD predicted a higher lung cancer risk in COPD patients.
Systemic inflammation was not associated with increased lung cancer risk.
1. Introduction
COPD and lung cancer are two major causes of morbidity and
mortality worldwide. COPD is the fourth leading cause of death in the
world, whereas lung cancer is the foremost cause of cancer deaths [1].
The incidence of both conditions have been increasing in the last years,
and this trend is expected to continue for the next decade [2]. Fur-
thermore, there is a known association between these two common
disorders [3]. One obvious explanation for the co-existence of these
conditions is their common risk factors, where tobacco-smoking is the
most important. However, several studies find that a diagnosis of COPD,
regardless of the amount of smoking, is an independent risk factor for
development of lung cancer [4,5]. Additionally, lung cancer incidence
has been also shown to be associated with the presence of emphysema
on CT scan independently of the degree of airway obstruction or
smoking history [6,7]. These findings might implicate a pathophysio-
logical link between COPD and lung cancer beyond that of smoking [8].
COPD, however, is a heterogeneous disease where the different
phenotypes may overlap, and it is unclear whether COPD patients with
predominant airway inflammation have a similar increased lung cancer
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risk. Earlier studies have found an association between systemic in-
flammation and both frequent exacerbations and a higher mortality in
COPD patients [9]. Nevertheless, a potential link between systemic
inflammation and lung cancer development has not been sufficiently
explored. Research on this topic may be useful both for finding cancer
biomarkers for detection of early cancer, as well as gaining a better
understanding of mechanisms by which lung tissue in some COPD pa-
tients undergo malignant transformation.
Our study aimed to evaluate several different COPD phenotypes and
characteristics as risk factors for the development of lung cancer,
combining clinical data and systemic inflammatory markers from a
large COPD cohort study with longitudinal follow up, merged with data
from the Norwegian cancer registry.
2. Materials and methods
2.1. Study population
433 subjects with COPD and 279 healthy controls, all between 40
and 76 years old, were recruited to the Bergen COPD Cohort Study
between 2006 and 2009 [10]. Both COPD patients and controls had a
smoking history of more than 10 pack-years. All COPD patients had a
clinical diagnosis of COPD, a post-bronchodilation test with FEV1/FVC-
ratio< 0.7, and FEV1< 80% of predicted value. Exclusion criteria
were known cancer within 5 years prior to entry, asthma or lung dis-
eases other than COPD, active inflammatory disorders, and COPD ex-
acerbations 4 weeks prior of inclusion, this latter category could be
included later. The Regional Committee for Medical and Health Re-
search Ethics, region west approved the study (REK-Vest, case number
2014/2153). Informed written consent was obtained from all partici-
pants.
2.2. Data collection
All subjects were evaluated by a study physician at inclusion, in-
cluding a clinical interview regarding respiratory symptoms, smoking
history, comorbidities and medication use. Comorbidities were pooled
to calculate Charlson Comorbidity Score (CCS). All patients performed
spirometry, before and after bronchodilation with 0.4 mg salbutamol.
COPD patients were categorized according to 2007 Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines. The diagnosis of
lung cancer was obtained from the Norwegian Cancer Registry, where
registration is mandatory by law, with near 100% coverage among both
healthy controls and patients (see also supplementary materials) [11].
Body composition was evaluated with bioelectrical impedance mea-
surements. Cachexia was defined as a fat free mass index (FFMI) less
than 17 kg/m2 or 14 kg/m2 in men and women, respectively [12],
which corresponds to the lower 95% confidence limit in a normal po-
pulation [13]. Obesity was defined as a fat mass index (FMI) of more
than 9.3 kg/m2 in men or more than 13.5 kg/m2 in women [13]. Em-
physema was assessed by computer tomography (CT) of the lungs, de-
fined as having more than 10% of emphysematous lung tissue, specified
as tissue density of less than −950 HU. Chronic bronchitis was defined
as having cough with phlegm for more than three months the year
before inclusion.
2.3. Laboratory measurements
Peripheral blood sampling was performed as previously described
[10]. The analysis of the 44 inflammatory markers was performed with
enzyme immunoassays (EIAs) and magnetic bead multiplex assays (see
supplementary files for details).
2.4. Statistical methods
The baseline comparison between the study populations (COPD
Table 1
Baseline characteristics of the study population.
Characteristics Smoking controls
(n= 279)
COPD (n= 433) p-Valuea
Age, mean (SD) 58.0 (10.0) 63.5 (6.9) < 0.01
Sex, No (%)
Female 128 (45.9) 175 (40.4) 0.15
Male 151 (54.1) 258 (59.6)
Smoking status, No (%)
Ex 103 (36.9) 243 (56.1) < 0.01
Current 176 (63.1) 190 (43.9)
Packyears, mean (SD) 32.1 (21.5) 40.4 (22.7) < 0.01
Body composition, No (%)
Normal 248 (88.9) 242 (55.9) < 0.01
Cachectic 11 (3.9) 123 (28.4)
Obese 20 (7.2) 68 (15.7)
Charlson Comorbidity Score, No (%)
0 197 (70.6) 0 < 0.01
1 61 (21.9) 250 (57.7)
2 16 (5.7) 102 (23.6)
3 5 (1.8) 51 (11.8)
4+ 0 30 (6.9)
Lung cancer, No (%) 3 (1.1) 28 (6.5) < 0.01
a χ2 or Wilcoxon rank-sum test.
Fig. 1. Distribution of lung cancer histology.
Table 2
Risk factors for the development of lung cancer in COPD patients vs smoking
controls, bi-and multivariable cox-regression.
Variables Bivariable Multivariable
HR 95% CI p-value HR 95% CI p-value
Age per 10 year
increase
1.97 (1.24–3.13) 0.004 1.82 (1.04–3.20) 0.04
Sex
Female 1 1
Male 1.08 (0.53–2.20) 0.84 0.86 (0.41–1.82) 0.69
Smoking status
Ex 1 1
Current 0.57 (0.28–1.18) 0.13 1.18 (0.55–2.57) 0.67
Packyears per 10
units increase
1.12 (0.99–1.25) 0.06 1.03 (0.90–1.18) 0.68
Body composition
Normal 1 1
Cachectic 0.92 (0.31–2.72) 0.88 0.48 (0.15–1.48) 0.20
Obese 2.91 (1.31–6.48) 0.009 2.13 0.92 to 4.92) 0.08
Patient categorya
Control 1 1
COPD-patient 6.33 (1.92–20.8) 0.002 4.98 (1.45–17.1) 0.01
a All controls and patients were current or former smokers.
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patients vs controls, and cancer vs non-cancer subjects), was done using
non-parametric tests (Wilcoxon rank-sum for continuous and χ2-test for
categorical variables).
A cox-regression model was fitted to evaluate risk factors of lung
cancer in COPD patients vs smoking controls. Age, sex, smoking status,
pack-years smoked, and body composition were adjustment factors.
Similarly, for the evaluation of risk factors for lung cancer in COPD
patients, a cox-regression model was fitted with adjustment using the
same variables as described above. In addition, the COPD character-
istics emphysema, chronic bronchitis, 2 or more exacerbations last year
before inclusion, and the use of inhalation medication was added to the
model one at a time, and kept in the model if the p-value was below
0.05.
The 44 biomarkers were to different degrees correlated, and for the
statistical evaluation the markers were added one at a time to the model
above. Due to multiple testing of biomarkers, a Bonferroni adjusted p-
value below 0.05/44= 0.0011 was demanded for statistical sig-
nificance.
The combined analysis of the variety of systemic inflammation be-
tween subjects was performed using a principal component analysis
(PCA). PCA is a data reduction method that extracts and transforms the
variance from multiple inter-correlated biomarkers into a smaller
number of independent variables/components [14]. Principal compo-
nents with eigenvalues above 1 (average) were retained for analysis in
the cox-regression model. The first four components, located above the
breaking point of the scree-plot, all with eigenvalues above 2, were also
visualized using scatterplots and correlation diagrams.
3. Results
The baseline characteristics of the study population are presented in
Table 1. COPD patients were older, had different smoking habits and
experienced cachexia and obesity more frequently than smokers
without COPD. Thirty-one subjects had a diagnosis of lung cancer
during follow up of which 28 where in the COPD group. The time be-
tween study inclusion and diagnosis of lung cancer varied between 48
days and 8.6 years.
3.1. Lung cancer histology
The different histology patterns are shown in Fig. 1. Non-small cell
lung carcinomas were dominant, with only one case of small-cell lung
carcinoma.
3.2. Comparison between COPD patients and controls
Table 2 shows unadjusted and adjusted hazard ratios in the com-
bined COPD and control groups. COPD patients had a significantly
higher risk of developing lung cancer during follow-up with a HR 5.0
(95% CI 1.5–17.1, p= 0.01) after multivariable adjustment. Smoking
status at inclusion or pack-years smoked were not associated with lung
cancer.
3.3. Lung cancer risk related to COPD characteristics
Fig. 2 shows the accumulated risk for developing lung cancer in
COPD patients with and without CT-defined emphysema.
Table 3 shows the hazard ratios of the association of different COPD
characteristics with lung cancer development. Factors associated with a
higher lung cancer risk after multivariable adjustments were the pre-
sence of emphysema and/or obesity, whereas the use of inhaled corti-
costeroids (ICS) was associated with a lower risk (Table 3). Use of
tiotropium was associated with a higher risk of lung cancer in the un-
adjusted model, but not after multivariable adjustment. When strati-
fying on gender, obesity only indicated a higher risk in males (HR 4.76;
1.4–16.0, p= 0.01), but not in females (HR 1.34; 0.2–8.0, p= 0.75).
Similarly, the use of ICS indicated a lower risk in patients without
emphysema (HR 0.13; 0.02–0.79, p=0.03), than in patients where
emphysema was present (HR 0.47; 0.15–1.50, p=0.20).
3.4. Biomarkers related to the development of lung cancer
Table 4a shows non-parametric analysis of 44 systemic biomarkers
measured at study inclusion. Of the 44 markers, interleukin-6 (IL-6;
p= 0.01) and interferon gamma-induced protein 10 (IP-10; p= 0.02)
were significantly associated with later development of lung cancer.
Evaluation of biomarkers one at a time in the adjusted cox-
Fig. 2. Incidence of lung cancer in patients with and without emphysema during follow up.
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regression analysis (Table 4b) showed that only IP-10 is significantly
associated with lung cancer (HR 1.80; 1.32–2.45, p < 0.001, per 1 SD
increase), after multivariate adjustment. Higher levels of IP10 indicated
a higher cancer risk in patients with emphysema (HR 2.05; 1.45–2.90,
p < 0.01), than in non-emphysema patients (HR 0.95; 0.38–2.40,
p=0.92).
The combined effect of the 44 biomarkers was evaluated by prin-
cipal component analysis using components 1–11 with eigenvalues
above 1, representing 71% of the cumulative variance of the bio-
markers. The values of the different eigenvectors, and the markers in-
cluded in each principal component, are shown in the supplementary
material. The principal components 1–11 were also analysed using the
cox-regression model described above, but no significant statistical
difference was observed between lung cancer and non-cancer patients
(Table 4b). The distribution of component 1–4 of the principal com-
ponent analysis of the 44 biomarkers in lung cancer vs non-cancer
patients is shown in Fig. 3.
Fig. 4 shows the correlations between the different COPD char-
acteristics and biomarkers of systemic inflammation represented by the
principal components 1–4. There was a higher degree of correlation
between the components and the COPD characteristics of frequent ex-
acerbations and chronic bronchitis, than with lung cancer or
emphysema.
4. Discussion
The results of this study showed that both current and ex-smoking
COPD patients, irrespective of packyears smoked, had an increased risk
of lung cancer. Further, the presence of emphysema and obesity was
associated with an increased lung cancer risk, whereas the use of ICS
was associated with a reduced risk. Among 44 systemic biomarkers,
only IP-10 was significantly associated with the development of lung
cancer after multivariable adjustment. The study did not demonstrate
any clear association between lung cancer and the COPD characteristics
of chronic bronchitis, frequent exacerbations, or markers of systemic
inflammation beside IP-10.
A diagnosis of COPD, and especially with the presence of emphy-
sema, was a risk factor for developing lung cancer in our study. Current
smoking or a high pack-year count did not increase the risk, suggesting
the persistence of lung damage even after quitting smoking, or after a
moderate amount of smoking. These findings are in accordance with
earlier studies which have demonstrated a relationship between a
Table 3
Risk factors for the development of lung cancer in COPD patients, bi-and
multivariable cox-regression.
Variables Bivariable Multivariable
HR 95% CI p-value HR 95% CI p-value
Age per 10 year
increase
1.76 (0.98–3.16) 0.06 1.77 (0.88–3.55) 0.11
Sex
Female 1 1
Male 0.93 (0.44–1.97) 0.86 0.61 (0.27–1.39) 0.24
Smoking status
Ex 1 1
Current 0.69 (0.32–1.49) 0.33 1.41 (0.57–3.48) 0.46
Packyears per 10
units increase
1.05 (0.92–1.21) 0.45 0.99 (0.85–1.17) 0.94
Body composition
Normal 1 1
Cachectic 0.58 (0.19–1.72) 0.32 0.32 (0.09–1.18) 0.09
Obese 1.99 (0.85 - 4.66) 0.11 3.25 (1.25–8.45) 0.02
Emphysema
No 1 1
Yes 2.74 (1.19–6.31) 0.02 4.35 (1.74–10.8) <0.01
Use of inhaled steroids
No 1 1
Yes 0.74 (0.35–1.58) 0.44 0.40 (0.17–0.93) 0.03
GOLD-status (2007)a
II 1
III 1.08 (0.50–2.34) 0.84
IV 0.78 (0.18–3.46) 0.75
Use of tiotropiuma
No 1
Yes 2.20 (1.05–4.63) 0.04
Use of long-acting β2-agonistsa
No 1
Yes 0.78 (0.40–1.97) 0.78
Exacerbations 12 months before inclusiona
0-1 1
2+ 0.62 (0.19–2.05) 0.43
Chronic bronchitisa
No 1
Yes 1.21 (0.58–2.54) 0.61
Charlson Comorbidity Scorea
1 1
2 0.83 (0.30–2.27) 0.71
3 2.29 (0.89–5.91) 0.09
4+ 1.44 (0.33–6.33)
a p > 0.05 in multivariable analysis.
Table 4a
Non-parametric analysis of biomarkers in non-cancer vs cancer in COPD-pa-
tients.
Biomarker Mean values p-valuea
non-cancer lung cancer
Hemoglobin 14.53 14.19 0.12
Leucocytes 8.13 7.63 0.42
Granulocytes 5.57 5.12 0.46
Eosinophils 2.54 2.57 0.95
Platelet count 293.89 279.48 0.30
Activin-A 0.32 0.33 0.37
ALCAM 73.94 71.87 0.67
Basic FGF 63.91 60.48 0.34
CD-163 315.46 293.59 0.75
CRP 8.50 5.08 0.22
s-Creatinine 67.84 67.36 0.69
CXCL-16 783.28 836.98 0.31
Eotaxin 92.33 87.10 0.17
s-Ferritin 136.29 143.07 0.65
G-CSF 216.23 217.29 0.18
GDF-15 0.98 0.92 0.52
GM-CSF 98.45 56.44 0.39
IFN-γ 330.46 271.55 0.31
IL-1 0.96 0.55 0.59
IL-2 39.41 12.73 0.60
IL-4 15.06 15.86 0.39
IL-5 13.12 12.43 0.97
IL-6 2.96 1.13 0.01
IL-7 30.60 31.92 0.47
IL-8 33.65 35.35 0.39
IL-9 38.32 34.29 0.37
IL-10 80.53 45.93 0.87
IL-12 259.89 77.80 0.82
IL-13 163.04 43.66 0.48
IL-17 93.26 96.41 0.37
IP-10 768.84 1057.31 0.02
MBL 828.55 525.29 0.10
MCP-1 63.57 59.30 0.85
MCP-4 90.59 85.02 0.62
MIF 24.79 21.41 0.50
MIP-1α 8.83 8.17 0.83
MIP-1β 53.88 52.87 0.90
NAP-2 170.89 165.91 0.41
NGAL 75.69 68.55 0.30
OPG 5770.63 6247.31 0.29
PDGF-BB 1128.54 1093.75 0.81
TNF-R1 736.45 752.24 0.78
TNF-α 1.80 1.68 0.59
VEGF 48.20 46.19 0.66
a Wilcoxon rank-sum test
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diagnosis of COPD and lung cancer or death of lung cancer irrespective
of the amount of smoking [3–5,15]. Subsequent studies have further
evaluated this relationship, where the presence of emphysema in COPD
patients was associated with both a diagnosis of lung cancer, but also
death due to lung cancer as well as non-pulmonary cancer [6,7,16]. The
co-existence of emphysema and lung cancer may obviously be ascribed
to their common risk factor of noxious airway exposure. However, a
common pathophysiology of these two conditions is nevertheless more
difficult to explain, with apoptosis and protein degrading as main
characteristics of emphysema as opposed to the excessive cell growth in
cancer. Possible mechanistic explanations of cancer development
include accelerated proliferation of epithelial cells resistant to apop-
tosis, dysfunction of proteinase-regulation, and increased generation of
pro-inflammatory cells, cytokines and reactive oxygen species [8,17].
There is extensive research data linking systemic inflammation and
cancer in general [18]. In lung cancer, this relationship is less well
described, but several studies have demonstrated elevated in-
flammatory mediators in patients with established lung cancer [19–22].
An important study question to address was whether indices of systemic
inflammation could predict lung cancer in COPD patients. Interrelated
phenotypic attributes such as chronic bronchitis and frequent exacer-
bations were also associated with increased systemic inflammation, but
none of them had a significant association with the development of lung
cancer. We evaluated inflammatory biomarkers both individually as
well as combined with principal component analysis, with mostly ne-
gative findings regarding any predictive value of lung cancer. However,
the principal component analysis indicated a closer association between
inflammatory markers and patients with mainly chronic bronchitis and
exacerbations, rather than in patients with emphysema or with high
lung cancer risk, suggesting the existence of different pathophysiolo-
gical/immunological pathways underlying the different COPD pheno-
types.
Among 44 serum/plasma biomarkers, only high levels of IP-10 were
associated with increased lung cancer risk. IP-10 (CXCL-10) is induced
by IFNγ, and is frequently used as a marker of viral infection [23,24].
Its functions include induction of chemotaxis, regulation of cell growth/
apoptosis and angiogenesis. Spaks et al. found elevated serum IP-10 in
lung cancer patients [25], and high expression is also seen in other
cancer types. The role of IP-10 in cancer may depend on its receptor; it
may be involved in tumor growth inhibition through angiostatic or
immunogenic actions or in direct tumor growth stimulation. The role of
IP-10 in either COPD or lung cancer is yet unclear, and thus it should be
further investigated.
The association between the use of ICS and a lower risk of lung
cancer is in accordance with prior observational studies [26–28], and
may indicate a protective effect of ICS. The above mentioned link be-
tween inflammation and cancer may be modified by ICS, and the po-
tential protective mechanisms of ICS may include reduced secretion of
carcinogenic cytokines or growth-factors in the lungs, as well as in-
hibition of proto-oncogene expression [29,30]. On the other hand, a
similar effect has not been found in randomized controlled studies
[31,32], and the observed effect of ICS may be due to a protopathic
bias. However randomized controlled trials are neither designed nor
have had a sufficient follow up time to evaluate lung cancer risk, thus a
potential preventive effect of ICS is still possible although unproven
[33,34].
A major finding in the present study was an independent association
between obesity and lung cancer development in COPD patients, pri-
marily reflecting an association in males. Obesity is described as a risk
factor of several variants of cancer [35], however, regarding lung
cancer, several prior studies report opposing findings where some have
reported a protective effect of high BMI [36,37]. This is, nevertheless, a
complex matter to study, where several confounding factors such as
smoking habits, genetics and dietary issues may affect the findings in
the different study populations [38,39]. Recently, a large study where
23,732 incident lung cancer cases were identified suggested that central
obesity, particularly concurrent with low BMI, could help identify high-
risk populations for lung cancer [40], and future studies in COPD pa-
tients in relation to cancer development should also include fat dis-
tribution as a parameter.
There is an ongoing international debate on lung cancer screening
[41]. Early detection of lung cancer using low-dose computer tomo-
graphy is probably the most important measure in reducing mortality
[42]. Most screening protocols consider smoking and aging as the most
important risk factors, though some recent studies promotes the in-
clusion of additional parameters to narrow the screening population
[43–45]. Screening appears to be more advantageous in case of
Table 4b
Multivariate cox-regression of biomarkers and principal components in non-
cancer vs cancer in COPD-patients.
Biomarker HR a 95% CI p-value
Hemoglobin 0.78 (0.52–1.17) 0.23
Leucocytes 0.80 (0.51–1.25) 0.33
Granulocytes 0.77 (0.49–1.22) 0.27
Eosinophils 0.89 (0.55–1.43) 0.64
Platelet count 0.88 (0.56–1.38) 0.58
Activin-A 0.87 (0.57–1.35) 0.54
ALCAM 0.73 (0.41–1.33) 0.31
Basic FGF 1.04 (0.70–1.54) 0.84
CD-163 0.82 (0.46–1.44) 0.48
CRP 0.66 (0.35–1.24) 0.20
s-Creatinine 0.88 (0.56–1.38) 0.58
CXCL-16 1.24 (0.81–1.89) 0.32
Eotaxin 1.01 (0.65–1.57) 0.96
s-Ferritin 1.09 (0.81–1.46) 0.58
G-CSF 0.98 (0.62–1.55) 0.94
GDF-15 0.99 (0.59–1.65) 0.98
GM-CSF 0.56 (0.13–2.34) 0.43
IFN-γ 0.89 (0.45–1.76) 0.74
IL-1 0.60 (0.29–1.24) 0.17
IL-2 0.72 (0.12–4.24) 0.71
IL-4 1.09 (0.76–1.57) 0.64
IL-5 1.03 (0.70–1.52) 0.89
IL-6 0.25 (0.02–3.61) 0.31
IL-7 1.08 (0.82–1.43) 0.59
IL-8 1.16 (0.80–1.68) 0.44
IL-9 0.93 (0.57–1.51) 0.77
IL-10 0.91 (0.50–1.66) 0.76
IL-12 0.16 (0.00–75.8) 0.56
IL-13 0.46 (0.07–3.06) 0.42
IL-17 1.05 (0.71–1.57) 0.80
IP-10 1.80 (1.32–2.45) < 0.001
MBL 0.68 (0.38–1.23) 0.20
MCP-1 0.97 (0.64–1.46) 0.87
MCP-4 0.82 (0.82–1.28) 0.37
MIF 0.78 (0.46–1.32) 0.35
MIP-1α 0.99 (0.48–2.02) 0.98
MIP-1β 0.92 (0.60–1.40) 0.68
NAP-2 0.87 (0.61–1.26) 0.47
NGAL 0.70 (0.47–1.11) 0.13
OPG 1.07 (0.72–1.60) 0.74
PDGF-BB 0.96 (0.63–1.48) 0.87
TNF-R1 0.92 (0.61–1.38) 0.69
TNF-α 1.04 (0.68–1.58) 0.84
VEGF 1.00 (0.67–1.51) 0.97
Principal components HR 95% CI p-value
PC1 1.00 (0.89–1.14) 0.94
PC2 0.96 (0.78–1.18) 0.69
PC3 0.87 (0.66–1.15) 0.34
PC4 0.74 (0.54–1.01) 0.06
PC5 1.26 (0.90–1.76) 0.17
PC6 0.71 (0.50–1.00) 0.05
PC7 0.89 (0.60–1.31) 0.54
PC8 1.04 (0.69–1.56) 0.85
PC9 1.17 (0.79–1.73) 0.44
PC10 0.83 (0.52–1.32) 0.43
PC11 0.59 (0.38–0.92) 0.02
a Per 1 SD increase.
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emphysema phenotype of COPD, but less in case of COPD with chronic
bronchitis or other forms of chronic inflammation. The results of our
study support narrowing the screening population based on presence of
airflow limitation as well as indications of emphysema.
The strengths of our study were its prospective design with out-
comes from a mandatory national registry, and the availability of
detailed information on a large number of patients allowing adjustment
of multiple variables.
Some limitations should be mentioned. First, the patients were not
randomized, and therefore data interpretation regarding causality is
difficult. Second, the serum/plasma inflammatory markers were mea-
sured only at entry, and thus it is uncertain to what extent this is
Fig. 3. Systemic inflammation in non-cancer vs lung cancer patients represented by principal components 1–4 of the systemic inflammatory markers, measured at
study inclusion. Scatterplots of components 1 vs 2 and 3 vs 4 shows no significant difference between the groups.
Fig. 4. Correlation diagram showing the relations between COPD characteristics and systemic inflammation at study inclusion represented by principal components
1–4. Thicker line indicates larger degree of correlation, solid line indicates positive correlation, dashed line indicates negative correlation.
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representative of lung inflammation or whether the degree of systemic
inflammation in the subjects is altered during follow-up. Third, the
study population represents an outpatient clinic population, with ex-
clusion of GOLD class 1 patients and, thus the results may not be ap-
plicable to a COPD population with early stage disease. Finally, there
was no systematic screening of lung cancer. Thus, although the
Norwegian Cancer Registry has a high degree of completeness, we
cannot exclude cases of non-reported lung cancer among patients or
controls.
The present study clearly underscores the necessity of looking at
COPD as a heterogeneous disease, where the different phenotypes not
only require different diagnostics and treatment, but where they also
incorporate different risks of adverse events such as lung cancer de-
velopment. The idea of using serum/plasma biomarkers in early lung
cancer screening may presently seem challenging, but an increasingly
easier access to large multiplex bioassays and a better understanding of
the pathophysiologic mechanisms behind the COPD phenotypes might
change this view in the near future.
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Note on missing data 
Data on spirometry, body composition, medical history, smoking habits and clinical 
phenotypes and lung cancer status were complete in all patients. CT scan was performed in 
384 patients at baseline, but it was unavailable in 49 patients. A complete biomarker analysis 
of all 44 inflammatory markers was unavailable in 39 patients.  
The main source of data on the diagnosis of lung cancer in 31 patients was the Norwegian 
Cancer Registry. The Norwegian health care system is predominantly public, and there are no 
centers for lung cancer diagnostics outside public hospitals and out-patient clinics. All 
inhabitants can be tracked by the national id-number across different hospitals and public 
accounts. Submission of data to the cancer registry is mandatory by law and has several 
validation systems based on both ICD10-registration as well as histological cancer 
diagnostics. For these reasons we can assume close to 100 % data completeness in both 
patients and controls. 
Note on bioassays  
Peripheral venous blood was drawn into pyrogen-free EDTA collection tubes and centrifuged 
within 30 minutes at 2150 g for 15 minutes at 4 
o
C. The plasma was aliquoted and stored in -
80 
o
C ultra-freezers until measurements, thus the samples were never previously thawed. The 
44 biomarkers were analyzed at different occasions after sampling:  
NGAL, MIF, ALCAM, CD163, OPG, CXCL16, TNF-R1, MCP4, NAP2, MBL were 
measured in 2007 and 2008 by enzyme-linked immunosorbent assays (EIAs) (R&D Systems, 
Inc, Minneapolis, MN, USA). The intra- and inter-assay coefficients of variation were <11% 
for all parameters. Hemoglobin, WBC, Granulocytes, TPC, s-Ferritin, s-Creatinine and CRP 
were measured in 2007 and 2008 by routine laboratory methods (Modular PP, Roche 
Diagnostics, Basel, Switzerland). Plasma levels of TNF-α, IL-1, IL-6, were measured in 2011 
using EIA kits (BD Biosciences Pharmingen, San Diego, CA). The intra-assay and inter-assay 
coefficient of variations were <10% for all parameters. Plasma levels of IL-1β, IL-1α, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, Basic FGF, G-
SF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, PDGF-BB, MIP-1β and VEGF were measured 
by Aveo Oncology in 2014 using a magnetic bead multiplex assay (Bio-Plex Pro, Bio-rad 
laboratories, Inc.). Plasma-levels of GDF15 and Activin A were measured by Aveo Oncology 
in 2014 using enzyme-linked immunosorbent assays (Quantikine, R&D Systems, Inc). All 
samples were measured in duplicates, and only accepted if intra-assay variance was less than 
10%.  
 
Note on principal component analysis 
For the combined evaluation of the biomarkers, a principal component analysis (PCA) was 
done. PCA is a data reduction method that extracts the variance of multiple and often 
correlated variables into a smaller number of principal components. The eigenvalue of the 
components corresponds to the variance explained by each component. All variables were 
standardized before using an orthogonal transformation. The largest principal components 
with eigenvalues above mean (=1), are shown in the table below. The total variance explained 
by the 11 largest components was 70.8 %. 
Component Eigenvalue Proportion Cumulative 
    Component 1 12.1798 0.2768 0.2768 
Component 2 4.51165 0.1025 0.3794 
Component 3 2.78334 0.0633 0.4426 
Component 4 2.26015 0.0514 0.4940 
Component 5 1.6773 0.0381 0.5321 
Component 6 1.56507 0.0356 0.5677 
Component 7 1.37711 0.0313 0.5990 
Component 8 1.30888 0.0297 0.6287 
Component 9 1.22387 0.0278 0.6565 
Component 10 1.16035 0.0264 0.6829 
Component 11 1.08142 0.0246 0.7075 
    
A screeplot of the eigenvalues shows a breaking point between components 4 and 5. 
 
For the statistical analysis in the regression model, we used the 11 largest principal 
components. The correlations between the 4 largest components and lung cancer/other COPD 
characteristic are shown in figure 3 and 4 in the main text.  
 
The eigenvectors and their loadings according to the original variables of principal component 
1-11. 
     
Original variables 
                       
PC1 GCSF IL7 IFN-γ BasicFGF MCP1 Eotaxin IL10 IL2 IL12 IL13 VEGF GMCSF IL4 
  0.2780 0.2769 0.2741 0.2712 0.2712 0.2691 0.2658 0.2636 0.2620 0.2618 0.2496 0.2451 0.2306 
PC2 IL8 IL17 PDGF MIP1b IL5 CD163 IL4 
        0.3330 0.3051 0.2851 0.2389 0.2114 0.2058 0.2038             
PC3 TNFR1 ActA s-Crea TPC GDF15 NGAL OPG NAP2 
       0.4060 0.3310 0.3090 -0.2799 0.2798 0.2368 0.2265 -0.2244      
PC4 Gran WBC NGAL CRP 
           0.5175 0.5079 0.2894 0.2350                   
PC5 ALCAM Ferr Hb TPC MIF s-Crea IL1 NAP2 
       -0.3636 0.3517 0.3312 -0.3250 -0.2545 0.2282 0.2266 -0.2112           
PC6 Hb MIF MCP4 OPG Ferr Eos IL6a 
        0.4582 0.4173 0.3464 -0.2409 0.2342 0.2307 -0.2146             
PC7 IL1 TNFα CXCL16 CRP IP10 Ferr TPC NAP2 IL6a MIP1a 
     0.4093 0.3843 0.3205 -0.2552 -0.2453 0.2435 0.2331 0.2327 -0.2317 -0.2289       
PC8 Eos MCP4 ALCAM IP10 MIF CD163 
         0.4489 0.4117 -0.3187 0.2695 -0.2655 -0.2332               
PC9 IL9 IL6a NGAL s-Crea OPG TNFα CD163 Hb CRP TNFR1 
     -0.3514 0.3467 -0.3131 -0.2960 0.2714 0.2592 0.2529 0.2445 0.2436 -0.2050       
PC10 OPG IL6a NAP2 MIP1b MIP1a MBL TNFα 
        -0.4084 0.3659 0.3392 0.2516 -0.2327 0.2110 0.2050             
PC11 CXCL16 Eos s-Crea MBL IP10 MCP4 MIF 
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